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Abstract 
Hepatocellular cancer (HCC) is the sixth commonest cancer worldwide and the second 
leading cause of cancer mortality. The majority of patients present with advanced 
disease, where cure is not an option and palliative therapies are limited. What is more, 
biomarkers to stratify available therapies effectively are lacking.  Tissue is not routinely 
obtained as diagnosis of HCC is largely reliant on imaging, as this is sensitive and 
specific in the majority of patients with cirrhosis and liver biopsy carries small but 
recognised risks - including tumour seeding and bleeding.  Serum AFP lacks HCC 
diagnostic sensitivity and specific, but remains the only clinically useful serum biomarker 
– employed despite its limitations in surveillance programmes as well as to monitor HCC 
progression and to stratify patients for therapy.  This highlights the need for alternative 
biomarkers for HCC management.  Sampling patient blood is a quick, non-invasive and 
inexpensive method and may be regarded as a ‘liquid biopsy’ if it could deliver clinically 
relevant molecular information about the tumour or its microenvironment.  Several liquid 
biopsy methods have been explored: circulating tumour cell (CTC) detection and 
characterisation; circulating tumour DNA (ctDNA) KRAS mutation detection; circulating 
immune cell counts and gene expression signatures of peripheral blood 
mononucleocytes (PBMCs). 
CTCs can be detected in patients with cancer and have the potential to provide 
diagnostic, prognostic and treatment stratifying information. A method for CTC detection 
using the Imagestream – an imaging fluorescent activated cells sorter with multi-channel 
immunofluorescence - was developed and optimised.  A CD45-immunomagnetic 
depletion resulted in ≥95% reduction in WBCs with the maintenance of a recovery rate 
of 51.3-65.37% of CTCs.  The remaining cell suspension was labelled with a panel of 
fluorescent antibodies to enable cell characterisation prior to running through the 
Imagestream. 
Between 1 and 1642 CTCs were detected in 65% of HCC patients.  The presence of 
CTCs indicated a worse median overall survival (OS) in HCC patients (24.5 months vs 
12 months, Log-Rank p>0.0001).  Expression of biomarkers on CTCs was 
heterogeneous with CK being the most commonly detected biomarker, followed by DNA-
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PK.  In some patients, CTCs observed were negative for all of the biomarkers in the 
panel but detectable on the basis of size and morphology.  Clusters of CTCs and 
leucocyte interactions with CTCs were also observed.   
Studies on plasma ctDNA detected KRAS mutation in 2/38 (5%) of patients with HCC.  
Retrospective patient blood data analysis demonstrated that circulating neutrophils were 
the key circulating immune cell driving HCC progression.  In two patient cohorts – 
Newcastle (n=583) and Hong Kong (n=585), circulating neutrophil counts were an 
independent predictor of prognosis.  Furthermore, in the combined cohort (n=1168), the 
neutrophil count, either alone or combined with platelets and lymphocytes, was 
associated with significant differences in patients survival. 
In a small pilot cohort, gene expression analysis of PBMCs identified NFAT in the 
immune response as being the top altered pathway in patients with NAFLD/NASH-HCC.  
DNA extracts prepared from PBMCs in patients with NAFLD-NASH-HCC were more 
similar to samples derived from patients with HCV-HCC compared to non-cancerous 
NAFLD/NASH controls. 
These pilot data were encouraging, supporting a potential role for future application of 
liquid biopsy tools in the clinical setting for patients with HCC. 
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Chapter 1.  Literature review 
1.1 Introduction to HCC 
Primary liver cancer constitutes of: cholangiocarcinomas (CCA) that originate from the 
bile duct epithelium; hepatocellular carcinomas (HCC) that originate from hepatocytes; 
hemangiosarcomas that arise from mesenchymal tissues, as well as hepatoblastomas, 
bile duct cystadenocarcinomas and epitheliod haemangioendotheliomas (Farazi and 
DePinho, 2006). Of all primary liver cancers, HCC is the most common primary liver 
cancer accounting for approximately 80-90% of all cases (El-Serag and Rudolph, 2007, 
Farazi and DePinho, 2006). 
1.1.1 Epidemiology of HCC 
HCC is the sixth most frequent cancer worldwide and the second most common cause 
of cancer mortality (Jemal et al., 2011).  It has a higher prevalence in males compared 
to females with a male to female ratio of 2.4:1 (Di Bisceglie, 2009, Ferlay et al., 2010).  
In the United Kingdom, liver cancer is the 18th most common cancer and rates have 
increased by 60-70% from 2003 to 2012 (Office for National Statistics, 2012).  Incidence 
increases with age; in the UK the average age of onset is 66 years old (Ryder, 2003). 
The overall incidence of HCC is rising, although its global prevalence geographically is 
variable with higher rates observed in the developing world such as Eastern and South 
Eastern Asia as well as Middle and Western Africa compared to developed regions 
(Ferlay et al., 2010, Jemal et al., 2011).  Since the introduction of the hepatitis B virus 
(HBV) vaccination programmes in the 1980’s (Beasley et al., 1983, Lo et al., 1985) and 
the implementation of new treatments leading to eradication of hepatitis C virus (HCV) 
(Lange and Sarrazin, 2015) it is likely that the burden of viral-induced HCC will decrease; 
on the other hand, an increase in obesity and associated metabolic risk factors is likely 
to lead to an increase in HCC with a non-alcoholic fatty liver disease (NAFLD)/ non-
alcoholic steatohepatitis (NASH) aetiology (Starley et al., 2010, Dyson et al., 2014).  
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1.1.2 Aetiology of HCC 
In 80% of cases, HCC develops on a background of cirrhosis or advanced liver fibrosis 
(Bosch et al., 2004, Severi et al., 2010, van Malenstein et al., 2011). It is well established 
that infection with HBV and HCV are contributing factors to the development of HCC 
(Severi et al., 2010).  The carcinogenic effect of prolonged excess alcohol consumption 
leading to alcoholic liver disease (ALD) increases the risk of HCC development (Morgan 
et al., 2004, Stickel et al., 2002).  The development of cirrhosis is a concern in patients 
with NAFLD and NASH (Severi et al., 2010).  Congenital disorders such as 
haemachromatosis and Wilson’s disease also contribute to cirrhosis or advanced fibrosis 
(Severi et al., 2010). Of the remaining cases of HCC that arise independently of cirrhosis 
or advanced fibrosis, risk factors include aflatoxin B1, exposure from contaminated food 
sources and the use of anabolic steroids or oral contraceptives (Bosch et al., 2004, 
Severi et al., 2010). 
1.1.3 Hepatitis virus-induced HCC 
Infection with either HBV/HCV are major causes of chronic liver disease associated with 
the development of 80% of cases of HCC (El-Serag, 2012).  Viral hepatitis B and C 
induced cirrhosis is associated with an increased risk of HCC development compared to 
other aetiologies (Perz et al., 2006).  Viral hepatitis caused by HBV or HCV infection 
leads to an inflammatory immune response in the liver leading to fibrosis and cirrhosis.  
HBV may exert mutagenic effects by integrating into the host genome and causing 
genomic instability (Blum and Moradpour, 2002).   
Chronic HBV infection is estimated to be present in 5% of the world population with 
prevalence varying between 0.1% and 20% between different geographical regions (El-
Serag, 2012, Mohr et al., 2015). Overall, HBV accounts for over 50% of HCC cases 
worldwide, rising to 70-80% of cases in highly endemic areas (Nguyen et al., 2009).  
Prophylaxis of HBV has been made possible by the introduction of vaccines against 
HBV, first introduced in the 1980s (Di Bisceglie, 2009).  The success of implemented 
vaccination programmes has led to a decline in incidence rates (Chang et al., 1997, Ni 
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et al., 2001).  It is predicted that with continuation of HBV vaccination programmes, the 
number of HCC cases attributed to HBV will continue to decrease. 
HCV is another leading cause of HCC development.  Akin to HBV, the incidence of HCV 
has varying prevalence globally.  HCV is the major risk factor for HCC patients in Japan 
where it accounts for approximately 80% of cases of HCC (Yoshizawa, 2002).  Advances 
in directly acting antiviral agents (DAAs), in combination with pegylated interferon (PEG) 
α and ribavirin are likely to lead to the eradication of HCV in a large proportion patients 
(Lange et al., 2014). 
1.1.4 Alcoholic liver disease 
Prolonged excess alcohol intake has been reported to increase the risk of HCC ~5-fold 
(Morgan et al., 2004).  The risk of HCC increases proportionally with the increased level 
of alcohol intake (Donato et al., 2002).  Alcohol has also been shown to have a 
synergistic effect with HBV and HCV, leading to increased virus replication (El-Serag 
and Rudolph, 2007, Stickel et al., 2002).  In the UK, alcohol is a major cause of chronic 
liver disease (CLD), resulting in liver injury and subsequent cirrhosis (Dyson et al., 2014).  
The effects of alcohol in the development of ALD are not entirely understood but alcohol 
can exert its effects at the DNA level (Morgan et al., 2004, Stickel et al., 2002).  In the 
liver, alcohol is first metabolised to acetaldehyde (AA) by hepatic enzymes alcohol 
dehydrogenase and cytochrome P450 2E1 (CYP2E1) (Stickel et al., 2002).  AA adducts 
bind readily to cellular proteins and potentially to DNA exerting a mutagenic and 
carcinogenic effect (Stickel et al., 2002).  Alcohol metabolism also leads to the production 
of free radicals which may be DNA-damaging or result in alterations in DNA methylation 
and expression (Morgan et al., 2004, Stickel et al., 2002).  The toxicity of alcohol and 
ethanol metabolites can also lead to the activation of inflammatory cells through the 
increase in reactive oxygen species (ROS) and stimulation of inflammatory cytokines 
(Niederau, 2015).  In addition to the carcinogenic effects of alcohol, malnutrition and 
vitamin deficiencies associated with alcoholism may also be contributory to an altered 
immune response (Stickel et al., 2002).  
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1.1.5 NAFLD and NASH 
NAFLD is the clinical manifestation of metabolic syndrome in the liver.  Features of 
metabolic syndrome include: impaired fasting glucose, type 2 diabetes mellitus (T2DM), 
dyslipidaemia, central obesity, and hypertension.  In the liver, NAFLD is histologically 
defined as excess steatosis (fat accumulation in greater than 5% of hepatocytes), NASH 
is a progression of simple steatosis, including inflammation and associated injured or 
‘ballooned’ hepatocytes (steatohepatitis) (Ratziu et al., 2010).  NAFLD is now the most 
predominant cause of CLD in developed countries and a predicted increase in obesity 
suggests that this trend is going to increase in the upcoming years (Dyson et al., 2014, 
Starley et al., 2010).  It is estimated that over the course of 5-7 years, 3.6-12% of patients 
with NASH/cryptogenic cirrhosis will develop cirrhosis-related complications including 
HCC (Starley et al., 2010).  
1.1.6 Pathogenesis of HCC 
Models of hepatocarcinogenesis have been used in attempt to describe the transition of 
hepatocytes to pre-neoplastic lesions that develop into HCC (Severi et al., 2010, 
Thorgeirsson and Grisham, 2002).  Although the model of hepatocarcinogenesis differs 
depending on the nature of injury, between the models there are shared cellular 
responses including inflammation and oxidative stress mechanisms, as well as common 
genetic and epigenetic events (Farazi and DePinho, 2006, Pons et al., 2005). 
Hepatic fibrosis is the wound healing response of the liver to chronic injury (Hui and 
Friedman, 2003). Prolonged liver injury reduces the regenerative potential of the liver 
leading to an accumulation of extracellular matrix (ECM) which is eventually replaced by 
scar tissue (Hui and Friedman, 2003).  A continual increase in cell turnover in response 
to liver insult results in the sensitisation of cells to mutagenic agents (Severi et al., 2010). 
In cirrhotic liver, regeneration occurs in a non-uniform manner leading to the creation of 
hyperplastic nodules (Farazi and DePinho, 2006, Kojiro, 2004). At this point it is 
suggested that there is some form of genetic instability, leading to the progression of pre-
malignant dysplastic nodules that are cytologically abnormal; differing in size, colour and 
cell density compared to the cirrhotic liver (Farazi and DePinho, 2006, Kojiro, 2004). 
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Dysplastic nodules can be classed as low-grade or high grade depending on their size, 
infiltration of fat, increased nuclear density and vascular involvement (Kojiro, 2004). Early 
stage HCC can be sub-divided into distinctly nodular (encapsulated, moderately 
differentiated, hypervascular) and indistinctly nodular (well-differentiated and 
hypovascular (Kojiro, 2004). As early stage HCC develops into advanced stage HCC 
there is an increase in size and pathologically it becomes less well-differentiated. It can 
often take on a ‘nodule-in-nodule’ appearance whereby areas of well-differentiated tissue 
exist within areas of poorly differentiated tissue (Kojiro, 2004). 
1.1.7 Molecular classification of HCC 
HCC is highly heterogeneous both inter-tumourally and intra-tumourally.  During the 
process of hepatocarcinogenesis there is an accumulation of mutations, changes in 
genomic stability, DNA hypomethylation and hypermethylation of CpG islands (Calvisi et 
al., 2007, Thorgeirsson and Grisham, 2002).  HCCs contain multiple chromosomal 
losses and gains which may encompass tumour suppressor genes e.g. TP53, 
Retinoblastoma protein (Thorgeirsson and Grisham, 2002).  Aberrations in pathways 
involved in cellular proliferation, differentiation, cell cycle and growth factor signalling 
have been associated with the process of hepatocarcinogeneis including: Wnt/β-catenin, 
PI3K/AKT/MTOR, RAS/MAPK, IGF, HGF/MET, EGFR, VEGF and PDGF (Cornellà et 
al., 2011, Llovet and Bruix, 2008).  β-catenin is the most frequently mutated oncogene 
in HCC and TP53 is the most frequently mutated tumour suppressor gene (Zucman-
Rossi, 2010).  Genome wide transcriptome analysis of 60 HCC tumours led to the 
proposal of six HCC subgroups (G1-G6) that are distinguishable on the basis of genomic 
stability, methylation and associated biological pathways (Zucman-Rossi, 2010).  
Telomerase reverse-transcriptase (TERT) promoter mutations have been identified as 
being the most frequent mutation in HCC, present in 40-59% of HCC patients and this 
mutation may be present in the early stages of hepatocarcinogenesis (Nault et al., 2013, 
Roberts and Wheeler, 2015)  
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1.1.8 Diagnosis of HCC 
As part of the EASL-EORTC guidelines a surveillance programme to monitor at-risk 
patients is suggested in attempt to detect HCC at an earlier stage when it can be 
managed more effectively (Bruix et al., 2001, Ryder, 2003, EASL-EORTC, 2012).  
Despite the implementation of surveillance programmes, patients with HCC often 
present at an advanced stage with symptoms including abdominal pain, fatigue, weight 
loss, jaundice and ascites.  Diagnosis of HCC is usually based on imaging e.g. CT, MRI 
and in some cases ultrasound-guided liver tissue biopsy.  In a recent report it was 
indicated that liver tissue biopsies are not always essential for the diagnosis of HCC  
(Sherman and Bruix, 2015).  Biopsies can be used to confirm diagnosis of HCC, provide 
molecular characterisation of the tumour and to assess the underlying liver disease.  
However, the size of biopsy – usually ~15 mm x 1.2-2 mm compared to the overall 
tumour is often relatively small (Rockey et al., 2009).  Therefore, a biopsy is likely to 
provide only a small snapshot of the complex molecular heterogeneity of HCC and does 
not necessarily give information about the driver cell population (Bruix et al., 2014).  
Furthermore, there are associated risks with liver tissue biopsies, commonly: pain at the 
site of biopsy and the risk of bleeding or tumour cell seeding (Rockey et al., 2009).  Other 
associated risks include infection and injury to nearby organs although these latter risks 
are rare.  Although the incidence of these risks are small, they can have serious 
implications for the patient including mortality (Rockey et al., 2009).  Despite this, liver 
tissue biopsies are still implemented to confirm diagnosis in instances where radiology 
is not diagnostic or to assess the aetiology and extent of underlying liver disease 
(Sherman and Bruix, 2015).   
1.1.9 Staging systems in HCC 
Multiple systems for the staging of HCC have been introduced and evolved over time 
Table 1.1. While attempts have been made to try and evaluate and validate existing 
staging systems in different subsets of patients, there is still not one universally accepted 
system. This is in part owing to the complexity of the disease, but also due to the 
differences in aetiology of the HCC geographically (Marrero et al., 2010, Pons et al., 
2005). The implementation of different staging systems means that it is difficult to directly 
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compare information from clinical studies. Although TNM (tumour, node, metastases) 
staging is widely implemented in the staging of different types of cancer, in HCC its utility 
is limited because it does not include an assessment of liver function or underlying liver 
disease which are primary determinants of prognosis and useful in guiding therapy.  
Assessment of the underlying liver disease can be performed using the Child-Pugh score 
which takes into account ascites, hepatic encephalopathy, albumin, bilirubin and 
prothrombin time (PT) Table 1.2.  Staging systems that have been developed Table 1.1 
have taken into account: tumour burden (tumour size, tumour number); liver function 
(Child-Pugh classification or its constituents); serum alphafetoprotein (AFP); portal vein 
invasion; the presence of extra-hepatic metastases or lymph node involvement and 
performance status.   
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Staging 
system 
Tumour staging Liver function Other 
features 
Okuda Tumour size, liver 
involvement<50% 
Ascites, albumin, bilirubin - 
CLIP Number of nodules, 
tumour extent 
Child-Pugh AFP 
BCLC Tumour size, tumour 
number, PVT 
Child-Pugh, bilirubin, portal 
hypertension 
ECOG 
GRETCH Tumour size, satellite 
nodules, resection margin, 
vascular invasion 
Bilirubin, alkaline phosphatase Karnofsky, 
AFP 
CUPI TNM Ascites, bilirubin, alkaline 
phosphatase 
AFP 
JIS Japanese TNM Child-Pugh - 
SLiDE Japanese TNM - DCP 
Tokyo Tumour size, tumour 
number 
Albumin, bilirubin - 
BALAD - Albumin, bilirubin AFP, AFP-
L3, DCP 
ALCPS Tumour size, PVT, lung 
metastases 
Child-Pugh, bilirubin, alkaline 
phosphatase, urea 
AFP 
ALBI - Albumin, bilirubin - 
Table 1.1 Staging systems in HCC include Cancer of the Liver Italian Programme (CLIP); 
Barcelona Clinic for Liver Cancer (BCLC); Groupe d’Etude et de Traitement du Carcinome 
Hépatocellulaire (GRETCH); French and Chinese University prognostic index (CUPI); 
Japanese Integrated Staging (JIS); Stage Liver Cancer DCP (SLiDe); bilirubin, albumin, 
Lens culinaris agglutinin-reactive alpha-fetoprotein (AFP-L3), alpha-fetoprotein (AFP), and 
des-gamma-carboxy prothrombin (DCP); bilirubin, albumin, lens culinaris agglutinin-
reactive AFP, AFP, des--carboxyprothrombin (BALAD); Advanced Liver Cancer Prognostic 
Score (ALCPS); Albumin-bilirubin (ALBI) grade (Johnson et al., 2015).  Portal vein 
thrombosis (PVT). 
 
Clinical parameter Points 
1 2 3 
Ascites None Slight Moderate 
Encephalopathy (grade) None I-II III-IV 
Bilirubin (µmol/L) <35 35-50 >50 
Albumin (g/L)  >35 28-35 <28 
INR <1.7 1.8-2.3 >2.3 
Total number of points 5-6 7-9 10-15 
Table 1.2 Child-Pugh assessment of underlying liver disease takes into account ascites, 
hepatic encephalopathy, raised bilirubin, lowered albumin and prolonged INR.  
INR=International normalised ratio. 
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Despite there being multiple staging systems for HCC, the Barcelona Clinic Liver Cancer 
(BCLC) classification system Figure 1.1 is most widely accepted clinically as well as in 
clinical trials for new HCC drugs (Bruix and Sherman, 2011).   
 
Figure 1.1 BCLC algorithm for the treatment of HCC.  From EASL-EORTC Clinical Practice 
Guidelines (EASL-EORTC, 2012). PS=performance status; CLT=cadaveric liver transplant; 
LDLT=living donor liver transplantation; PEI=percutaneous ethanol injection; 
RFA=radiofrequency ablation. 
1.1.10 Treatment of HCC 
Treatment for HCC is dependent on the stage of the disease, portal pressure and clinical 
performance (Severi et al., 2010). The BCLC treatment algorithm for HCC is widely 
clinically adopted and is used in the treatment stratification process Figure 1.1.  It is 
considered the gold standard in Europe by the European Association for the Study of the 
Liver (EASL) and the American Association for the Study of Liver Diseases (AASLD).  
Due to HCC often occurring in the background of liver disease, the use of 
chemotherapeutic agents as treatment is often limited (Farazi and DePinho, 2006).   
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Treatment can be divided into curative or palliative treatments.  Curative treatments 
include: liver transplant, resection and in some instances, tumour ablation.  Although 
preferred, surgery is not always a suitable option: HCC is often multifocal and technically 
difficult to resect; transplantation relies on the availability of donors and rates of 
recurrence  post-surgery  are  high  although  the  latter  may  in  part  be  due  to  poor  
patient selection (Lencioni and Crocetti, 2012, Roayaie et al., 2004). It is estimated that 
in patients with cirrhosis only around 5% would be suitable for surgery (Lencioni and 
Crocetti, 2012).   
Resection is the recommended treatment option for patients with BCLC stage 0 HCC 
Figure 1.1.  Resection leads to removal of the primary tumour but does not resolve the 
underlying cause of liver disease that is present in the majority of cases and so carries 
the risk of recurrence.  In patients with BCLC stage A HCC, local ablation is considered 
the next most preferable option in patients that are not suitable for surgery Figure 1.1. 
This is also a potentially curative treatment, the success of which is largely determined 
by the size of HCC and also its location. Generally patients are considered for this mode 
of treatment when they have a tumour that is less than 5 cm or there are 3 nodules 
<3 cm, there is no vascular involvement or metastasis and also have a Child-Pugh score 
of A or B (Lencioni and Crocetti, 2012).  Local ablation therapies include: percutaneous 
ethanol injection (PEI), radiofrequency ablation (RFA), microwave ablation and 
cryoablation (EASL-EORTC, 2012).  Ablative therapies may be performed 
percutaneously, laproscopically or as open-surgical procedures and may be carried out 
under local or general anaesthetic (NHS, 2016).  During ablative therapies, imaging 
technology is implemented to specifically induce cellular damage – by dehydration, 
protein denaturation or thermal injury – to the tumorous tissue whilst protecting the 
normal liver (Lencioni et al., 2004).  The choice of ablative therapy used is dependent on 
local guidelines. 
In patients where curative treatments cannot be implemented, the palliative treatments 
of choice include chemoembolization and trans-catheter therapies (EASL-EORTC, 
2012).  Transarterial chemoembolization (TACE), delivered using drug-eluting beads 
(DEB) has superseded gel-foam lipiodol particles since its use is associated with less 
systemic adverse events (EASL-EORTC, 2012).  TACE treatment involves the injection 
of DEBs containing cytotoxic drug – usually cisplatin or doxorubicin – through a catheter 
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that is inserted through the femoral artery which tracks up to the hepatic artery.  Due to 
the complex nature of the blood supply in the HCC, prior to treatment patients receive a 
visceral angiogram to identify vessels that require embolization to prevent the delivered 
treatment spreading to organs such as the lungs and also the peripheral blood supply 
therefore reducing treatment side effects. Despite this, side effects of TACE are frequent 
and in cases severe, highlighting the importance to consider patient contraindications 
prior to treatment (Beaugrand et al., 2004).  
Selective internal radiation therapy (SIRT) is an alternative treatment option for patients 
with non-resectable HCC. This method involves the injection of 32 micron microspheres 
coated in yttrium - a beta radiation-emitting isotope which causes necrosis of tumour 
cells usually about 10 days following treatment (Rossi et al., 2010). Trials to compare its 
efficacy relative to TACE, or in combination with medical therapy, are ongoing.  
Few medical treatments have offered survival benefit in patients with HCC despite the 
recognition of a wide network of cellular signalling pathways involved in the development 
of HCC Section 1.1.7. Currently, Sorafenib (Nexavar, Bayer) – a multi-kinase inhibitor - 
has been recommended for patients with advanced HCC; showing an improved survival 
benefit of 2.3-2.8 months in both the SHARP and Asia-Pacific trials (Cheng et al., 2009, 
Llovet et al., 2008).  Sorafenib targets kinases Raf-1 and B-Raf whilst also blocking the 
activity of the VEGF receptor and PDGF receptor; thus reducing proliferation and 
angiogenesis.  Systemic radiotherapy may also be offered in patients with bone 
metastases as a palliative treatment to alleviate pain (EASL-EORTC, 2012). 
1.1.11 Prognosis 
In HCC factors affecting patient survival include, tumour burden, extent of the underlying 
liver disease, treatment (curative or non-curative) and performance status (Cabibbo et 
al., 2010, Gallo et al., 1998, Okuda et al., 1985).  Currently there is not one single 
biomarker that is used for the prediction of prognosis in HCC based on the criteria set 
out by the EASL-EORTC clinical practice guidelines for the management of HCC (EASL-
EORTC, 2012).  A comparative analysis of seven different staging systems in a US 
patient cohort was performed to assess the prognostic potential of different staging 
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systems.  The study concluded that although all staging systems showed a decline in 
survival with increased stage, the BCLC stage had the best predictive potential 
compared to the other six staging systems (Okuda, TNM, Cancer of the Liver Italian 
Programme (CLIP), French and Chinese University prognostic index (CUPI), Japanese 
Integrated Staging (JIS) and Groupe d’Etude et de Traitement du Carcinome 
Hépatocellulaire (GRETCH) (Marrero et al., 2005).  In this patient cohort, consisting 
mostly of HCC patients with an HCV aetiology and the presence of cirrhosis, the factors 
impacting survival of non-transplant patients that were independent in a multivariate 
analysis included: performance status, model for end-stage liver disease (MELD), 
tumour diameter and portal vein thrombosis (PVT) (Marrero et al., 2005).   
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1.2 Circulating tumour cells 
The concept of circulating tumour cells (CTCs) was first described by Thomas Ashworth 
in 1869 (Ashworth, 1869). Ashworth microscopically observed cells in the peripheral 
circulation that resembled those from the primary tumour in a patient with advanced 
metastatic disease (Ashworth, 1869). CTCs are shed from a primary or metastatic 
tumour and subsequently circulate in the peripheral bloodstream. In the literature there 
is also referral to disseminated tumour cells (DTCs), although this description is usually 
limited to describe tumour cells that reside in the bone marrow (Pantel et al., 2008). A 
limitation to studying DTCs lies in the acquirement of the sample – bone marrow 
sampling is not a routine procedure and more invasive in comparison to a blood draw. 
Clinical implications of the detection and characterisation of CTCs in patients with cancer 
have been widely implied. However, due to the rarity of CTCs - sometimes as low as 
≤1/ml or 1 CTC/1 billion normal blood cells in patients with advanced cancer - it is only 
with the recent advent of suitable technologies that such investigations are clinically 
feasible (Allard et al., 2004).  Multiple studies have indicated that the detection and 
characterisation of CTCs may be clinically beneficial by providing novel, less invasive 
methods of diagnosis; monitoring disease progression; predicting prognosis and guiding 
and monitoring response to therapy. Further investigation into CTCs may also contribute 
to understanding the biology of the metastatic process. 
1.2.1 CTCs in the process of metastasis 
In the majority of patients, the primary tumour is not the principle cause of death – it is 
more often the case that the patient will die as a result of metastatic disease (Chaffer 
and Weinberg, 2011). Although the process of metastasis remains to be fully elucidated, 
it is considered that haematogenous dissemination of CTCs is an early event in the 
process, occurring following neovascularisation (Parkinson et al., 2012). Two main 
models have been proposed in attempt to explain the process of metastasis: the linear 
progression model and the parallel progression model.  In the linear progression model 
the primary tumour is considered the main driver of cancer growth and metastatic cells 
derive from the primary lesion over a given period of time following accumulation of 
genetic and epigenetic alterations (Klein, 2009).  In contrast, the parallel model assumes 
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that prior to symptoms or diagnosis of the primary tumour there is early dissemination of 
tumour cells providing justification for the growth rates of secondary tumours (Klein, 
2009). 
Not all CTCs/DTCs have the ability to form metastases – it is unknown which 
characteristics are important and furthermore, how some cells are able to populate at 
distal sites having evaded detection by the immune system (Klein, 2009). Detection of 
‘circulating tumour microemboli’ (CTM) in blood samples from patients have suggested 
that CTCs may not always circulate as single cells but may form groups, which are more 
readily able to form metastatic lesions (Krebs et al., 2010, Vona et al., 2004). It is possible 
that there is a subset of the CTC population which have a more aggressive phenotype 
and an increased capability of forming secondary tumours leading to the conclusion that 
the number of CTCs by itself may not be the best indication of prognosis or response to 
treatment; instead the molecular characteristics of the CTCs present may be more 
informative (Sun et al., 2013). 
It is difficult to ascertain how representative the CTCs detected are of the primary tumour.  
It has been noted that there is great intra-tumoural and inter-tumoural heterogeneity and 
it may be the case that CTCs are neither reflective of the primary tumour or the metastatic 
lesion.  Advances in deep sequencing have now made it possible to identify niche cell 
populations in a heterogeneous tumour cell population that may have previously gone 
unnoticed due to amplification of larger cell populations. With the advent of microarray 
platforms, it is possible to compare the genetic profile of metastatic cells with those 
derived from primary tumours and it is possible that this can provide information to 
determine whether or not primary tumours display a metastatic phenotype (Pantel and 
Brakenhoff, 2004). A study isolated CTCs from patients with colorectal cancer (CRCa) 
using the CellSearch system and performed array-comparative genomic hybridisation 
(array-CGH) (Heitzer et al., 2013). In two patients, profiles from the primary tumour, 
circulating tumour cells and metastases were compared to a panel of 68 CRCa-
associated genes resulting in the identification of mutations that were common in the 
primary tumour and circulating tumour cell population as well as novel mutations that 
were exclusive to the CTC population (Heitzer et al., 2013). 
15 
 
1.2.2 CTCs and epithelial-mesenchymal-transition 
Epithelial-mesenchymal transition (EMT) is an embryonic process that is also thought to 
play a key role in tumour cell invasion and metastasis by epithelial cells losing their 
polarity, enabling them to migrate and survive in an extracellular environment (Mima et 
al., 2013, Thiery, 2002). Characteristically during EMT there is a down-regulation of 
factors that give the cell its epithelial phenotype such as epithelial cell adhesion molecule 
(EpCAM), E-cadherin and N-cadherin.  Concomitantly there is an up-regulation of 
mesenchymal markers such as vimentin, Twist, Slug, Snail1/2 and zinc finger E-box 
binding homeobox 1/2 (ZEB1/2). The reverse process of MET can also occur and it has 
been hypothesised that in order to metastasise from the primary site, cells may undergo 
EMT then revert back to an epithelial phenotype at the secondary site. It has been noted 
that in order for a cell to display a mesenchymal phenotype there are not always dramatic 
changes in the cell phenotype and importantly, EMT is not a requirement for cells to 
metastasise (Christiansen and Rajasekaran, 2006). The process of EMT is reliant on 
embryonic pathways; notably in HCC this includes the wnt/β-catenin pathway and 
transforming growth factor-β (TGF-β) signalling pathway (Mikulits, 2009). 
1.2.3 Clinical utility of CTCs  
In a clinical setting there are numerous potential uses of CTCs including aiding in 
diagnosis, predicting prognosis and guiding and monitoring response to therapy. In the 
first instance it has been suggested that CTC detection and characterisation in the blood 
may serve as a ‘liquid biopsy’ in which characteristics of the tumour are able to be 
identified instead of using traditional imaging methods or invasive biopsies which carry 
the risks of tumour spread and bleeding. At this stage the full clinical implications of CTCs 
remain to be determined, but retrospective studies have shown that CTC enumeration 
statistically links to clinical parameters such as prediction of progression-free survival 
(PFS) and overall-survival (OS) in breast, prostate and colorectal cancer (Cohen et al., 
2008, Cristofanilli et al., 2004, de Bono et al., 2008).  Currently, there is only one US food 
and drug administration (FDA)-approved CTC detection platform – the CellSearch – 
which has been clinically validated in metastatic breast, prostate and colorectal cancer 
(Cohen et al., 2008, Cristofanilli et al., 2004, de Bono et al., 2008).  Various other CTC 
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enrichment methods and detection platforms exist and studies have shown that CTCs 
may have clinical utility but none of these studies have been verified in large patient 
cohorts using reliable detection methods that have reached clinical validation.   
It has also been proposed that CTCs may have an impact in guiding therapy and 
measuring response to treatment. While studies have attempted to link the number of 
CTCs with response to treatment – by taking baseline CTC measurements pre- and post-
treatment, there is perhaps a wider application with regards to the characteristics of the 
CTCs that are observed.  Biomarker characterisation of CTCs may be useful in terms of: 
monitoring treatment response, determining resistance to therapy or in attempt to treat 
minimal residual disease. The use of biomarkers in the monitoring of treatment is 
however dependent on the use of a suitable technology that is able to characterise the 
CTCs with enough confidence to base a treatment decision on. It is difficult to ascertain 
a suitable threshold when basing this decision on enumeration and it is difficult to assess 
particular cases which fall on the threshold, especially if this would result in withholding 
of treatment. 
1.2.4 Methods of CTC detection 
Since interest in the area of CTC research has grown over the last decade, there has 
been a surge in the development of new CTC detection platforms and methods of CTC 
isolation and characterisation. A review by Parkinson et al., summarises 43 CTC 
technologies that have been developed or are in the process of development for 
commercial use (Parkinson et al., 2012). In the past, CTC detection has relied on either 
imaged-based technologies, fluorescent-activated cell sorting (FACS) or polymerase 
chain reaction (PCR) methods to detect circulating free DNA (cfDNA).  Only recently has 
it been achieved to combine these approaches into a single platform. Due to the rarity of 
CTCs in the peripheral blood of patients (as low as 1 cell/ 1 x 107peripheral blood 
mononucleocytes) there is a drive for platforms to be highly sensitive but there is also a 
requirement for them to be highly specific (Sleijfer et al., 2007). The ability to detect CTCs 
in such a high background of other cells usually leads to the integration of an enrichment 
technique as part of the sample processing. Methods of CTC enrichment can be 
categorised into those that are based on physical properties of the tumour cell versus 
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those that are dependent on biological properties; usually epitope characteristics.  
Alongside growing interest in the field of CTCs there has been an advent of new CTC 
detection platforms of which some of the most commonly used ones will be further 
discussed.  When considering a technology platform for the detection CTCs, there are 
certain criteria that should be considered. Currently the Veridex CellSearch system is 
referred to as the gold standard for CTC detection and is the only system that has been 
clinically validated to stratify patients into groups that are considered to have a better or 
worse prognosis; however there are still limitations to this system that are beginning to 
be addressed and overcome by the advent of new technologies. Since there is potentially 
a wide clinical utility in the detection and characterisation of CTCs, the ability to integrate 
a detection platform into a clinical setting should be considered. In a review by Parkinson 
et al., the important clinical considerations of CTC assays are discussed, including pre-
analytical variables (materials, sample collection, storage and shipping); analytic 
variables (sensitivity, specificity, reproducibility and controls); as well as post-analytical 
variables where multiple laboratories are involved in sample processing (inter-laboratory 
performance) (Parkinson et al., 2012). The numbers of variables that are involved in 
processing patient samples for CTC characterisation or enumeration are vast, 
highlighting the potential difficulties in implementing such a method clinically. 
1.2.5 The CellSearch system 
The CellSearch system is currently the only FDA-approved CTC detection technology in 
clinical use in the US for CTC detection in metastatic breast, prostate and colorectal 
cancer (Cohen et al., 2008, Cristofanilli et al., 2004, de Bono et al., 2008).  In patients 
with metastatic breast cancer, metastatic sites were assessed using imaging and CTC 
measurements in the blood were taken before commencement of subsequent therapy 
(Cristofanilli et al., 2004). A threshold of 5 or more detectable CTCs was determined to 
be a worse predictor for OS and PFS (Cristofanilli et al., 2004). Furthermore, the same 
study showed that a high baseline level of CTCs was independently associated with 
worse OS (Cristofanilli et al., 2004). 
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The CellSearch processes 7.5 ml blood samples for the presence of CTCs defined by 
the expression of EpCAM, cytokeratin (CK) 4',6-diamidino-2-phenylindole (DAPI) and 
absence of haematopoietic marker common leucocyte antigen (CD45).  Blood collected 
in CellSave tubes containing a preservative can be kept at room temperature (RT) for 96 
h.  This method utilises an automated CellTracks system whereby CK and EpCAM-
positive cells are magnetically retained.  Captured cells are permeabilised and 
fluorescently labelled enabling visualisation and enumeration using a CellTracks 
Analyser II (Janssen Diagnostics, 2016). 
Although the CellSearch is the only CTC technology that has been implemented in a 
clinical setting - along with other CTC platforms available - it still has limitations. Firstly, 
the detection of CTCs is based on the criteria of the tumour cell being of epithelial origin 
and therefore does not address the problem of a heterogeneous CTC population. Since 
it has been hypothesised that cells metastasize by undergoing EMT, it is possible that 
they lose their epithelial phenotype and resort to a cell that would be more readily 
detected if a panel of mesenchymal markers was included in the positive selection. The 
CellSearch CTC isolation and detection technology was subject to extensive validation 
experiments to assess recovery; precision; intra-user, inter-user and inter-laboratory 
reproducibility; and the detection of CTCs in control groups.  (Allard et al., 2004) 
1.2.6 The Imagestream as a CTC detection platform 
The Imagestream combines FACS with high resolution fluorescent, brightfield and 
darkfield microscopy; combining the speed and information produced by FACS with the 
detail and characterisation ability of microscopy. One of the major advantages of this 
technology is that whilst many other CTC platforms tend to rely on epithelial markers 
such as EpCAM or CK, the Imagestream has the ability to detect up to 10 different 
proteins of interest, providing they are structurally and spectrally different. It also has the 
additional feature extended depth of field (EDF) which enhances its use for applications 
such as fluorescent in situ hybridisation (FISH) or the counting of foci. The IDEAS 
software (Amnis, Seattle) has been specifically designed to complement the 
Imagestream technology. The system incorporates a virtual cell sorting feature which 
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enables the tracking of individual cells within populations and also has the ability to 
analyse the cells based on multiple features (Basiji et al., 2007). 
A cell suspension is passed into a flow cell and focussed into a core through a sheath 
fluid which acts to separate out the cells and provide a clear background for imaging. 
Cells are illuminated by 5 excitation lasers which sit behind an LED array enabling 
brightfield imaging. Darkfield imaging is produced by an infra-red laser. Selected probes 
are detected by excitation with 5 different lasers (405 nm; 488 nm; 561 nm; 642nm and 
785 nm). Three objectives are available for use (x20, x40, x60) which are used to collect 
light which is then passed through two arrays of dichroic mirrors – each set reflecting 
light of different bandwidths and producing 6 separate images, giving a total of 12 images 
per cell which are captured by a 12-bit charge coupled device (CCD) camera. 
A comparison of the CellSearch system versus the Imagestream was conducted on the 
basis of CTC enumeration in spiking experiments (Lopez-Riquelme et al., 2013). The 
study concluded that both technologies were similar in terms of their performance of 
enumeration although the Imagestream was not as precise at detecting CTCs when in 
low numbers (1 or 10 CTCs) (Lopez-Riquelme et al., 2013). It is however important to 
note that this was not a direct comparison since the processing of the two samples relied 
on two different enrichment techniques: the CellTracks system was used for the 
CellSearch technology whereas EpCAM magnetic beads (MACS) were used prior to 
sample processing using the Imagestream. Furthermore different pan-CK antibodies 
were used for the two different technologies; suggesting that slight differences in CTC 
detection may not be as a result of the technologies but due to slight variations in the 
methods that were used during the processing of the sample. 
While there is only one limited study comparing the Imagestream and the CellSearch 
system, the comparative advantages of each of the systems have been summarised 
below Table 1.3.  CTC detection platforms should enable the characterisation of CTCs; 
based on cell morphology and biomarker expression.  High resolution brightfield images 
that can be obtained using the Imagestream permit this – allowing 60x magnification 
whereas the CellSearch only enables 20x.  As part of the characterisation of CTCs, the 
desired features of a CTC detection platform should include the freedom of the user to 
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implement biomarkers of interest to the cancer type or study.  It is possible to implement 
biomarkers of interest into an assay design for the Imagestream, but currently the 
CellSearch is limited to epithelial biomarkers.  Ideally the CTC detection platform should 
be highly sensitive and specific but also be practicable – enabling samples to be 
processed quickly.  Only the CellSearch is currently FDA-approved; having undergone 
rigorous validation.      
Optimal features CellSearch Imagestream 
Independent of 
epithelial biomarkers 
Dependent on EpCAM and CK User may select antibodies of 
choice 
Characterisation of 
cells 
CTCs defined as 
EpCAM+ve/CK+ve/CD45-ve 
and nucleated 
Interrogation of up to 10 cancer-
specific biomarkers 
Sensitive Able to detect ≥1 CTC/ 7.5 ml of 
blood 
Able to detect ≥1 CTC/ 8 ml of 
blood 
Specific Baseline levels of CTCs defined 
for different types of cancer.  
Biomarkers identify cells of 
epithelial origin 
Able to implement cancer-
specific biomarkers 
Fast Processing time ~24 h Processing time ~4 h with 
enrichment 
Clinically validated FDA-approved Not yet clinically validated 
High resolution 
images 
Magnification x20 available Magnification x60 available 
Table 1.3 Comparison of the Imagestream and CellSearch with the desired features of a 
CTC detection platform. 
1.2.7 Alternative CTC isolation methods 
One limitation with the detection of CTCs in the peripheral blood of patients is the volume 
of blood that is processed in many of the assays that have been developed. Despite the 
CellSearch system showing that there is a link between the number of CTCs detected 
and prognosis, there will always be a question of how representative a small aliquot of 
blood is of blood-borne metastasis and the metastatic process as a whole. Whereas 
most of the assays developed use 5-10 ml of blood, one such detection device – the 
GILUPI nanodetector – uses an in vitro approach to analyse the equivalent of 
1500-3000 ml of blood (Saucedo-Zeni et al., 2012). The device consists of a gold-coated 
wire that is covered in a hydrogel coated with the anti-EpCAM antibody (Saucedo-Zeni 
et al., 2012). The device is inserted into a peripheral vein in the arm using a cannula and 
it is then left in situ for 30 min. CTCs are defined on the basis of CK positivity, CD45 
negativity and nuclear staining (Hoeschst) (Saucedo-Zeni et al., 2012).  Although this 
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technique may be considered to be more invasive, it is claimed to provide a similar level 
of discomfort to a regular blood draw. A limiting factor to this technique is that it relies on 
the capture of EpCAM-positive CTCs and would require clinical facilities for patients to 
undergo the procedure.  
Another technique that has been proposed in order to evaluate a higher percentage of 
the patient’s blood is to use the process of apheresis which entails processing 150 ml of 
buffy coat (an 8 ml blood sample usually yields ~1 ml of buffy coat) by filtering the blood 
of a patient and isolating the layer using density gradient centrifugation (Fischer et al., 
2013). Although this method will result in an increased CTC yield, the clinical feasibility 
of such a method is questionable (Fischer et al., 2013). 
To address the issue of having a method available to identify CTCs that is easily 
implemented in a clinical setting, several attempts have been made to create a CTC chip 
with the aim of producing a ‘liquid biopsy’. One example is the microfluidic herringbone 
chip (HB-chip) which processes a 4 ml blood sample at rate of 1.5-2.5 ml/hour by 
subjecting it to a number of micro-vortices resulting in EpCAM-expressing cells being 
captured on a series of microposts (Stott et al., 2010). This chip has been used to test 
for the isolation of CTCs from patient with prostate cancer, after which cells were fixed 
and stained with prostate-specific antigen (PSA), CK and CD45 (Stott et al., 2010). 
The dielectrophoresis (DEP) array (Silicon Biosystems) is another example of a 
microfluidic chip-based technique although it also combines the ability to image and 
isolate cells (Gascoyne et al., 2009, Gascoyne and Shim, 2014). The DEParray exerts 
dielectrophoretic forces around polarisable cells to form a ’cage’. Cells can be identified 
and imaged based on morphology or fluorescent markers. By altering the magnetic field, 
the cages can be moved by creating a magnetic field over a set of electrodes, enabling 
the isolation of single, viable cells (Gascoyne and Shim, 2014). 
Vona and colleagues developed an assay that enables the separation of CTCs based 
on isolation of epithelial cells by size (ISET) (Vona et al., 2000). This process relies on 
passing whole blood through a set of filters that have 8 µm pores under a gentle vacuum. 
Filters can then be washed and collected cells can be analysed using 
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immunofluorescence, FISH and PCR following laser microdissection (Vona et al., 2000).  
Another CTC detection method that isolates CTCs on the basis of size is the Parsortix 
(Angle PLC, UK) (Parsortix PLC, 2016).  The Parsortix is an automated, microfluidic 
device that captures CTCs based on the assumptions that CTCs are larger in size and 
less deformable in nature than haematopoietic cells (Parsortix PLC, 2016).   
Another method of CTC isolation based on size is that of the micro- electro-mechanical 
system (MEMS). This consists of a polycarbonate filter that has pores etched into the 
surface at random intervals to capture cells that can then be lysed and assessed using 
PCR (Zheng et al., 2007).  Size-based isolation methods are limited by the assumption 
that CTCs are notably larger than white blood cells (WBCs). Differences in size of CTCs 
compared to WBCs is one of the parameters that FACs relies on and methods of CTC 
isolation have been developed on this premise; however due to the heterogeneity of 
CTCs, there remains a possibility that the size of CTCs is similar to that of WBCs (Vona 
et al., 2000). Furthermore, size filtration methods may be limited in terms of recovery due 
to the blocking of pores by the agglutination of WBCs. 
1.2.8 CTCs in HCC 
So far there have been a limited number of studies into the presence of CTCs in HCC 
Table 1.4. In HCC, patients often present at an advanced stage at which point treatment 
options are limited.  There may be a role for CTCs in in the earlier diagnosis of HCC; 
perhaps as a surveillance tool in patients with cirrhosis, if such a test that was 
inexpensive and sensitive could be developed. Currently the use of biomarkers used to 
monitor or stratify patients for treatment is limited to the use of AFP in combination with 
additional clinical parameters.  In the UK, AFP is used as a stratification biomarker for 
patients in the assessment procedure for liver transplant.  Serum AFP >1000 IU/ml is 
considered an absolute contra-indication for liver transplant in HCC patients in the UK 
due to the associated recurrence risk as outlined in research published by Duvoux and 
colleagues in France (Duvoux et al., 2012, Powell, 2014).  Conversely, improved OS was 
observed in patients with elevated serum AFP levels (≥400 ng/ml or 1.5 times upper 
normal limit) in the REACH trial (Zhu et al., 2015).  This was a phase III study of the use 
of ramucirumab versus a placebo in patients with advanced hepatocellular cancer as a 
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second line treatment to sorafenib (trial identifier: NCT01140347) (Zhu et al., 2015).  The 
lack of clinical biomarkers in HCC indicates that validating HCC-specific CTC biomarkers 
could have a role in this context.  
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Method Observations 
CellSearch vs ISET (Morris et al., 
2014) 
Compared use of the CellSearch with the ISET for CTC detection 
Recovery rates were 28% (14/50) using the CellSearch and 100% (19/19) using the ISET 
GPC3 IHC was performed following CTC isolation with the ISET and compared to primary tumour biopsies 
18/19 of the ISET samples had paired samples that were tested using the CellSearch system.  Only 6/18 of these 
paired samples contained ≥1 CTC per 7.5 ml using the CellSearch system compared to 100% using the ISET 
technology. 
CellSearch (Schulze et al., 2013) CTCs were detected using EpCAM and CK-dependent CellSearch technology 
≥1 CTCs were detected in 18/59 (30.5%) of HCC patient samples and 1/19 of the control group 
OS was shorter in the CTC-positive cohort (460 vs 746 days, p = 0.017) 
CTC number also increased with BCLC stage and AFP (>400 ng/mL)  
ISET (Vona et al., 2004) Microemboli were observed in 23/44 patients 
Presence correlated with raised AFP, diffuse tumours and PVT 
No association between tumour size or the number of nodules and number of CTCs 
Single CTCs were assessed for the presence of β-catenin mutations which were observed in 3/60 samples 
RT-PCR (Wong et al., 1999) AFP and albumin mRNA levels measured in 13 HCC patients compared to healthy control, patients with cirrhosis 
and spiked samples 
Determined  that  albumin-expressing  cells  were  released  intra-operatively whereas AFP-expressing cells were 
disseminated post-operatively 
Patients with consistently high AFP post-operatively   died within 1 year following surgery 
Positive magnetic selection based 
on asiaglycoprotein  receptor  
expression (Xu et al., 2011) 
Detection of circulating hepatocytes based on asiaglycoprotein expression 
Reported a minimum recovery rate of 61% based on spiking experiments using between 10 and 810 Hep3B cells 
Analysed isolated cells using immunofluorescence and FISH 
Reported the presence of CTCs in >80% of HCC patients tested and none were detected in healthy volunteers 
or patients with benign liver disease 
Table 1.4 Summary of CTC studies in HCC. ISET=isolation by size of epithelial cell; CTC=circulating tumour cell; GPC3=glypican-3; 
IHC=immunohistochemistry; CK=cytokeratin; OS=overall survival; BCLC=Barcelona Clinic for Liver Cancer; AFP=alphafetoprotein; mRNA=messenger 
ribonucleic acid; RT-PCR=reverse transcriptase PCR; FISH=fluorescent in situ hybridisation 
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1.2.9 Circulating tumour DNA 
In addition to investigations into the role of CTCs, studies into circulating free nucleic 
acids (cfDNA/cfRNA) also termed circulating tumour DNA (ctDNA) have been carried out 
in attempt to determine if the blood can be used as an indicator of tumour burden and in 
attempt to decipher the process of metastasis.  ctDNA is DNA circulating in the peripheral 
bloodstream that is thought to be derived from the primary tumour.  Initially this was 
based on the observation that levels of ctDNA are increased in individuals with cancer 
compared to healthy volunteers (Leon et al., 1977).   
Many methods to detect ctDNA are heavily reliant on PCR.  Although PCR-based 
methods are highly sensitive and relatively inexpensive, initial methods were not always 
highly specific and are subject to contamination by leucocytes (Smirnov et al., 2005, 
Vona et al., 2000).  Such methods were also dependent on there being no circulating 
DNA from normal tissues although in order to compensate for this, many studies include 
a control group and looked at differences above the threshold of the control group.  
Improved PCR-based technologies such as allele-specific PCR and mutation-specific 
PCR improve the reliability of such methods.  Specificity can be improved by 
investigating characteristics consistent with that of tumour DNA such as mutations in 
oncogenes, tumour-suppressor genes, allelic gain or loss and strand instability (Anker et 
al., 1999).   
In HCC, a study carried out by Wong and colleagues demonstrated that p16 methylation 
status could be detected in tumour tissues from 16/22 patients (73%) and out of those 
patients 13/16 (81%) had p16 methylation detected in their serum/plasma (Wong et al., 
1999).  A more recent study of 142 plasma samples from patients with HCC, cirrhosis or 
chronic viral hepatitis quantified ctDNA using PCR to amplify the human telomerase 
reverse transcriptase (hTERT) concluded that although the concentration of ctDNA may 
not be useful as a HCC diagnostic biomarker, however in viral HCC it may be a useful 
prognostic indicator (Piciocchi et al., 2013).  The concentration of ctDNA increased in 
patients with multinodular HCC (>3 nodules) and tumour size (p=0.002) and hTERT 
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levels (p=0.02) were independent predictors of prognosis although there were no 
significant associations between ctDNA and age, sex, AFP, tumour grading or Child-
Pugh score (Piciocchi et al., 2013).   
One of the disadvantages of detecting ctDNA as opposed to CTCs is that the origin of 
the ctDNA cannot be determined.  Although without the use of a viability marker in CTCs 
it cannot be determined whether or not the cells are capable of forming extra-hepatic 
metastases, however by detecting ctDNA it cannot be known whether the DNA detected 
is due to the presence in cells, or whether it is an artefact from cells that have undergone 
cell death.  There still remains a difficulty in detecting low amounts of mutant DNA 
amongst a high background of wild type (wt) DNA.  Furthermore they do not enable 
conclusions about cell morphology to be made (Vona et al., 2000).  A recent study by 
Bettegowda and colleagues demonstrated that ctDNA was detected in cases where 
CTCs were not detected implying that ctDNA and CTCs are separate entities 
(Bettegowda et al., 2014). 
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1.3 HCC biomarkers  
Biomarkers are defined as “objectively measured indicators of biological processes or 
response to a therapeutic intervention.” (Firestein, 2006).  As stated previously, there is 
no single biomarker that can be used for prognosis in HCC.  The EASL-EORTC 
guidelines state that in order for a biomarker to be implemented into the clinical 
management of HCC it should “(1) demonstrate prognostic prediction in properly 
powered randomised studies or in training and validation sets from cohort studies; (2) 
demonstrate independent prognostic value in multivariate analysis, including known 
clinic-pathological predictive variables; and (3) demonstrate confirmation of results using 
the same technology in an external cohort reported by independent investigators.” 
(Simon et al., 2009, EASL-EORTC, 2012). 
Current methods of CTC identification tend to rely on the definition that a CTC derived 
from an epithelial tumour will be nucleated and express epithelial markers – commonly 
EpCAM and cytokeratin in addition to being negative for the haematopoietic marker 
CD45.  Some studies also include morphological characteristics of the cell as an 
important determinant of the CTC definition – for example size - however it has been 
noted that there is great heterogeneity within the morphological characteristics of CTCs.  
In order to positively differentiate CTCs from other circulating cells – for example 
circulating endothelial cells (CECs), there is a requirement to include markers that are 
sensitive and specific to hepatocellular carcinoma. Currently there is no single marker 
that is able to positively identify all cases of HCC. Whilst AFP remains to be the most 
widely clinically used serum biomarker, not all HCCs are AFP positive and serum 
elevation of AFP is also indicative of benign inflammatory liver conditions or during liver 
repair. 
In order to detect CTCs in patients with HCC with a confident degree of sensitivity and 
specificity it is likely that a panel of biomarkers will need to be used.  In this research, the 
expression on CTCs of a combination of markers was investigated.  This included the 
epithelial biomarkers EpCAM and CK; the clinically implemented HCC biomarker AFP 
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and several exploratory biomarkers that may be used to guide therapy including: 
glypican-3 (GPC3), sulfatase 2 (SULF2) and DNA-dependent protein kinase (DNA-PK).  
The common leucocyte antigen CD45 was used to distinguish WBCs from CTCs. 
1.3.1 Cytokeratin 
CKs are intermediate filaments that are considered to have a regulatory role in cell 
migration and invasion (Barak et al., 2004, Ding et al., 2004). There are over 20 different 
CKs, although 8, 18, and 19 are the most commonly expressed in epithelial cells (Barak 
et al., 2004). The expression of CK is retained in malignant cells, making them a choice 
candidate for the recognition of tumour cells (Barak et al., 2004). Cytokeratins have been 
used as a serum biomarker in patients with epithelial cancers. In the field of CTCs, CKs 
are commonly used to form part of the CTC definition for epithelial neoplasms. In HCC 
the expression of CK-7 and -19 may be expressed in hepatic progenitor cells and 
cholangiocytes but not in normal hepatocytes (Durnez et al., 2006). Furthermore, the 
expression of CK-19 correlated with raised serum AFP and a higher rate of recurrence 
following transplantation (Durnez et al., 2006).  CK-19 was initially used to differentiate 
between HCC and cholangiocarcinoma (Balaton et al., 1988). Ding and colleagues 
reported increased protein expression of CK-19 in HCC cell lines with higher metastatic 
potential and in patient samples using immunohistochemistry (IHC) (Ding et al., 2004).  
CK-19 expression was associated with more poorly-differentiated tumours and has been 
reported as being indicative of poor prognosis in HCC; arising as a result of expression 
of progenitor cell features or a mixed hepatocellularcholangio phenotype (Ding et al., 
2004, Roskams, 2006, Razumilava and Gores, 2013). 
1.3.2 EpCAM 
EpCAM is a 40 kDa single-pass type I membrane protein encoded by the TACSTD1 
gene (Yamashita et al., 2007). It is classed as a hepatic stem cell marker that is 
expressed on the majority of hepatocytes in embryonic liver and it a direct transcriptional 
target of the wnt/β-catenin pathway (Yamashita et al., 2007). EpCAM is expressed in the 
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majority of neoplasms that are of epithelial origin; though in HCC this overexpression is 
mirrored by elevated serum levels which are detected in 60-70% of patients (Balzar et 
al., 1999, Yamashita et al., 2008). 
There is conflicting evidence for the utility of EpCAM as a biomarker in many different 
types of cancer and this extends to its role in HCC. Mature hepatocytes do not express 
EpCAM although its expression is highly elevated in pre-malignant hepatic tissues and 
a subset of HCC (Yamashita et al., 2007).  A study carried out by Gorges et al., who 
performed spiking experiments using the AdnaTest – an EpCAM –positive selection 
technique - alongside gene expression of CTCs to look at changes during EMT noted 
that EpCAM expression was downregulated (Gorges et al., 2012). 
It has been proposed that EpCAM-positive cells may represent a more phenotypically 
aggressive proportion of the CTC population. Yamashita and colleagues categorised 
HCC cases into four sub-types based on the expression of EpCAM and AFP. Results of 
a HCC cDNA microarray, oligonucleotide microarray and IHC were analysed to explore 
the differential expression of genes between the groups of HCC based on EpCAM and 
AFP expression (Yamashita et al., 2008). In total there were 71 differentially expressed 
genes between EpCAM-negative and EpCAM- positive cases of HCC. Furthermore each 
of the four categories displayed a different pattern of gene expression which correlated 
to that of hepatic cell lineages: EpCAM-positive cases of HCC displayed a unique 
molecular signature consistent with hepatic progenitor cells whereas the genetic profile 
of EpCAM-negative HCC cases was similar to that of mature hepatocytes (Yamashita et 
al., 2008). The same research group went on to further characterise the subtypes of HCC 
cells based on their AFP and EpCAM expression; concluding that EpCAM and AFP 
positive cells had a hepatic stem/progenitor cell phenotype with activated wnt/β-catenin 
signalling  (Yamashita et al., 2009).  These  cells  had  increased  tumour  initiating  
capabilities determined by the results of subcutaneous injection of EpCAM positive cells 
in a non-obese severe combined immunodeficient (NOD/SCID) mouse model in 
comparison to EpCAM negative cells (Yamashita et al., 2009). Consistent with this data 
are results of a study carried out by Sun and colleagues who injected EpCAM-positive 
and EpCAM-negative cells into two different groups of NOD/SCID mice (Sun et al., 
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2013). The same study also investigated the prognostic relevance of the detection of 
EpCAM positive cells in the blood of patients both pre- operatively and post-operatively. 
This was carried out using the CellSearch system (Veridex) on three groups of patients 
that were classified as healthy individuals (n=10); patients with benign liver disease (n=5) 
and patients with HCC (n=123) (Sun et al., 2013). The study concluded that a pre-
operative measurement of ≥2 EpCAM positive CTCs was indicative of tumour 
recurrence, even in cases of HCC where AFP levels were ≤400 ng/ml (Sun et al., 2013). 
1.3.3 AFP 
AFP is a glycoprotein that is first produced in the yolk sac and expressed in the 
embryonic liver (Arrieta et al., 2007).  Post-natal production of AFP decreases rapidly 
and AFP expression is not a normal characteristic of adult liver. AFP is detected normally 
in the serum of healthy individuals at a level of ≤20 ng/ml although this varies slightly 
between different ethnicities (Zhou et al., 2006).  AFP elevation (>20 ng/ml) is associated 
with the onset of HCC and is currently the most widely used clinical marker. However 
AFP elevation cannot be used singly as a diagnostic marker of HCC due to serum levels 
above the normal range also being indicative of CLD such as infection with HCV which 
is considered to be a pre-malignant condition. It is generally estimated that AFP elevation 
occurs in approximately 50-70% of cases of HCC and it has been suggested that AFP 
levels are representative of tumour burden, though some reports in the literature quote 
the incidence of elevated AFP in HCC is even higher than this (Johnson, 1999, Kawai et 
al., 2001, Zhou et al., 2006). Measurement of serum AFP has been used to monitor 
response to treatment (Johnson, 1999). Studies have shown that dramatically elevated 
AFP pre-treatment is predicative of prognostic outcome in patients receiving a liver 
transplant or TACE treatment (Yokoo et al., 2004, Samad et al., 2012, Wang et al., 
2012b).  Yokoo and colleagues showed the protein expression of AFP in 11 liver cancer 
cell lines (Huh-1 and -7; JHH-7 and -5; HepG2; HT17; Hep3B; Li-7; PLC/PRL/5; KIM-1; 
KYN-2) (Yokoo et al., 2004).  
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cDNA microarray analysis of 5 hepatoma cell lines (PLC/PRF/5HepG2, Hep3B, Huh-7 
and -6,) showed that AFP-producing cell lines have a shared genetic profile but more 
specifically, cell lines with higher AFP expression (HepG2, Hep3B and Huh7) are more 
closely associated in terms of the expression of sub-sets of oncogenes and genes that 
are associated with apoptosis, cell-cell interaction and cell cycle (Kawai et al., 2001). A 
limitation with the use of AFP as a biomarker is that it is often only expressed in the later 
stages of HCC and in some cases it is not expressed during any stage of the disease 
course, indicating that from a diagnostic aspect its detection is of limited value (Lopez, 
2005). 
1.3.4 Glypican-3 (GPC3) 
Located at Xq26, the GPC3 gene encodes a phosphatidylinositol-anchored plasma-
membrane heparan sulfate proteoglycan (HSPG) that exists in four isoforms of which 
isoform 2 is the most commonly expressed (Ho, 2011). GPC3 is expressed in foetal liver 
tissue but repressed following DNA methylation in adults (Sakamoto et al., 2010). 
HSPGs mediate and modulate signalling with growth factors and chemokines such as 
IGF-2 and Wnt complexes; regulating proliferation and cell survival (Suzuki et al., 2010, 
Ho, 2011, Yao et al., 2011). The roles of GPC3 on the proliferation and invasive potential 
of cells appears to vary depending on expression levels (Ho, 2011, Kwack et al., 2006). 
Microarray data has shown levels of GPC3 mRNA are significantly increased in patients 
with HCC compared to healthy controls or patients with CLD (Zhu et al., 2001). 
Furthermore, it has been identified that GPC3 mRNA levels are higher in HCC cases 
that are considered to be more successfully resected and have a less aggressive tumour 
phenotype compared to tumours exhibiting the opposite properties (Zhu et al., 2001).  
The use of GPC3 as a diagnostic serum marker has been investigated concluding that 
the serum concentration of GPC3 is not correlated with AFP serum concentration and 
that the use of both markers may increase the sensitivity of diagnostic testing using HCC 
tumour markers in the blood of patients (Capurro and Filmus, 2005, Nakatsura et al., 
2003). However a limitation associated with use of GPC3 as a diagnostic marker is that 
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despite being highly specific, sensitivity is low (40%), detecting GPC3 in only 16/40 of 
HCC patients (Nakatsura et al., 2003). 
Overexpression of GPC3 in HCC has suggested its potential as a therapeutic target, 
leading to the development of a humanised monoclonal antibody against GPC3 (GC33) 
(Zhu et al., 2013). Phase II clinical trials have recently been completed for the use of 
GC33 concluding that it is well tolerated (Zhu et al., 2013). 
1.3.5 Sulfatase 2 (SULF2) 
Sulfatase 1 (SULF1) and sulfatase 2 (SULF2) are cell-surface secreted endosulfatases 
that catalyse the 6-O desulfation of HSPGs (Lai et al., 2010, Rosen and Lemjabbar-
Alaoui, 2010). Functioning as a tumour suppressor, SULF1 has opposing activity to 
SULF2 due to the abrogation and activation of fibroblast growth factor (FGF) signalling 
pathways respectively (Lai et al., 2010, Yang et al., 2011). SULF2 exerts an oncogenic 
effect in HCC: increasing cell growth and migration in vitro as well as Hep3B SULF2 
over-expressing cells increasing tumour grow in xenografts in mice (Lai et al., 2010).  
Desulfation of HSPGs (e.g. GPC3) releases growth factors, increasing their availability 
to receptors, resulting in the activation of downstream signalling pathways including FGF 
and Wnt/frizzled/β-catenin (Lai et al., 2010). SULF2 expression is increased in 
approximately 60% of HCCs and has been shown to up-regulate GPC3 at the protein 
level. In 11 HCC cells lines, 8 positively expressed SULF2 (HepG2, Huh-7, SkHep1, 
SNU182, SNU387, SNU423, SNU449 and SNU475) and immunocytochemistry revealed 
that SULF2 co-localises with GPC3 (Lai et al., 2010). Furthermore, knockdown of GPC3 
led to a decrease in FGF2 binding suggesting it plays an important role mediating 
signalling through FGF-activated pathways (Lai et al., 2010). Clinically high SULF2 
mRNA expression correlated with worse OS and PFS (Lai et al., 2010). 
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1.3.6 DNA-PK 
DNA protein kinase (DNA-PK) is a protein kinase involved in non-homologous end 
joining (NHEJ) of lethal DNA double strand breaks (DSBs) (Collis et al., 2005).  The 
catalytic subunit of DNA-PK (DNA-PKcs) is recruited to the site of a DSB and activated 
by autophosphorylation following recognition and binding of the Ku70/80 heterodimer to 
the broken DNA strands (Chan et al., 2002, Collis et al., 2005). The nuclease Artemis is 
also recruited and the DNA-PK complex is able to align the strands of DNA which are 
then joined back together through the DNA ligase IV/ X-ray cross complementation group 
4 protein (XRCC4) complex (Collis et al., 2005).   
Deregulation of DNA-PK has been identified in multiple solid tumours including colorectal 
cancer (Hosoi et al., 2004), gastric cancer (Lee et al., 2005) and haematological cancers 
including acute lymphoblastic leukaemia (ALL) and chronic lymphoblastic leukaemia 
(CLL) (Holgersson et al., 2004, Willmore et al., 2008) as well as others.  It was 
hypothesised that inhibition of DNA-PK may result in sensitisation of cells to ionising 
radiation since cells would be unable to repair DNA DSBs via the NHEJ pathway. 
In HCC, total DNA-PK and DNA-PKcs expression and activity was increased in tumour 
tissue from patients undergoing surgical resection compared to surrounding liver and 
normal liver tissue (Evert et al., 2013).  Patients undergoing partial hepatectomy 
surviving less than 3 years had higher levels of DNA-PK protein expression and activity 
compared to those surviving more than 3 years (Evert et al., 2013). 
Previous work in Newcastle, carried out by Cornell and colleagues, further explored the 
role of DNA-PK in HCC (Cornell et al., 2015).  Increased DNA-PK copy number and 
protein expression levels were reported in association with advanced HCC stage. 
Inhibition using a selective inhibitor of DNA-PK (NU7441) potentiated ionising radiation 
and chemosensitised HCC in cell line and murine models (Cornell et al., 2015).  DNA-
PK expression levels assessed using IHC in HCC patient tissue biopsies suggested that 
it may be an independent predictor of response to TACE, with patients with low DNA-PK 
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expression in tissue biopsy samples having a longer time to progression (TTP) 
(16.9 months vs 4.5 months) and a longer median survival (35 months vs 9.9 months) 
(Cornell et al., 2015).  This data suggests DNA-PK may be a useful biomarker to stratify 
HCC patients for treatment with TACE (Cornell et al., 2015).   
1.3.7 c-Met 
c-Met – mesenchymal epithelial transition factor - is a receptor tyrosine kinase that binds 
its ligand the hepatocyte growth factor (HGF) which is secreted by stellate cells leading 
to activation of multiple signalling pathways (Llovet and Bruix, 2008).  Such signalling 
pathways include PI3K-Akt, ERK/MAPK, Crk/Rap and Rac/Pak (Birchmeier et al., 2003).  
Under normal physiological circumstances, HGF and c-Met are required for embryonic 
viability, normal liver formation and regeneration in response to injury (Bladt et al., 1995, 
Schmidt et al., 1995).  In cancer, altered MET activity as a result of mutations or 
overexpression have been associated with increased tumour growth, evasion of 
apoptosis, angiogenesis and metastasis, contributing to a poorer prognosis (Farazi and 
DePinho, 2006, Migliore and Giordano, 2008, Organ and Tsao, 2011, Wang et al., 2001). 
In HCC functional genomic cluster analysis demonstrated that aberrant c-MET activity 
was associated with a poor prognosis and indicative of an aggressive phenotype 
(Kaposi-Novak et al., 2006).  In a tetracycline-inducible Met transgenic mouse model, it 
was found that Met was activated by cell adherence in a ligand-independent fashion, 
leading to the development of liver tumours in mice that regressed following inactivation 
of the MET transgene (Wang et al., 2001).  Another study showed that binding of HGF 
to Met leads to phosphorylation of beta-catenin leading to its activation and translocation 
to the nucleus in hepatocytes (Monga et al., 2002).   
Due to the downstream effects of HGF/c-Met binding and its overexpression in cancers 
- including HCC, attempts have been made for the therapeutic targeting in cancer using 
monoclonal antibodies against HGF/c-Met, selective c-Met tyrosine kinase inhibitors 
(TKIs) and multi-TKIs (Goyal et al., 2013, Matsumoto et al., 2008, Migliore and Giordano, 
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2008, Santoro et al., 2013b, Wang et al., 2001).  In a study of 21 HCC patients with HCC 
staged as BCLC B/C and Eastern cooperative oncology group (ECOG) performance 
status 0-1, a phase 1b trial of tivantinib (ARQ197) was designed (Santoro et al., 2013b).  
Tivantinib is a selective competitive inhibitor of c-Met that had been trialled in other 
cancers, though it was not known whether or not the drug would further impair liver 
function in patients with HCC (Santoro et al., 2013b).  Initial studies showed that   there 
was no drug-related worsening of liver function leading to further trialling of tivantinib in 
a randomised control trial (RCT).  Although there was no significant differences in 
outcome  between the two groups of randomised patients,  a subanalysis suggested that 
in patients with high tumour Met expression, tivantinib resulted in a longer TTP compared 
to those receiving a placebo (2.7 months vs 1.4 months) (Santoro et al., 2013a).  The 
study similarly suggested Met levels predicted a response to tivantinib in terms of OS 
(p=0.039) and that Met was an independent prognostic factor for previously treated 
patients with HCC (Santoro et al., 2013a).  The use of tivantinib in patients with high 
tumour MET expression - determined by IHC - showed promising results in phase 2 RCT 
studies (Giordano and Columbano, 2014, Rimassa et al., 2015). 
1.3.8 pERK as a surrogate marker of activation of the Ras/Raf/MAPK pathway 
Evidence of aberrant Ras/ERK activity as a result of upregulation, genomic amplification 
or methylation of constituents of the pathway has been identified in HCC (Llovet and 
Bruix, 2008, Newell et al., 2009).  Phosphorylated ERK (pERK) can be used as a 
surrogate marker for the activation of the Ras/Raf/MAPK pathway since pERK leads to 
the activation of transcription factors responsible for genes involved in the regulation of 
proliferation and survival (Newell et al., 2009).  In HCC compared to non-tumour tissue 
there was decreased sprout-related protein with Ena/vasodilator-stimulated 
phosphoprotein homology-1 domain (Spred) which is a physiological inhibitor of 
Ras/Raf-1/ERK pathway (Yoshida et al., 2006).  Overexpression of ERK has been 
associated with disease progression in HCC (Ito et al., 1998).  Furthermore, Spred 
expression inversely correlated with invasion and metastasis indicating that inhibition of 
the Ras/Raf-1/ERK pathway may be a potential therapeutic target in HCC (Yoshida et 
al., 2006).   
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Previous studies within the hepatology research group at Newcastle have indicated 
increased activation of the RAS signalling pathway in a murine model of carcinogenesis.  
A C3H/He murine model fed the American lifestyle diet (ALIOS) was shown to have an 
increased mean number of tumours compared to the DEN control group as well as 
developing histopathological features of steatohepatitic-HCC (SH-HCC) at 1 year 
including: microvesicular steatosis, ballooning and inflammation of hepatocytes 
(Whitehead et al., 2015).  Additionally, there was increased expression of AFP, GPC3, 
neighbour of punc-E11 (NOPE), inducible nitric oxide synthase (iNOS) and tumour 
necrosis factor α (TNFα) at the mRNA level in liver tumours compared to normal liver 
tissue; indicating that this murine model could be a promising animal model for the study 
of human MetS associated HCC.  Initial exploration into rat sarcoma viral oncogene 
homolog (RAS) pathway activation in this murine model was carried out.  There was 
increased expression of pERK in tumour tissue compared to non-tumour tissue at the 
protein level assessed by Western analysis and measured using densitometry (99.8 ± 
26.0 compared to 5.5 ± 0.6, p=0.004) (Whitehead et al., 2015).  Furthermore, HRAS 
mutations at codon 61 were found to be present in 5/20 (25%) of mice confirmed by 
sequencing (Whitehead et al., 2015).   
Results demonstrating increased activation of the RAS signalling pathway led to the 
hypothesis that RAS signalling may also be activated in human MetS-associated HCC.  
Paraffin-embedded needle biopsies from 20 HCC patients were assessed for pERK 
expression using IHC.  Expression was digitally quantified using an algorithm developed 
using Aperio Imagescope.  Minimal expression was defined as <5% tumour nuclei 
positive for pERK, excess as >50% pERK positive nuclei.  3/20 (15%) MetS-HCC 
patients had minimal pERK expression, 11/20 (55%) had moderate expression and 6/20 
(30%) had excess expression (Whitehead et al., 2015). 
Refametinib (BAY86-9766), a MEK1/2 inhibitor is currently in clinical trials (trial identifier: 
NCT01915589) for the treatment of HCC patients with unresectable or metastatic 
disease with a known KRAS or NRAS mutation confirmed by a beads, emulsification, 
amplification, and magnetic technology, sensitive mutation detection (BEAMing) plasma 
test (Schmieder et al., 2013). 
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1.3.9 Common leucocyte antigen - CD45 
The inclusion of a haematopoietic marker enables differentiation between cells of interest 
and WBCs. Often CD45 is used to negatively select for CTCs in a sample through the 
means of WBC depletion. Similar to the method for positive EpCAM selection, antibodies 
against CD45 are conjugated to magnetic beads. This method does not rely on the 
tumour cells having a specific characteristic and depletion methods that have 
implemented this system have achieved relatively high recovery rates of 46-62% (Lin et 
al., 2013).  A possible disadvantage of this method is that it may deplete CTCs that are 
surrounded by and interacting with WBCs.  
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1.4 The role of immune the immune system and tumour microenvironment 
in HCC 
In HCC it is not only tumour cells that are considered to contribute to the process of 
hepatocarcinogenesis and predict outcome.  In 90% of cases, HCC is developed on a 
background of inflammation (Nikolaou et al., 2013).  Activated immune cells infiltrate the 
liver and contribute to the tumour microenvironment.  In the final section of this literature 
review, the immune system and the tumour microenvironment in HCC will be discussed. 
1.4.1 Components of blood 
Constituents of blood include: plasma, leucocytes, erythrocytes and platelets.  Blood 
cells are derived from multipotent haematopoietic stem cells and mature to form 
differentiated cells during the process of haematopoiesis Figure 1.2.  Erythrocytes are 
the most abundant blood cell type, making up between 93-96% of blood cells.  
Erythrocytes - derived from myeloid lineage - are the oxygen transporting cells in the 
blood and are therefore rich in haemoglobin.  Under normal physiological conditions, 
leucocytes make up just 0.1-0.2% of blood cells.  They have an important role in the 
immune system and the individual roles of each cell type will be discussed in Section 
1.4.2.  Platelets are anuclear cells derived from megakaryocytes that are required for the 
maintenance of haemostasis (Semple et al., 2011).  Platelets contribute to 4-7% of blood 
cells.  During normal physiological conditions, platelets circulate in the blood in a 
quiescent state but they may be activated in response to vessel injury, or as part of their 
role in inflammation (Semple et al., 2011, Stanger and Kahn, 2013).   
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Figure 1.2 Haematopoiesis demonstrating the derivation of cells present in the blood.  
Adapted from (Ramsay and Gonda, 2008). 
1.4.2 The immune system 
The immune system is broadly divided into cells and molecules which either make up 
the innate response or the adaptive response Table 1.5-Table 1.6 and Figure 1.3 
(Dranoff, 2004, Peakman, 2009).  The innate response is an unspecified but immediate 
form of first-line defence against pathogens which is usually responsive within hours 
(Male, 2006).  Adaptive immunity is a slower (within days) but specific response 
dependent on antigen expression (Male, 2006).  Following first exposure to the antigen, 
there is clonal expansion of cells specific to that antigen and an immunological memory 
is built up so that on second presentation of the same antigen a faster response is elicited 
(Male, 2006).  Additionally, chemical messengers such as chemokines and cytokines 
contribute to the immune response.  Chemokines are a family of cytokines that are 
associated with chemotaxis of cells; their main roles include regulation of lymphoid organ 
development and T cell differentiation but they have also been recognised mediators of 
tumour metastasis (Keeley et al., 2011).  Cytokines are proteins or glycoproteins that are 
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important cell signalling molecules that orchestrate coordination and function of 
haematopoietic cells and inflammatory cells during an inflammatory response (Peakman, 
2009, Male, 2006). 
Cells and molecules associated with the innate immune response  
Classification  
Granulocytes Neutrophils Phagocytose and kill microorganisms 
Release anti-bacterials 
  
 Eosinophils 
Basophils 
Mast cells 
Release pro-inflammatory mediators 
Mononucleocytes Monocytes  
Macrophages 
Ingest and kill bacteria 
Release pro-inflammatory mediators 
Antigen presentation 
Dendritic cells Myeloid dendritic 
cells 
Plasmocytoid 
dendritic cells 
Migrate to inflammatory sites 
Antigen presentation 
Release interferons 
Lymphoid cells Natural killer cells Lyse infected cells 
Kill target cells spontaneously 
Secrete cytokines 
Properties associated with both innate 
and adaptive function 
Complement 
proteins 
Cascade of >40 
proteins 
Promote inflammation 
Recruit cells 
Kill targeted cells 
Remove immune complexes 
Table 1.5 Cells of the innate immune system.  Adapted from (Peakman, 2009). 
Cells associated with the adaptive immune response  
Cell Classification  
T-lymphocytes T-lymphocytes Organise killing of microorganisms 
Activate macrophages 
Helper T 
lymphocytes 
Organise killing of parasites via 
eosinophil recruitment  
Cytotoxic T-
lymphocytes 
      Ill-defined 
      Recruit cells 
T regulatory cells Regulate inflammation 
   
B-lymphocytes   
Lymphoid cells Natural killer cells SeeTable 1.4 
γδ T cell γδ T cell Secrete IL-17/ IFNγ 
Mediate rapid response to specific 
pathogens similarly to NK cells 
Paradoxical role in cancer 
Table 1.6 Cells of the adaptive immune system.  Adapted from (Peakman, 2009, Vantourout 
and Hayday, 2013, Silva-Santos et al., 2015, Vivier et al., 2011). 
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Figure 1.3 Cells and molecules of the innate and adaptive immune responses (Dranoff, 
2004). 
1.4.3 Immune surveillance in the liver in normal physiological conditions 
In order to prevent infection from blood-borne infection, the liver performs immune 
surveillance under normal physiological conditions.  The anatomy and blood supply to 
the liver aids in the role of immune surveillance. Additionally, the liver is populated with 
resident immune cells that occupy the liver parenchyma and vasculature including: 
Kupffer cells, hepatic stellate cells, dendritic cells and lymphocytes (Jenne and Kubes, 
2013).  Located in the vasculature, Kupffer cells adhere to liver sinusoidal endothelial 
cells (LSECs) and are densely populated in the liver, accounting for approximately 80-
90% of the total macrophages in the body (Jenne and Kubes, 2013).  Of the residing 
lymphocyte population in the liver, there is a high proportion of innate natural killer (NK) 
cells and NK T-cells (NKT cells) compared to the peripheral blood (Racanelli and 
Rehermann, 2006).  NK and NKT cells have roles implicated in tumour surveillance 
(Racanelli and Rehermann, 2006).  Parenchymal liver cells can also contribute to the 
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immune surveillance of the liver.  This may be via the production of cytokines which have 
been associated with hepatocarcinogenesis – for example hepatocytes and Kupffer cells 
produce cytokines including interleukin-1 (IL-1), TNFα and interleukin-6 (IL-6) (Budhu 
and Wang, 2006).  Liver endothelial cells are present in the sinusoidal lumen and are 
imperative for pathogen detection and capture; whilst hepatocytes have been associated 
with secretion of inflammatory cytokines (Rowell et al., 1997).  Activated macrophages 
are the main source of cytokines though they may be secreted by any nucleated cell 
(Coussens and Werb, 2002).   
1.4.4 Immune response in HCC  
An exacerbated immune response is characterised by the infiltration of immune cells; a 
common feature of most neoplastic lesions at varying degrees (Hanahan and Weinberg, 
2011). Innate immune cells recognise cellular damage, pathogen invasion and metabolic 
stress (Bieghs and Trautwein, 2013, Gorham, 2007).  This is characterised by 
dysregulated cytokine production mainly consisting of: tumour necrosis factor α (TNFα), 
interleukin-6 (IL-6) and transforming growth factor β (TGFβ) which collectively activate 
downstream signalling pathways resulting in pro-/anti-apoptotic responses, acute-phase 
protein synthesis and altered hepatocyte proliferation (Bieghs and Trautwein, 2013).  The 
adaptive immune response is characterised by the activation of lymphocytes and 
macrophages.  There is a resident population of adaptive immune cells in the liver which 
is comprised mostly of T cells (~50%) and NK cells (~33%) (Gorham, 2007).  Adaptive 
immune cells have been recognised as having both pro-tumorigenic and anti-
tumourigenic roles in HCC (de Visser et al., 2006, Schneider et al., 2012).  One study 
that utilised a N-nitrosodiethylamine (DEN) model of hepatocarcinogenesis in Rag1-/- 
mice (lacking mature T- and B-cells) showed that tumour growth occurred earlier and 
there was an increased number of tumours compared to wild type mice; in this instance 
indicating that T- and B-lymphocytes offer an protective anti-tumourigenic mechanism 
(Schneider et al., 2012).  Gene microarray studies of 139 HCC human samples - 
performed by the same group – showed that unsupervised clustering gave rise to two 
groups of patients based on the differential expression of genes associated with T-cells 
and B-cells and that prognosis was different between the two groups of patients.  It 
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should be noted that the innate and adaptive immune systems do not act independently 
– there is interplay between both systems.   
1.4.5 The role of inflammation in cancer 
The immune system has a paradoxical role in many types of cancer, including HCC.  
Initially it was thought that the immune system would offer a protective role against 
tumour cells by recognising and destroying them.  However, it is now also considered 
that the immune system can have a pro-tumorigenic effect; enabling tumour cells to 
evade immune destruction as well as contributing to an inflammatory response adding 
to the pro-tumourogenic properties of the tumour microenvironment (Hanahan and 
Weinberg, 2011).  Historically, the first link between inflammation and cancer was made 
by Rudolf Virchow in 1863 who documented infiltrating leucocytes in cancerous tissue 
and associated this with cancer development in the presence of chronic inflammation 
(Balkwill and Mantovani, 2001).  Recently, the importance of the role of the immune 
system in the development and progression of cancer has been recognised.  In an 
updated version of Hanahan and Weinberg’s “Hallmarks of cancer: the next generation”, 
inflammation was identified as an enabling characteristic in tumorigenesis (Hanahan and 
Weinberg, 2011).   
Chronic inflammation can pre-dispose individuals to cancer (e.g. inflammatory bowel 
disease is associated with the development of colorectal cancer and inflammation of the 
prostate is associated with an increased risk of prostate cancer) (Mantovani et al., 2008, 
Shacter and Weitzman, 2002).  Furthermore, the link between the use of anti-
inflammatory drugs and a reduced cancer risk has emerged: with the use of non-steroidal 
anti-inflammatory drugs (e.g. aspirin) resulting in a reduced cancer risk in patients with 
oesophageal, gastric and colorectal cancers (Thun et al., 1993, Thun et al., 1991).  More 
recently, studies have shown that non-steroidal anti-inflammatory drugs (NSAIDs) – 
which inhibit cyclooxygenase 2 (COX2) and hence the signalling of prostaglandins – also 
reduce the risk of breast and lung cancer; however there has been associated cardiac 
associated toxicity with the long term use of NSAIDs (Ulrich et al., 2006). 
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The link between inflammation and cancer can be divided into two separate but 
interconnected pathways: the intrinsic and the extrinsic pathway (Mantovani et al., 2008).  
The extrinsic pathway is defined as that which occurs in response to chronic 
inflammation, whereby transcription factors are activated leading to the secretion of 
chemokines, cytokine and prostaglandins which leads to the recruitment of inflammatory 
cells (Mantovani et al., 2008).  The intrinsic pathway follows the process of events 
characterised by activation of oncogenes (Mantovani et al., 2008).  One of the most 
common examples in human cancers are the mutations of the RAS family of oncogenes, 
resulting in activation of the RAS/RAF signalling pathway, leading to the production of 
inflammatory cytokines and chemokines (Sparmann and Bar-Sagi, 2004).  Pro-
tumourogenic effects of downstream Ras signalling include proliferation, angiogenesis, 
metastasis and modulation of the tumour microenvironment (Pylayeva-Gupta et al., 
2011). 
1.4.6 The tumour microenvironment  
The tumour microenvironment is made up of the tumour cells, immune cells, associated 
stroma and vasculature as well as the signalling and interactions that take place between 
these features.  The concept is derived from Paget’s ‘seed and soil’ hypothesis whereby 
it was suggested that specific environmental conditions were required in order for tumour 
cells to grow (Weber and Kuo, 2012).  The tumour microenvironment is not static and it 
changes over time throughout tumour development (Quail and Joyce, 2013).  It has been 
suggested that both innate and adaptive immune cells contribute to the tumour 
microenvironment (Whiteside, 2008).  Various features of the tumour microenvironment 
result in favourable conditions for the initiation, proliferation, growth, angiogenesis and 
metastasis of tumour cells (Weber and Kuo, 2012).   
It was initially considered that cells in the microenvironment were present to provide 
immune surveillance and remove tumour cells (Joyce and Pollard, 2009); however recent 
evidence suggest that infiltrating immune cells provide favourable environmental 
conditions for the progression of cancers and may suppress the host’s immune 
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response, facilitating metastasis (Whiteside, 2008).  Albini and Sporn highlighted some 
of the targetable features of the tumour microenvironment using chemoprevention 
including COX 1/2, hypoxia-inducible factor 1α (HIF-1α), TGFβ and VEGF (Albini and 
Sporn, 2007).  There has also been a drive towards re-programming of stromal cells in 
the tumour microenvironment so that they have an anti-tumourigenic effect (Quail and 
Joyce, 2013).   
1.4.7 The tumour microenvironment in HCC 
In HCC, the tumour microenvironment is emerging as a current topic of interest.  In one 
study, assessment of tumour resections for the presence of tumour infiltrating 
lymphocytes (TILs) showed that increased numbers of TILs and increased expression of 
inflammatory and immune genes led to increased patient survival (Chew et al., 2010). It 
was also noted that numbers of NK and T cells were increased in HCC resections 
compared to non-tumour tissue and this correlated positively with the number of 
apoptotic cells and negatively with the number of proliferating tumour cells (Chew et al., 
2010).  In general, the tumour microenvironment in HCC is associated with increased 
production of cytokines e.g. IL6; chemokines e.g. chemokine (C-X-C motif) ligand 
(CXCL2), chemokine C-C motif ligand 20 (CCL20); fibrosis; matrix metalloproteinases 
(MMPs) which can degrade the basement membrane; reduce pO2 resulting in hypoxia; 
and increase production of ROS resulting in oxidative stress (Hernandez-Gea et al., 
2013). There is also a change in the number of cell types that contribute to the tumour 
microenvironment including: increased numbers of CD4+ Tregs, tumour-associated 
fibroblasts (TAFs), tumour-associated macrophages (TAMs) and a decrease in the 
number of dendritic cells leading to a reduced ability to produce an immune response 
against tumour cells (Hernandez-Gea et al., 2013).  Adipocytes have recently been 
recognised as cells that contribute to the tumour microenvironment which is relevant to 
patients with NAFLD (Albini and Sporn, 2007).  Targets associated with the tumour 
microenvironment in HCC include STAT3 which is activated via the cytokine interleukin-
22 (IL22) secreted by T-helper 17 (Th17) cells and Kupffer cells and is associated with 
a poorer prognosis (Hernandez-Gea et al., 2013, Jiang et al., 2011).   
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1.4.8 Neutrophils in HCC 
Neutrophils are the most abundant leucocyte comprising 50-70% of circulating WBCs 
(Sionov et al., 2015).  Inappropriate activation of neutrophils induces liver damage 
alluding to the conflicting role of neutrophils in HCC (Xu et al., 2014).  In cancer, 
neutrophils are attracted to the tumour environment through TAMs and tumour cells 
(Mantovani et al., 2011).  Tumour associated neutrophils (TANs) exhibit opposing roles 
in cancer dependent on their phenotype (N1 or N2) which is determined by the presence 
of environmental signalling molecules such as TGFβ (Fridlender et al., 2009, Piccard et 
al., 2012).  The role of N2 neutrophils include: tumour growth, invasion, metastasis, 
angiogenesis (increased MMP9 and VEGF production), the evasion of apoptosis, 
genetic instability and promotion of EMT (Dumitru et al., 2013, Piccard et al., 2012, 
Sionov et al., 2015, Imai et al., 2005). Conversely, neutrophils with an N1 phenotype 
have a cytotoxic role in response to tumour cells (Xu et al., 2014).  In HCC, neutrophils 
have been recognised as key immune cells in the inflammatory response associated with 
various aetiologies of HCC (Xu et al., 2014).  Neutrophil depletion in DEN murine models 
resulted in attenuation of liver tumours, indicating that neutrophil inhibition in CLD may 
be a therapeutic avenue for HCC (Wilson et al., 2015).  NFB was shown to exert a 
tumour suppressor effect with NFB p50:p50 dimers able to repress transcription of a 
neutrophil chemokine network including calprotectin, CXCL1 and CXCL2 (Wilson et al., 
2015).  Multiple studies have shown that it is the ratio of neutrophils to lymphocytes that 
has predictive prognostic value in HCC and this is further discussed in Section 1.4.12.  
1.4.9 Tumour infiltrating lymphocytes in HCC 
In cancer, the presence of infiltrating lymphocytes has been recognised as a good 
prognostic indicator, with attempts to use this as immunotherapy dating back to 1986 
(Rosenberg et al., 1986).  More recent studies have explored the effects of different 
subtypes of T-lymphocytes and their ratios in attempt to elucidate whether or not a 
specific phenotype of T-lymphocytes has a more favourable effect on prognosis.  A meta-
analysis was performed across various cancer types revealed that in general CD3+ and 
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CD8+ lymphocytes were positively associated with increased survival benefit; the 
presence of CD4+ TILs had a less pronounced effect on survival and Forkhead box P3 
(FoxP3) TILs were not associated to an improvement in survival (Gooden et al., 2011).  
The same study concluded that differences may be observed for different cancer types 
and that in some cases, the ratios of subsets of TILs might be more indicative in terms 
of prognosis (Gooden et al., 2011).   
The role of B-lymphocytes in cancer is less well established.  Recent research has 
alluded to the effect of CD20+ B-lymphocytes and the association with T-lymphocytes 
as having a positive outcome on survival in cancer (Nelson, 2010).  NK cells were 
identified as possessing cytotoxic properties towards cancer cells (Herberman et al., 
1975).  It has been considered that the mechanism of action by which NK cells exert 
cytotoxic properties towards tumour cells may be reliant on the recognition of cells to 
recognise autologous changes surface markers (Waldhauer and Steinle, 2008).  Follow-
up studies over 11 years demonstrated that decreased counts of cytotoxic NK cells in 
peripheral blood led to an increased risk of developing cancer (Imai et al., 2000).   
1.4.10 Activated platelets are involved in the immune response and are involved 
in the growth and metastasis of tumours 
The role of platelets in cancer was recognised by Trousseau in the late 19th century; who 
associated an increase in thrombotic events in patients with cancer (Stanger and Kahn, 
2013). This led to the understanding of the role of platelets in cancer including the part 
they play in the process of metastasis in addition to tumour progression, angiogenesis, 
cell invasion, vascular permeability, mitogenesis and the production of pro-inflammatory 
cytokines and chemokines (Gay and Felding-Habermann, 2011, Smyth et al., 2009).  
Increased circulating platelet counts – or thrombocytosis - has been associated with 
various cancer types, including ovarian and breast cancer (Rao and Rao, 2012).  It has 
also been proposed that platelets serve as protective cells that are able to assist CTCs 
evading the immune system (Plaks et al., 2013). 
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In a HBV transgenic murine model of HCC associated with chronic inflammation, 
administration of aspirin and clopidogrel alone or in combination resulted in a reduction 
of HBV specific (CD8+ T-cells) and non-specific inflammatory cells (neutrophils, 
macrophages, dendritic cells and NK cells) proposing platelets could be a potential 
therapeutic option in HCC patients (Sitia et al., 2012).  In one cohort of 634 HCC patients, 
52/634 (8.2%) patients were identified as having above normal platelets (>400 x 109/L) 
(Carr and Guerra, 2013). In this study, elevated platelets were associated with an 
increased tumour size compared to patients with a platelet count within the normal 
reference range (Carr and Guerra, 2013).  
1.4.11 Tumour-associated macrophages (TAMs) 
The population of macrophages in the liver is described as heterogeneous with varying 
functions ranging from pathogen clearance to promoting liver fibrosis (Tacke and 
Zimmermann).  Hepatic macrophages that reside in the lumen of the liver sinusoids - 
Kupffer cells - are capable of releasing multiple inflammatory mediators including 
cytokines and reactive oxygen species (ROS) (Tacke and Zimmermann).  Two 
overarching types of macrophages have been described: pro-inflammatory (M1) or 
immunoregulatory (M2), though these two classifications of macrophages are further 
sub-divided dependent on their biological properties (Murray and Wynn, 2011).   
In addition to Kupffer cells, there are TAMs that have been recognised as having multiple 
pro-tumourigenic roles including: angiogenesis, proliferation, metastasis, re-modelling of 
the ECM and suppression of the host immune response (Weber and Kuo, 2012, Murray 
and Wynn, 2011).  Macrophages with an M2 phenotype have been implicated to be pro-
tumorigenic in HCC in both in vitro and in vivo studies (Yeung et al., 2015).  Assessment 
of 95 HCC samples using IHC and quantitative PCR (qPCR) demonstrated that there 
was an increase in macrophage and M2 macrophage markers (CD14, CD68 and CD163) 
and that that this increase in expression was more pronounced in the peri-tumoural 
tissues compared to the intra-tumoural tissues (Yeung et al., 2015).  In cell line studies, 
co-culturing MHCC97L cells with macrophages led to an increase in number of cells and 
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migration when M2 macrophages were used but not M1 (Yeung et al., 2015).  In HCC, 
there is activation of stellate cells and TAMs which lead to a release epidermal growth 
factor (EGF), chemokines, MMP and VEGF (Hernandez-Gea et al., 2013, Wu et al., 
2012). 
1.4.12 Circulating immune cells 
It has been considered that an increase in the counts of immune cells is indicative of 
immune response in patients, but additionally it may be the ratio of subtypes of immune 
cells that may be more reflective of the immune status of individuals.  Commonly, the 
neutrophil to lymphocyte ratio (NLR) has been calculated for patients with HCC and has 
been shown to serve as a useful prognostic indicator in patients receiving a variety of 
treatment regimens.  A higher NLR has been associated with a worse prognosis in terms 
of PFS and OS in multiple studies comparing cohorts of HCC patients receiving different 
treatments.  In a study of patients with HCC in China, an immune-inflammation score 
was developed using the neutrophil: lymphocyte ratio as well as the platelet count (Hu 
et al., 2014).  Patients with a high systemic immune-inflammation index (SII) had a 
shorter OS and relapse-free survival compared to patients with a low SII; furthermore SII 
correlated with large tumours, vascular invasion and CTC count using the CellSearch 
(Hu et al., 2014). 
Although evaluation of the tumour microenvironment may be more indicative of the 
factors that are specifically driving the tumour, obtaining this information is not practical 
in the majority of patients.  If clinically relevant information could be obtained from blood 
sampling, this would be ideal. Assessment of patient circulating immune system status - 
in terms of numbers and phenotypes of immune cells or through microarray studies to 
identify differentially expressed genes in peripheral blood mononucleocytes (PBMCs) - 
may yet yield clinically relevant information that will aid in the future management of 
patients. 
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Chapter 2. Imagestream method development and optimisation 
In order to detect CTCs in HCC patient samples, it was first important to develop a robust 
method of CTC isolation and detection.  A major difficulty in detecting CTCs is their rarity 
(≤1 CTC/ml or ≤1 CTC/billion haematopoietic cells) amongst a high background of RBCs, 
WBCs and platelets (Allard et al., 2004, Yu et al., 2011).  Due to the heterogeneity of 
HCC, CTCs may vary in size and biomarker expression.  Furthermore, the expression of 
a single epithelial marker may not be consistent during the process of metastasis – it has 
been suggested that CTCs may undergo EMT as part of the process of metastasis 
(Yilmaz and Christofori, 2009).  Difficulty in deciding the most suitable method stems 
from there having been little characterisation of CTCs in HCC.  It has been hypothesised 
that cancer cells may have increased deformability which aids in the process of 
metastasis, enabling CTCs to travel through restricted spaces (Byun et al., 2013). 
2.1.1 CTC Isolation 
Most downstream CTC applications require an enrichment technique to reduce the 
background of haematopoietic cells and make the possibility of detecting CTCs more 
likely.  Enrichment techniques can be reliant on the physical properties of CTCs for 
example the ISET method which relies on size of CTCs (Vona et al., 2000); the DEParray 
which isolates CTCs using dielectrophoresis (Peeters et al., 2013); or density-gradient 
centrifugation methods where it is hypothesised that CTCs will be captured within the 
PBMC layer (Rosenberg et al., 2002).  Alternatively, enrichment can be performed using 
the epitope characteristics of cells.  Positive enrichment can be used by implementing a 
tumour cell-specific marker to select positively expressing cells, for example using an 
EpCAM-coated chip (Nagrath et al., 2007).  Negative enrichment can be used to deplete 
the sample of WBCs using the common leucocyte antigen CD45 (Alix-Panabieres and 
Pantel, 2014). 
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2.1.2 CTC detection platforms 
The FDA-approved CellSearch system (Janssen Diagnostics, 2016) remains to be the 
only clinically validated CTC detection platform in metastatic breast, prostate and 
colorectal cancer (Cohen et al., 2008, Cristofanilli et al., 2004, de Bono et al., 2008).  
Studies that have been compiled using the CellSearch system have determined a 
threshold number of CTCs that can be used to predict prognosis in terms of overall 
survival (OS) and PFS.   This is variable amongst the different cancer types for which 
the CellSearch system has been clinically validated with cut-off levels of ≥5 CTCs in 
metastatic breast and prostate cancer but ≥3 in metastatic colorectal cancer (Cohen et 
al., 2008, Cristofanilli et al., 2004, de Bono et al., 2008).  Studies implementing the 
CellSearch system have quoted variable recovery rates using cell spiking experiments 
ranging from 4.3%-14% (Ghazani et al., 2012) to 80-82% (Riethdorf et al., 2007). 
A CellSearch study in a small cohort of pre-treatment HCC patients (n=20), CTCs were 
detected in 7 patients (45%) (Zee et al., 2007).  In a study by Wege and colleagues, 
CTCs were detected in 18/59 (30.5%) of HCC patients using the CellSearch and these 
18 CTC-positive patients had a shorted median OS compared to those that were CTC-
negative (460 days vs 746 days) (Schulze et al., 2013).  Another research group 
enumerated CTCs in 50 HCC patients using the CellSearch system finding between 1-8 
CTCs per 7.5 ml in 14/50 samples (28%) (Morris et al., 2014). In this study, 19 samples 
were also assessed using the ISET method where results showed that CTCs were 
detected in all of these 19 samples of which all had GPC3-positive CTCs (Morris et al., 
2014). 
2.1.3 The Amnis Imagestream as a CTC detection platform 
Despite technological advances there are still many advantages and disadvantages to 
each CTC detection platform.  An ideal CTC detection platform would be sensitive due 
to the rarity of CTCs.  It should also be specific and produce high-resolution images – to 
ensure that the cells detected are cancer cells.  In order to be able to implement it 
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successfully clinically, it should be fast so that results can be processed in a reasonable 
amount of time.   
The Imagestream (Amnis, Seattle) combines the quantitative capabilities of fluorescent-
activated cell sorting (FACS) with the qualitative results of multi-channel, high-resolution 
and high-throughput fluorescent microscopy.  Up to ten fluorescent channels are 
available for the user to implement biomarkers of interest and high resolution bright field 
images are produced alongside.  Analysis is performed using IDEAS® software (Amnis, 
Seattle) which enables the user to interrogate multiple cell features and also enable the 
visualisation of each event recorded.  Limited work has been published on the use of the 
Imagestream as a CTC detection platform.  One study comparing CellSearch and 
Imagestream spiked varying numbers of PANC-1 cells into 7.5 ml blood samples and 
processed them using the CellSearch or subjected them to an EpCAM-positive 
enrichment followed by detection using the Imagestream (Lopez-Riquelme et al., 2013).  
The study concluded that there was no significant difference between the two methods 
in terms of recovery rates although the Imagestream  may be less accurate when low 
numbers of cells were spiked; however it is important to note that the two technologies 
were not directly comparable since different enrichment methods were used (Lopez-
Riquelme et al., 2013).  The perceived advantages and disadvantages of the CellSearch 
and Imagestream have been summarised in Table 2.1. To date there have been no 
comprehensive studies of using the Imagestream as a CTC detection platform in cancer 
patients. 
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Optimal features CellSearch Imagestream 
Independent of 
epithelial biomarkers 
Dependent on EpCAM and CK User may select antibodies of 
choice 
Characterisation of 
cells 
CTCs defined as 
EpCAM+ve/CK+ve/CD45-ve 
and nucleated 
Interrogation of up to 10 cancer-
specific biomarkers 
Sensitive Able to detect ≥1 CTC/7.5 ml of 
blood 
Able to detect ≥1 CTC/8 ml of 
blood 
Specific Baseline levels of CTCs defined 
for different types of cancer.  
Biomarkers identify cells of 
epithelial origin 
Able to implement cancer-
specific biomarkers 
Fast Processing time ~24 h Processing time ~4 h with 
enrichment 
Clinically validated FDA-approved Not yet clinically validated 
High resolution 
images 
Magnification x20 available Magnification x60 available 
Table 2.1 Comparison of the CellSearch and Imagestream CTC detection platforms. 
2.1.4 CTC Biomarkers 
Initially, in the method development phase, it was decided that classical CTC epithelial 
biomarkers EpCAM and CK should be included in the biomarker panel since previous 
studies have shown that these two markers can be detected in HCC CTCs (Morris et al., 
2014, Schulze et al., 2013).  Furthermore, EpCAM-positive CTCs have been associated 
with increased tumour-initiating potential (Sun et al., 2013) and serum CK-18 which is 
detected by the pan-CK antibody has been shown to be an independent predictor of 
NASH (Feldstein et al., 2009).  Since AFP is the only currently used clinical serum 
biomarker, it was also included.  GPC3 was also included due to its overexpression in 
HCC and the possibility of it being used as a therapeutic target (Filmus and Capurro, 
2013).  In a study carried out by the Dive group, GPC3 expression was observed in CTCs 
isolated using the ISET followed by downstream IHC (Morris et al., 2014).  CTC GPC3 
expression correlated with GPC3 expression in matched patient tumour biopsies 
although this was in a small patient cohort (n=5) (Morris et al., 2014).   
Two additional exploratory markers – DNA-PK and SULF2 – were also included in the 
study Sections 1.3.6 and 1.3.5.  SULF2 desulfates GPC3 enabling it to act as a 
morphogen promoting Wnt signalling (Lai et al., 2008).  It is hypothesised that if SULF2 
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expression could be detected in CTCs, it could be used as a biomarker for stratification 
with anti-GPC3 or anti-SULF2 treatments.  Previous data has shown that DNA-PK 
expression in HCC patient biopsies is a predictor of patient response to TACE indicating 
that if it was possible to detect DNA-PK expression in CTCs from the peripheral blood it 
could serve as a less invasive test to predict patient response (Cornell et al., 2015).   
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2.2 Aims 
 To develop a suitable CTC enrichment technique that is possible to implement 
for use with the Imagestream. 
 To test the recovery rate of cells using an enrichment method in combination with 
the Imagestream using spiking experiments.   
 To develop an analysis strategy using the IDEAS® software to identify CTCs 
amongst a background of haematopoietic cells. 
 To develop an antibody panel for the detection of CTCs in HCC. 
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2.3 Materials and methods 
2.3.1 Mammalian cell culture 
HCC cell lines HepG2, Hep3B, Huh-7, PLC/PRF/5, SNU182 and SNU475 acquired from 
ATCC and ECACC were grown in RPMI 1640 medium (Sigma-Aldrich, UK) 
supplemented with 10% foetal bovine serum (FBS) (Gibco, UK) or Dulbecco’s modified 
eagle’s medium (DMEM) with 15 mM HEPEs, pyridoxine and NaHCO3 (Sigma-Alrich, 
UK) supplemented with 10% FBS and 2.5% 200 mM L-Glutamine solution (Sigma-Alrich, 
UK). PreB697 cells were used as a positive control for CD45 and were kindly donated 
by Dr Lindsay Nicholson.  SJSA1 osteosarcoma cells were kindly donated by Dr Arman 
Esfandiari.  Cells were sub-cultured when 70-80% confluent by removing the media, 
washing with PBS and adding an appropriate volume of trypsin EDTA then incubating 
for 2-5 min until cells detached. Following cell detachment, trypsin was neutralised with 
an appropriate volume of media and cells were spun at 1000 x g for 5 min. The 
supernatant was removed and the cell pellet was re-suspended in an appropriate volume 
of fresh media. Cells were seeded back down at an appropriate density depending on 
the cell line or cells were counted using an improved Neubauer haemocytometer 
(Hawksley, UK) for further application. 
2.3.2 Ficoll-Paque™ density gradient centrifugation  
2 ml blood samples collected from healthy volunteers in EDTA tubes were spiked with a 
1 ml suspension of 5000 Hep3B cells.  Samples were diluted in 4 ml of AutoMACS rinsing 
solution (Miltenyi Biotec) pH 7.2, 2mM EDTA.  Diluted blood samples were carefully 
layers over 4.5 ml of Ficoll-Paque™ PLUS (GE Healthcare) in a 15 ml Falcon tube.  
Samples were centrifuged at 400 x g for 40 min at 20 oC. This resulted in separation of 
the blood sample into plasma, PBMCs, density gradient medium and RBCs in order from 
top to bottom based on density Figure 2.1. The top plasma layer was carefully removed.  
The following PBMC layer was transferred to a clean 15 ml Falcon tube.  AutoMACS 
rinsing solution was added at a volume of at least three times the volume of the PBMC 
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layer.  Cells were spun at 100 x g for 10 min at 20 oC.  The supernantant was gently 
removed to prevent disturbance of the cell pellet.  6 ml of fresh AutoMACS rinsing 
solution was added and cells were spun at 100 x g for a further 10 min at 20 oC.  The 
supernatant was removed and the cell pellet was ready for immunofluorescent antibody 
staining.  
 
Figure 2.1 Separation of blood sample into plasma, PBMCs and erythrocytes.  Adapted 
from GE healthcare. 
 
2.3.3 Density gradient centrifugation using OncoQuick™ tubes 
OncoQuick™ tubes (Greiner Bio-one) contain a porous barrier on top of a density 
gradient medium.  Rather than isolate CTCs with the PBMC layer, the density gradient 
medium in OncoQuick™ tubes claims to eliminate granulocytes, lymphocyte and 
mononucleocytes as well as RBCs.  A wash buffer was prepared by making up a PBS 
(Gibco) solution containing 0.5% BSA (Sigma).  The centrifuge and OncoQuick™ tubes 
were pre-cooled to 4 oC.  15 ml blood samples were collected in EDTA tubes from healthy 
volunteers and spiked with 5000 Huh-7 cells in a 1 ml volume.  Blood samples were 
incubated on ice for 15 min.  Blood samples were added to OncoQuick™ tubes by gently 
pipetting the sample down the side of the tube.  Samples were centrifuged at 1600 x g 
for 20 min at 4 oC without a brake.  Following centrifugation the samples above the 
porous layer was divided into a top brown platelet layer above a blue interphase layer 
that should capture the spiked cells Figure 2.2.  The platelet layer was carefully 
discarded leaving 2-3 ml to prevent disturbance of the blue interphase layer.  The 
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interphase layer was then transferred into a clean Falcon tube.  The OncoQuick™ tube 
was rinsed with 5 ml of wash buffer to remove any residual cells.  This was added to the 
interphase layer and the sample volume was made up to a total of 50 ml with wash buffer.  
Tubes were inverted 5 times and centrifuged at 200 x g for 5 min.  The supernatant was 
removed leaving ~5 ml to prevent disturbance of the cell pellet.  Wash buffer was added 
again to make up the volume to 50 ml.  The sample was centrifuged once more at 200 x 
g for 5 min.  The supernatant was removed leaving the cell pellet remaining for 
downstream antibody staining and Imagestream analysis. 
 
Figure 2.2 OncoQuick CTC enrichment tubes contain a porous filter above a density 
gradient medium.  Following centrifugation, CTCs and platelets are retained above the 
porous filter whereas leucocytes and erythrocytes pass through the filter. Adapted from 
Greiner Bio-one. 
 
2.3.4 RBC lysis 
8 ml of 5x phosflow lyse/fix buffer (BD Bioscience, US) was diluted in 32 ml of diH2O 
and pre-warmed to 37 oC. 50 ml Falcon tubes were blocked with BSA solution (MACS) 
diluted 1:20 in AutoMACS wash solution. 5 ml of the resulting solution was used to block 
each Falcon tube. Following blood collection, the BSA solution was removed from the 
tube and 8 ml of the blood was transferred to the blocked Falcon tube. This was stored 
at 4 oC for 15 min.  200 ml of FcR blocking reagent (MACS) was added per 8 ml of blood 
and incubated for 15 min. The sample was then divided up into 2 ml aliquots in blocked 
Falcon tubes. Following 30 min incubation at 37 oC, 40 ml of the 1x phosflow lyse/fix 
buffer was added to each 2 ml of aliquot of blood. The tube was inverted 10x and then 
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incubated at 37 oC for 10 min. The RBC lysis was then centrifuged at 500 x g for 8 min 
at RT. The supernatant was discarded and the remaining cell pellet was re-suspended 
in PBS and transferred to a siliconised eppendorf tube (Sigma Aldridge, UK). The Falcon 
tube was washed 4 times to retrieve any remaining cells and then the cells were spun at 
470 x g for 5 min at RT. The supernatant was removed and the cell pellet re-suspended 
in 1 ml of permeabilisation/wash buffer containing saponin (BD Biosciences) for 1 h at 
RT. Following incubation, the cell suspension was centrifuged at 470 x g for 5 min and 
the remaining cell pellet was re-suspended in 100 μl of permeabilisation/wash buffer to 
which antibodies were added. Following antibody incubation, cells were spun at 470 x g 
for 5 min and the pellet was re- suspended in an appropriate volume of PBS. Samples 
were run on the Imagestream (Amins, US). 
2.3.5 Immunomagnetic CD45 depletion 
The above protocol Section 2.3.4 was followed with the additional step of a negative 
enrichment step - CD45 depletion using immunomagnetic CD45 coated nanoparticles 
Figure 2.3. Following the RBC lysis, the supernatant was removed and the remaining 
cell pellet was re-suspended in 500 μl of RoboSep buffer (Stem Cell technologies). The 
suspension was transferred to a 14 ml polystyrene round-bottom tube (BD Falcon) and 
the previous Falcon tube was washed with 4 x 1 ml volumes of 10% PBS/BSA solution 
to remove any residual cells. Cells were spun at 500 x g for 8 min and the remaining cell 
pellet was re- suspended in 500 μl of RoboSep buffer. EasySep™ CD45 depletion 
cocktail was added for 15 min followed by 50 μl of EasySep™ magnetic particles for 10 
min incubation.   The volume of cell suspension was made up to 5 ml with RoboSep 
buffer and the tube was then incubated in the magnet for 10 min. The unbound cells 
(CD45 negative) were poured off into a blocked falcon tube and a subsequent wash of 
the magnet was carried out. Cell suspensions were centrifuged for 5 min at 800 x g and 
then permeabilised using either ice cold methanol for 20 min or Perm/Wash™ (BD 
Biosceinces) buffer containing saponin for 1 h at RT. Following permeabilisation, cells 
were spun at 250 x g for 5 min and re-suspended in 100 μl of Perm/Wash™ buffer or 1% 
BSA/PBS solution. Antibodies Table 2.2 were added in the order described in Table 2.3.  
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Following antibody incubation, cells were spun at 470 x g for 5 min and re-suspended in 
an appropriate volume of PBS, then processed through the Imagestream. 
Primary/conjugated antibodies Species Dilution Company (catalogue #) 
 488 anti-human CD326 (EpCAM) 
antibody (clone 9C4) 
Mouse 1:50 AlexaFluor (324210) 
PerCP/Cy5.5  CD326 (EpCAM) 
antibody (clone 9C4) 
Mouse 1:50 Biolegend (324214) 
Cytokeratin PE (C-11) Mouse 1:100 Cayman Chemical 
(10478) 
V450 anti-human CD45 (clone HI30)  Mouse  1:20 BD Bioscience (560367) 
PE/Cy7 anti-human CD45 (clone HI30) Mouse 1:50 BioLegend (304016) 
Alphafetoprotein   (3H8) Mouse mAb 
(AlexaFluor 594 conjugate) 
Mouse 1:20 Cell signalling Technology 
(7877S) 
Glypican-3 (IG12) Mouse  1:50 Santa Cruz (Sc-65443) 
DNA-PKcs (H163) Rabbit 1:100 Santa Cruz (Sc-9051) 
SULF2  Mouse 1:100 Serotec (MCA5692GA) 
 
Secondary antibodies    
Goat anti-rabbit AF488 Goat 1:1000 Invitrogen (A11034) 
Goat anti-mouse AF488 Goat 1:1000 Invitrogen (A11001) 
 
DNA dyes 
   
DRAQ5  1:5000 Cell Signalling Technology 
(1-877-616-23537) 
DAPI  1:2000 Biolegend (422801) 
Table 2.2 Antibodies used in the development of an antibody panel for HCC patient 
samples using the Imagestream. 
 
Order Antibody/dye Incubation 
time 
1 Primary un-conjugated 1h 
2 Secondary 1h 
3 Intracellular 30 min 
4 Membrane/DNA dye 1h 
Table 2.3 Order of antibody staining for cells processed using the Imagestream. 
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Figure 2.3 Overview of the EasySep™ immunomagnetic depletion.  Adapted from StemCell 
Technologies. 
 
2.3.6 Haematopoietic cell depletion - spiking experiments 
A stock suspension of 20,000 Huh-7 cells/ml was made up determined by cell counts 
using a haemocytometer. From this, serial dilutions were made to produce stock 
solutions of the lower cell counts so that 2000, 200 and 20 cells were spiked in to 4 ml 
blood samples in a volume of 100 µl.  Samples were processed according to sections 
2.3.4 and 2.3.5.  The resulting cells were stained with fluorescent conjugated antibodies 
Table 2.2 against EpCAM (AlexaFluor 488, AlexaFluor), pan-CK (PE, Cayman 
Chemical) and CD45 (V450, BD Bioscience).  DRAQ5 (Cell Signalling Technology) was 
used as a nuclear stain.  Cell pellets were re-suspended in 50 µl of PBS and processed 
through the Imagestream. 
2.3.7 Antibody optimisation 
Initial antibody optimisation was carried out using HCC cell lines grown on glass 
coverslips.  1 x 105 cells were seeded out per coverslip in a 6-well plate.  Cells were left 
to grow until ~70-80% confluent then fixed in either 1% formalin for 20 min at RT or in 
methanol at -20 oC for 20 min.  A permeabilisation step for cells fixed with formalin was 
included by incubating with a saponin-containing Perm/Wash™ buffer.  Cells were 
washed and blocked with 5% BSA solution for 20 min at RT.  Coverslips were then 
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immersed in 1% BSA solution containing primary antibody for 1 h at RT.  Cells were then 
washed three times with PBS for 5 min and incubated in secondary antibody for 1 h at 
RT in the dark.  Following incubation with secondary antibody cells were washed for 
three times in PBS then for 10 min with diH2O.  A secondary antibody only control was 
included to determine any background staining caused by the fluorescent antibody.   
Coverslips were left to dry then fixed onto slides using Vecta mounting media containing 
DAPI (Vector Laboratories, US).  Slides were viewed using the Leica DMR fluorescent 
microscope (Leica, Germany).   
2.3.8 Antibody staining of cells prior to Imagestream processing 
Optimal conditions for antibodies were then tested in cell lines using the Imagestream.  
Fluorophores were selected on the basis of excitation lasers and emission spectra.  
Where antibodies were unconjugated, secondary antibody only controls were included 
and any background was removed during analysis.  Single colour controls were also 
included to compensate for spectral overlap between fluorophores during the analysis 
process. 
Cells from Section 2.3.1 were fixed in 1% formalin for 20 min at RT.  Cells were then 
centrifuged at 500 x g for 5 min, the supernatant was removed and the cell pellet was 
incubated in Perm/Wash™ buffer for 1 h at RT.  A further 5 min centrifugation at 500 x g 
was used to pellet cells, the supernatant was removed and cells were re-suspended in 
100 µl of fresh Perm/Wash™ buffer.  Antibodies were added at appropriate dilutions 
Table 2.2 for 1 h at RT.  Cells were centrifuged again at 500 x g, supernatant removed 
and replaced with 100 µl of fresh Perm/Wash™ buffer.  Secondary antibodies were 
added for 1 h at RT with a DNA dye and cells were incubated in the dark.  Where multiple 
antibodies were used, they were added in the order according to Table 2.3. 
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2.3.9 Imagestream processing 
Final cell pellets were suspended in an appropriate volume of PBS and aliquoted into 60 
µl samples in siliconized Eppendorfs so that the object rate remained below 1000 
objects/s when running the sample through the Imagestream.  Samples were processed 
through the Imagestream using an 8 µm core at 60 mm/s with 7% SpeedBeads® to 
enable calibration and hydrodynamic focussing.  Lasers 405 nm, 488 nm, 561 nm and 
642 nm were used to excite fluorophores.  The 785 nm laser was used to collect side 
scatter profiles or switched off the enable detection of the PE/Cy7 fluorophore in channel 
7.  Cell images were captured using a 40x objective and charged-coupled device (CCD) 
camera.  
2.3.10 IDEAS® Analysis –measuring biomarker expression 
To measure expression of the relevant biomarkers in a panel of HCC cell lines, the mean 
pixel intensity feature in IDEAS® was used.  Firstly, round single cells were identified by 
creating a scatterplot of aspect ratio against brightfield area.  The round single cell 
population was gated and boundaries were checked to ensure that no double cells or 
debris was included.  This population was then gated for the in focus cell population by 
creating a histogram of gradient root mean square which measures large differences in 
pixels, with objects in focus usually having a gradient root mean square value of >50.  
The focussed, single cell population was then assessed for the mean pixel intensity of 
the biomarker of interest. 
2.3.11 IDEAS® Analysis –gating strategies to identify spiked cells 
Data from the Imagestream was initially in the form of a raw information file.  A 
compensation matrix built using the single colour control was applied to this file to 
compensate for spectral overlap between fluorophores used.  Where unconjugated 
antibodies were used, background from the secondary-only antibody control was 
removed from the appropriate channel.  Scatterplots of EpCAM or CK intensity versus 
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CD45 intensity were plotted.  Populations with a low CD45 intensity and high EpCAM/CK 
intensity were gated.  To exclude the possibility of counting spiked cells twice, a further 
population of either EpCAM+ve/CD45-ve or CK+ve/CD45-ve was created.  This 
population was then inspected by eye and cells that had a consistent cell morphology 
based on the brightfield image, were CD45-ve, EpCAM/CK+ve and nucleated were 
tagged to create a population of spiked cells.  This population was then enumerated and 
recovery was calculated as a percentage of the total cells spiked.    
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2.4 Results 
2.4.1 Erythrocyte depletion of whole blood samples resulted in high CTC 
recovery but large, unmanageable data files 
 It is possible to stain whole blood and process it through the Imagestream  but in an 8 
ml blood sample, this would result in approximately 3.04 - 4.96 x 1010 erythrocytes, 1.12 
– 3.6 x 109 platelets and 8.8 -28 x 106 leucocytes resulting in data files containing >30 
billion images.  Even with stringent gating techniques, management and analysis of this 
data would be unfeasible.  To reduce the majority of erythrocytes, samples were subject 
to a RBC lysis as described in Section 2.3.4.  Although minimal processing following a 
RBC lysis led to a high recovery of cells, processing took up to 24 h and data files were 
unmanageable to continue this method in large numbers of patients.     
2.4.2 Density gradient centrifugation methods resulted in a poor recovery of 
spiked cells 
As a collaborative effort between people working on CTCs indifferent cancer types – 
namely Dr David Jamieson, Mr Barry Dent and Dr Rachel O’Donnell – different 
enrichment approaches were tested.  These included the CD45-coated beads (MACS) 
and DynaBeads® (Thermo Fisher); MagSweeper (Talasaz et al., 2008) and 
RosetteSep™ (Stemcell Technologies).  Aside from the RosetteSep™, which is a density 
gradient centrifugation method that also depletes the sample of unwanted cells by 
binding them to erythrocytes, recovery rates were poor.  The RosetteSep™ achieved 
good recovery however, also produced large amounts of debris; making it unsuitable for 
use with the Imagestream since each piece of debris would be counted as an object.  
Density gradient centrifugation using Ficoll-Paque™ PLUS as described in Section 2.3.2 
achieved poor recovery rates of 12% (data not shown).  Similar results were achieved 
using the OncoQuick™ Section 2.3.3 tubes (10.2%, data not shown).  These methods 
were clean in that debris was minimal, but recovery rates were low.  In parallel, 
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preliminary results were promising with immunomagnetic depletion using the EasySep™ 
magnet Section 2.3.5, so this method was pursued further.       
2.4.3 Immunomagnetic CD45 depletion resulted in ~50% recovery of CTCs and a 
reduction of ≥95% of CD45+ leucocytes 
Recovery rates of three different concentrations of HCC cell lines spiked into healthy 
volunteer blood were determined.  Samples were processed using a protocol that would 
be transferable to patient sample processing.  Following RBC lysis Section 2.3.4, 
removal of platelets by a low centrifugation spin (270 x g) and the immunomagnetic 
depletion of CD45+ WBCs using the EasySep™ technique Section 2.3.5, recovery was 
65.7% (SEM±8.2), 51.3 (SEM±10.2) and 57.3 (SEM±3.9) for 2000, 200 and 20 spiked 
cells per ml respectively.  Similar recovery rates were achieved in spiking experiments 
with cell lines from three different cancer types: oesophageal, ovarian and thyroid (Dent 
et al., 2015).  Leucocyte number pre- and post-depletion samples was measured using 
a haemocytometer.  Results showed that in post-depletion samples there was a 
reduction in WBCs by ≥95% Figure 2.5.  This would result in decreased processing time 
using the Imagestream as well as manageable data files and shorter analysis time. 
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Figure 2.4 Recovery rates for 500 (65.7%±SEM 8.2), 50 (51.3±SEM 10.2) and 5 (57.3±SEM 
3.9) Huh-7 cells spiked into whole blood and processed using an erythrocyte lysis and 
CD45 immunomagnetic depletion. 
 
Figure 2.5 Pre and post-depletion counts of leucocytes demonstrated that depletion of 
CD45 positive leucocytes was consistently ≥95%. 
2.4.4 Antibody optimisation of biomarkers of interest for the Imagestream 
Antibodies to be included in the biomarker panel were optimised using 
immunofluorescence in HCC cell lines Figure 2.6.  For epithelial biomarkers, SJSA1 
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osteosarcoma cells which have a mesenchymal phenotype were included as a negative 
control.  PreB697 cells were used as a positive control for CD45 and WBCs were used 
a negative control for other biomarkers of interest.  Conditions tested included dilution of 
primary antibody Figure 2.7, fixation and permeabilisation techniques Figure 2.8 as well 
as the effects of any preservatives contained in blood collection tubes Figure 2.9. 
Optimum antibody dilutions for antibodies for use with the Imagestream are summarised 
in Table 2.2. 
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Figure 2.6 Initial optimisation of antibodies for biomarkers of interest was performed using 
standard immunofluorescence.  Secondary antibody only controls were included for 
unconjugated antibodies (C-D). A. Hep3B cells stained with EpCAM AF488 (AlexaFluor). 
B.Hep3B cells stained with AFP AF594 (Cell Signalling Technology). C. HepG2 cells 
incubated with primary glypican-3 (Santa Cruz) and secondary goat anti-mouse AF488 
antibody.  D. PLC/PRF/5 cells incubated with primary DNA-PK (cs) and secondary goat 
anti-rabbit AF488 antibody. 
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Figure 2.7 Huh-7 cells stained with pan-CK (Cayman chemical) in varying dilutions: A. 1:50, 
B. 1:100 and C. 1:250. 
The RBC lysis buffer contained a fixative (unspecified by the manufacturer) and initially 
a saponin permeabilisation was used.  However, the DNA-PK antibody required an ice 
cold methanol permeabilisation.  In order to determine whether or not this would have 
any effect on recovery rates, cells fixed in methanol and formalin were processed through 
the Imagestream and recovery was determined as 96.9% for methanol-fixed cells and 
97.9% for formalin fixed cells.   
 
Figure 2.8 Huh-7 cells were fixed with A. formalin followed by a saponin permeabilisation 
or B methanol.   
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CellSave tubes are used alongside the CellSearch technology.  Data from cell line 
experiments has shown that these fixative-containing tubes mean that samples can be 
collected, fixed immediately and can be processed up to 96 h later (Qin et al., 2014).  In 
our HCC cohort, this would mean that it would be possible to collect samples from other 
cancer centres across the UK and enable sub-cohort analysis of CTCs in patients in 
specific treatment groups.  However, tests using cell lines demonstrated that the fixative 
(unspecified by the manufacturer) used in the CellSave tubes had an antigen masking 
effect on DNA-PK Figure 2.9.  Huh-7 cells fixed and permeabilised using methanol 
displayed nuclear DNA-PK in 88% of the cell population Figure 2.9 A.  A magnified 
image of Huh-7 cells fixed in a CellSave tube displays unspecific DNA-PK staining 
Figure 2.9 B.  Only 55% of the cell population was DNA-PK positive indicating antigen 
masking with the CellSave preservative, despite a methanol permeabilisation.  Following 
this we decided to collect in EDTA tubes and process samples immediately to avoid loss 
of CTCs.   
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Figure 2.9 Huh-7 cells stained with primary DNA-PKcs antibody (Santa-Cruz) and AF488 
(AlexaFluor) goat anti-rabbit antibody.  A.  Cells were incubated in a K3 EDTA tube for 1h 
and methanol fixed (x40 objective). The preservative in the CellSave tubes appeared to 
have an antigen-masking effect in B. Cells fixed in a CellSave preservative tube for 1h 
followed by a methanol permeabilisation (x60 objective). 
2.4.5 HCC cell lines display heterogeneity in biomarker expression 
Expression of biomarkers was measured using mean pixel intensity in the IDEAS® 
software as described in Section 2.3.10.  Heterogeneity was observed between the HCC 
cell lines tested and there was variability observed in the range of mean pixel intensities 
within each cell line Figure 2.10.  The osteosarcoma cell line SJSA1 which was used as 
a negative control for the epithelial biomarkers had low expression of EpCAM and CK 
compared to the HCC cell lines as expected since they have a mesenchymal phenotype 
Figure 2.10 A-B.  Hep3B cells had a large range of pixel intensities for EpCAM, AFP 
and GPC3 but low range for CK compared to the other HCC cell lines Figure 2.10.  The 
graph profile of mean pixel intensities of AFP and GPC3 was similar although the range 
of pixel intensities for GPC3 were generally higher compared to AFP.  This data 
demonstrates the heterogeneity of biomarker expression amongst HCC cell lines, 
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indicating that the CTC population may also be heterogeneous; supporting the use of 
multiple biomarkers for the detections of CTCs. 
 
Figure 2.10 Data displaying the mean pixel intensities of A. EpCAM B. CK C. AFP and D. 
GPC3 in HCC cell lines.   
2.4.6 6-channel antibody staining 
Although the Imagestream has 12 channels, 2 are retained for brightfield images.  Of the 
remaining 10 channels, different fluorophore combinations were trialled to determine 
which fluorophores would be best to use for an antigen panel.  Initially an antibody panel 
of EpCAM (AF488), pan-CK (PE) and CD45 (V450) with DRAQ5 as a DNA dye was used 
Figure 2.11.  After trialling different antibody combinations, the use of 6 different 
fluorophores led to a panel that could be applied to detect biomarkers in CTCs in HCC 
patient samples Figure 2.12.  It is possible to utilise further fluorophores but there would 
be increased spectral overlap which would make compensation difficult. 
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Figure 2.11 PreB697 cells stained with CD45-V450 (BD Bioscience). B. SNU182 cells 
stained with anti-human EpCAM- AlexaFluor488. C. SNU182 cells stained with pan-CK-PE. 
D. DRAQ nuclear stain. E-F. SNU182 cells stained with CK-PE and EpCAM-AlexaFluor488. 
G. CD45 positive WBC stained with all antibodies.  
 
Figure 2.12 Antibody panel that enables detection in six channels. A. Hep3B cells stained 
with DAPI. B. HepG2 cells stained with glypican-3 (Santa Cruz) primary antibody and goat 
anti-mouse AlexaFluor488 secondary antibody (Invitrogen).  C. Hep3B cells stained with 
pan-CK-PE (Cayman Chemical).  D. Huh-7 cells stained with AFP-AlexaFluor594 (Cell 
Signalling). E. Hep3B cells stained with EpCAM- PerCP/Cy5.5. F. PreB697 cells stained with 
CD45-PE/Cy7. G-H. Huh-7 cells stained with all antibodies. I-J. CD45-positive WBCs 
stained with all antibodies. 
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2.4.7 HCC CTCs can be gated based on area of the brightfield image 
Initially it was not known whether or not CTCs were larger in size compared to 
haematopoietic cells.  Despite depletion, data analysis files produced following 
compensation still contained large numbers of objects >50 µm in diameter.  In order to 
analyse these data efficiently, a gating strategy was implemented.  Based on the CTC 
definition that objects that were cellular in morphology, nucleated, CD45-negative and 
positive for one or more of the biomarkers in the panel were classified as CTCs, gating 
was reliant on biomarker expression. 
During analysis, objects that appeared to be cellular in morphology, nucleated, CD45-
negative but also negative for biomarkers tested in the CTC panel were observed, 
indicating that the initial gating strategy may be excluding CTCs that did not express 
biomarkers in the panel i.e. cells that may have undergone EMT or expressed 
biomarkers not included in the panel.  Additionally, objects that appeared to be larger 
than cell lines and have a morphology consistent with that of a macrophage were also 
noted but failed to be detected using the initial gating strategy due to expression of one 
or more CTC biomarkers and CD45 positivity.  A new gating strategy was developed that 
took into account nuclear intensity.  Using a histogram of intensity of the nuclear stain 
against frequency resulted in distinct populations of cells with a nuclear intensity of single 
WBCs, double WBCs and anything greater in nuclear intensity than a doublet of WBCs.  
The single WBC population could then be further gated on the basis of CD45 intensity 
using a second histogram to identify any CD45 negative objects.  Cells with a nuclear 
intensity greater than a single WBC were then assessed for the expression of candidate 
biomarkers.  A final population of cells that had either a nuclear intensity of a single WBC 
but were CD45 negative and cells with a nuclear intensity greater than a single WBC and 
were biomarker positive were combined into a single population and assessed by eye.  
Objects that had a consistent cellular morphology, were CD45 negative and biomarker 
positive were tagged to form a population of spiked cells or CTCs. 
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Figure 2.13 Analysis algorithm to identify spiked cells or CTCs against a background of 
haematopoietic cells. 
Following the analysis of blood samples from a HCC patient cohort (Chapter 3), CTCs 
observed appeared to be larger in size.  A mask was modified (standard features 
brightfield area mask, eroded by 3 pixels) in IDEAS® to measure the area of the 
brightfield image.  This mask was then created as a feature in IDEAS® to measure the 
brightfield area of objects in a population.  When the brightfield area of WBCs, HCC cell 
lines and CTCs was measured, CTCs had a significantly larger area than WBCs.  Of the 
gating methods tested to identify CTCs in HCC, this last method lead to a reduced final 
population to be viewed by eye whilst including biomarker negative cells and other 
objects of interest e.g. macrophages.  
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2.5 Discussion 
Initially, whole blood samples were processed through the Imagestream, though an 8 ml 
blood sample took ~24 h to run, produced large data files and resulted in a lengthy 
analysis process.  This was not going to be feasible in larger patient cohorts so a pre-
enrichment step was required.  In HCC there have been no reports in the literature about 
the size of HCC CTCs, so methods dependent on size e.g. filtration, ISET were not 
considered.  One of the major advantages of the Imagestream is that antibodies of choice 
can be incorporated into a biomarker panel that is tailored to cancer type.  This also 
means that there is no selection bias towards the CTC population studied.  Therefore, 
enrichment based on expression of epithelial markers was excluded.   
Due to lack of knowledge about CTCs in HCC, we hoped to develop a method that would 
result in the least selection bias in the CTC population detected, did not deplete the 
sample of any CTCs based on assumptions made on size and that would significantly 
reduce processing and analysis time compared to using whole blood.  Depletion methods 
tested were mostly based on the depletion of CD45-positive leucocytes.  The 
RosetteSep™, MagSweeper and DynaBeads® were trialled though the former resulted 
in a large amount of debris and the latter two methods resulted in poor recovery rates.  
Density gradient centrifugation methods also resulted in poor recovery (~10%).  The 
combination of an erythrocyte lysis along with a CD45 immunomagnetic depletion using 
the EasySep™ resulted in a recovery of >50% based on cell spiking experiments Figure 
2.4.  It also led to the depletion of ≥95% of CD45 positive leucocytes resulting in a sample 
that was faster to process using the Imagestream and quicker to analyse using the 
IDEAS® software Figure 2.5. 
When generating a biomarker panel for the identification and characterisation of CTCs 
in HCC patient samples, we decided to include some of the classical epithelial markers 
that have already been identified on CTCs from HCC patients.  These included EpCAM, 
CK and GPC3 (Morris et al., 2014, Schulze et al., 2013).  We also wanted to exploit the 
potential of the Imagestream by including biomarkers that have not previously been 
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explored in CTC research.  We also wanted to include markers with potential clinical 
utility in terms of stratifying patients for therapy or those that could be used to predict 
response (Cornell et al., 2015, Filmus and Capurro, 2013, Lai et al., 2008).  Expression 
of HCC biomarkers was variable amongst HCC cell lines; indicative of heterogeneity 
which may be observed in the CTC population Figure 2.10.  The data presented in this 
chapter show that it was possible to optimise and antibody panel for up to five different 
fluorescent markers and a nuclear stain Figure 2.12.  It was decided that EpCAM, CK, 
AFP, GPC3, DNA-PK and SULF2 expression in CTCs would be explored in HCC patient 
samples in a series of biomarker panels including CD45 and a nuclear stain. 
Initially, a gating algorithm was developed to identify spiked cells or CTCs based on 
nuclear intensity, the absence of CD45 and the expression of biomarkers Figure 2.13.  
However, despite depletion, this still led to a large population of cells to view by eye.  
Gating based on measurements of the brightfield area in HCC CTCs following results 
showing that CTCs were larger than WBCs Section 3.3.2, resulted in an efficient gating 
strategy that also retained the inclusion of other cells of interest e.g. biomarker negative 
cells and macrophages.    
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2.6 Conclusion 
 Depletion of haematopoietic cells using RBC lysis, a low centrifugation step to 
deplete platelets and a CD45 immunomagnetic depletion resulted in ≥95% 
reduction in WBCs with the maintenance of a recovery rate of 51.3-65.37% of 
CTCs. 
 Optimal antibody conditions for biomarkers of interest for use with the 
Imagestream were determined and panel of 6 different fluorophores was 
developed for use on patient samples. 
 Retrospectively, a gating strategy based on the size of HCC CTCs could be used 
to improve the speed and efficiency of analysis while maintaining other cells of 
interest e.g. biomarker-negative cells and macrophages. 
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Chapter 3. CTCs and ctDNA in HCC patient samples 
3.1 Introduction 
Patients with HCC often present at an advanced stage when treatment options are 
limited.  Additionally, due to the underlying CLD, standard anti-cancer cytotoxic options 
for HCC are limited since the potential benefit is often outweighed by the likelihood that 
such agents will induce further liver damage.  Although recently there has been an 
increase in the number of targeted therapies for use in cancer, there has been little 
success in HCC; partly owing to the lack of the identification of key molecular drivers of 
HCC but also due to the lack of identification of biomarkers that could be used in trials 
for molecular therapies in HCC.   
Relatively few studies have investigated the presence of CTCs in patients with HCC 
(Section 1.2.8).  Furthermore, studies that have been compiled have mainly focussed 
on the enumeration of CTCs in patients with HCC rather than the molecular 
characteristics of CTCs, which is a field of growing interest (Morris et al., 2014, Schulze 
et al., 2013).  It is proposed that characterisation - as opposed to CTC count - may be 
able to provide clinically relevant information in terms of diagnosis, prognosis, therapy 
stratification and treatment response or development of resistance.  
3.1.1 CTCs in HCC 
Studies that have investigated CTCs in HCC have been summarised in Table 1.4, 
Schulze and colleagues tested the CellSearch system for the detection of CTCs in HCC.  
18/59 (30.5%) of samples tested positive for CTCs defined as ≥1 CTC/7.5 ml (Schulze 
et al., 2013).  In this study the presence of CTCs correlated with OS, Barcelona Clinic 
Liver Cancer (BCLC) staging, AFP, macro- and microscopic vessel invasion.  It is 
however important to note that the threshold of ≥1 CTC/7.5 ml is lower than other studies 
for which the CellSearch is clinically validated and 1/19 of the control patients consisting 
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of patients with cirrhosis or benign hepatic tumours had a positive result by the definition 
set by the study itself (Schulze et al., 2013).   
Morris and colleagues explored identifying CTCs in HCC using the ISET method and 
comparing this to use of the CellSearch (Morris et al., 2014).  During this study they 
identified CTCs in 15/50 (28%) of patients using the CellSearch and 19/19 (100%) 
patients using the ISET method, following which they performed downstream IHC using 
GPC-3 as a HCC biomarker (Morris et al., 2014).  They then went on to correlate GPC-
3-positive CTCs with expression of GPC-3 in the primary tumour using tissue biopsy; 
concluding a correlation of 100% in 5 paired samples (Morris et al., 2014).  No 
associations were made between CTC number and tumour stage or outcome (Morris et 
al., 2014). 
Other investigators have used methods based on the positive selection of epithelial 
marker positive cells and then investigated the expression of markers including ASPGR 
using cytospinning and immunofluorescence to investigate the expression of epithelial 
and mesenchymal markers and changes of these markers during treatment (Li et al., 
2014, Nel et al., 2013).  Alternative studies have also used in situ molecular hybridisation 
to detect genetic aberrations in CTCs including TP53 deletion and HER-2 amplification 
(Xu et al., 2011).   
3.1.2 HCC Biomarkers 
The use of clinically-implemented biomarkers in HCC is limited.  Serum AFP is routinely 
measured as part of surveillance programmes for at-risk patients with cirrhosis and also 
throughout a HCC patient’s treatment and follow-up.  However, it lacks sensitivity (50-
65%) and specificity (76-91%); sometimes not being elevated until late stage disease 
and in some cases not at all (Sherman, 2001).  CA19-9 is another serum marker that is 
associated with worse prognosis in HCC, but it is also elevated in other cancer types 
including pancreatic, oesophageal and colorectal cancer (Hsu et al., 2015). 
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Previous work within our group has indicated that tumour tissue expression the enzyme 
central to DNA damage repair by NHEJ, namely DNA-PK, in patients with HCC may be 
a predictor of response to HCC treatment with TACE (Cornell et al., 2015).  DNA-PK 
expression was assessed in liver biopsies from patients receiving TACE using IHC.  
Patients with a DNA-PK expression higher than median had shorter TTP compared to 
those that exhibited lower levels of DNA-PK expression (18.8 months vs 31.4 months; 
p=0.54) (Cornell et al., 2015).  Consequently we hypothesised that if DNA-PK was 
detectable on CTCs in peripheral blood it may be a less invasive predictor of response 
to TACE. 
Other selected biomarkers of interest included the heparin sulphate proteoglycan GPC3 
and its modifying endosulfatase, SULF2.  From a diagnostic perspective GPC3 is highly 
specific for HCC.  Although it lacks sensitivity, serum levels do not correlate with AFP 
and it was hoped that used in combination, serum AFP and GPC3 might detect a higher 
proportion of patients with HCC (Capurro and Filmus, 2005).  Also, GPC3 exploration as 
a treatment candidate targeting GPC3 tumoural overexpression has led to the 
development and clinical trials of monoclonal antibody GC33 (Zhu et al., 2013).  If it was 
possible to detect tumour specific GPC3 in the blood, it may be possible to identify 
patients that might benefit from such a treatment should it progress to clinical use.  
SULF2 removes sulfate groups from GPC3, facilitating its role as a morphogen 
promoting Wnt signalling. SULF2 has an oncogenic role in HCC and is found to be up-
regulated in 57% (79/139) of cases of HCC at the RNA level (Lai et al., 2008).  
Furthermore, research has shown that targeting SULF2 may repress its oncogenic 
effects in HCC (Lai et al., 2008).  Exploration of this alternative biomarker may shed light 
on HSPG modification of cancer cell growth, but may also be used as a biomarker for 
stratifying with anti GPC3 or anti SULF2 treatments. 
Following the optimisation of a suitable method of CTC detection in blood Chapter 2, it 
was necessary to see if this method was applicable to detect CTCs in HCC patient 
samples.  Initially samples were collected from a range of patients with varying treatment 
regimens and clinical parameters.  Samples were collected throughout method 
optimisation in order for any alterations in sample processing to be tested on patient 
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samples.  Two groups of control patient samples were collected: healthy volunteers and 
cirrhotic patients to ensure that events observed were not a normal occurrence or as part 
of an immune response. A definition was proposed for the identification of CTCs in 
patients samples based on the CellSearch definition of EpCAM+/CK+/DAPI+/CD45-.  
Objects that did not fit these criteria but appeared to have a cellular morphology and 
were larger in size compared to a WBC and CD45-ve were also recorded and will be 
discussed. 
Two further biomarkers – c-Met and pERK Section 1.3.7-1.3.8– were also explored in a 
small cohort of 14 HCC patients as part of a Masters project carried out by M. McCain.  
C-Met was selected on the basis that HCCs with altered c-Met expression resulted in a 
more aggressive phenotype and poorer prognosis (Kaposi-Novak et al., 2006).  Due to 
altered C-Met expression in multiple cancers, c-Met is an attractive therapeutic target 
and early trials of tivantinib (ARQ197) in patients with high c-Met expression had longer 
TTP than those receiving placebo (Santoro et al., 2013a, Santoro et al., 2013b). 
Aberrant Ras/ERK activity has been identified in ~5% of HCC for which pERK can be 
used as a marker since it leads to the activation of transcription factors of genes 
responsible for proliferation and survival (Llovet and Bruix, 2008, Newell et al., 2009, 
Zucman-Rossi, 2010).  Previous research has also shown that activation of the RAS 
signalling pathway in a murine model of hepatocarcinogenesis led to increased tumour 
number and features of SH-HCC; in human HCC pERK expression in 20 HCC tissue 
biopsies, 85% had elevated pERK expression (Whitehead et al., 2015).  From a 
therapeutic perspective refametinib (BAY86-9766), a MEK1/2 inhibitor is being trialled in 
HCC patients with unresectable or metastatic disease with a known KRAS or NRAS 
mutation; demonstrating the potential for blood tests to be able to stratify patients for 
therapy (Schmieder et al., 2013).   
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3.1.3 ctDNA in HCC 
Detection of ctDNA in HCC has largely focussed on quantification and comparing the 
expression of biomarkers in HCC patients compared to controls Section 1.2.9.  The 
detection of ctDNA may be improved in terms of specificity using mutation-specific PCR 
(Anker et al., 1999).  In this chapter, in addition to pERK expression being explored in 
HCC patients, a method of ctDNA extraction from stored HCC plasma samples was 
developed in order to investigate the KRAS mutational status in patients with HCC that 
had developed tumours on a background of NAFLD/NASH.    
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Materials and Methods 
3.1.4 HCC cell lines 
A panel of 6 HCC cell lines (HepG2, Hep3B, Huh-7, PLC/PRF/5, SNU182 and SNU475) 
were assessed for the expression of classical epithelial and exploratory biomarkers using 
the Imagestream.  HCC cell lines were grown and maintained as described in Section 
2.3.1.  Cells were trypsinised and centrifuged at 1000 x g for 5 min.  Cell density was 
determined using a haemocytometer. The cell pellet was washed in PBS then cells were 
fixed in 1% formalin for 20 min at RT or 5 ml ice cold methanol for 20 min. Cells were 
spun at 1000 x g for 5 min and the fixative was replaced with 1 ml of 
permeabilisation/wash buffer (BD Bioscience) containing saponin for 1 h at RT. Cells 
were centrifuged at 1000 x g for 5 min and re-suspended in 100 µl of 
permeabilisation/wash buffer to dilute the appropriate antibodies. Antibodies were added 
in order, depending on the localisation of the protein of interest.  Following antibody 
staining, cells were re-suspended in PBS and ran through the Imagestream with 
appropriate laser settings.  Single colour controls were also ran alongside to enable 
compensation between adjacent channels. 
3.1.5 Imagestream IDEAS® analysis for assessing the expression of HCC 
biomarkers in HCC cell lines 
HCC cell lines were used to assess the expression of biomarkers of interest.  The SJSA1 
human osteosarcoma cell line was used as a negative control for the expression of 
epithelial biomarkers.  Cells were discriminated from debris by creating a scatterplot of 
area vs aspect ratio.  Single cells that were used for analysis were gated.  A histogram 
of the gradient root mean square of each image was plotted to identify the population of 
cells that were in focus.  The gradient root mean square feature detects changes in pixel 
values within an object.  Round, single and in-focus cells were then assessed for the 
expression of biomarkers of interest.  The percentage of cells within the final population 
that were positive for the biomarker of interest were measured.  Secondly, the expression 
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of biomarkers was measured using the mean pixel intensity feature.  Data was then 
exported to GraphPad Prism Software, Version 6 (GraphPad Prism Software Inc, 
California, USA). 
3.1.6 CTC HCC patient cohort 
69 patient blood samples were collected alongside 15 healthy volunteer samples and 16 
cirrhotic control samples.  16 of the aforementioned control samples were collected and 
analysed by Dr D. Jamieson and Dr C. Hutton.  Patient blood samples were collected 
from the Newcastle Freeman Hospital with ethical approval obtained through the 
Newcastle Hepatopancreatobiliary and Gastroenterology Research Tissue Bank.  
Samples were collected from patients with various disease stages and receiving different 
treatment regimens.  A minimum patient dataset was recorded, including patient age; 
sex; body mass index (BMI); underlying cirrhosis or not; associated chronic liver disease; 
mode of presentation; stage at presentation (including Childs-Pugh stage of underlying 
liver function; and TNM stage of the cancer, as well as the BCLC stage).  Liver function 
features recorded included serum bilirubin, albumin, prothrombin time, as well as the 
presence of ascites or encephalopathy. Tumour features recorded included tumour 
number and size, as well the absence or presence of extrahepatic disease and portal 
vein involvement.  Additional data collected included the presence of features of 
metabolic syndrome and ECOG Performance Status.  A record was also made of 
treatments received or anticipated, and ethical approval permitted the follow up of 
patients to determine response to treatment, time to progression and survival where 
possible.  Time to progression data was collected by Dr H. Reeves and Dr J. Orr. 
3.1.7 Patient blood sample collection 
Patient blood samples were collected in either EDTA tubes (BD Vacutainer) and 
transported on ice; or CellSave preservative tubes (Janssen Diagnostics) and incubated 
at RT for cells to fix for a minimum of 1h.  Samples were processed as outlined in Section 
2.3.4-2.3.5.  Following enrichment, the pellet of cells were re-suspended into 100 µl of 
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perm-wash buffer and incubated with appropriate antibodies Table 2.2-Table 2.3.  
Following antibody incubation, cells were spun at 470 x g for 5 min then re-suspended 
in 50 µl of PBS prior to being ran though the Imagestream with the suitable template that 
enabled collection of everything that was bigger than an Amnis SpeedBead. 
3.1.8 Imagestream IDEAS Analysis for CTC detection 
Single colour conjugate controls were collected to create a compensation matrix to 
account for spectral overlap between different fluorescent antibodies.  Analysis was 
carried out on the basis of cell area.  A brightfield analysis mask was created based on 
the standard brightfield mask and eroded by 3 pixels to give a tighter fit to the brightfield 
image.  A feature was then created from this mask to enable area calculations and further 
analysis.  A histogram of brightfield area with the modified brightfield mask was created.  
Single WBCs formed a single peak and then anything that was larger in area compared 
to a WBC was gated into a separate population.  This population was then assessed for 
the presence of CTCs.  CTCs were identified on cell morphology, the positive expression 
of biomarkers included in the panel and the absence of positive CD45 staining.  From 
this a further population of CTCs and objects that appeared to have a cellular morphology 
and nuclear stain but did not positively express the biomarkers tested was created.   
3.1.9 Statistical Methods 
Statistical analyses were performed using SPSS, version 21 (SPSS Inc, Chicago, USA) 
and GraphPad Prism Software, version 6 (GraphPad Prism Software Inc, California, 
USA).  Pearson or Spearman correlations were used to assess bivariate correlations for 
parametric and nonparametric data respectively.  The t-test or Mann-Whitney test was 
used to investigate differences between groups where data was parametric or non-
parametric respectively.  Pearson Chi square was used to assess differences between 
categorical variables and where data sets where small the Monte-Carlo approach was 
adopted.  Survival differences were assessed using the Kaplan-Meier and Log-Rank 
method.  To identify factors associated with survival, initially univariate Cox proportional 
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hazards-regression model was used.  Factors that were identified as significant in the 
univariate analysis (p<0.05) were then entered into a multivariate analysis to determine 
factors that were independent predictors of prognosis. 
3.1.10 DNA extraction from cell lines 
DNA was extracted from a panel of six HCC cell lines using the Qiagen mini DNA kit as 
per manufacturer’s protocol.  Briefly, 5 x 106 cells were trypsinised and loaded onto a 
DNA binding column.  DNA was then subject to a series of wash steps to desalt and 
purify extracted DNA prior to elution. 
3.1.11 DNA extraction from FFPE sections 
DNA was extracted from slides of formalin fixed paraffin embedded (FFPE) sections from 
colorectal cancer patients.  Tumourous or normal areas of FFPE liver resections slides 
were scraped using a needle and added to a centrifuge tubes.  Tissue sections were 
washed twice in xylene to remove wax from the embedding procedure.  Samples were 
then subject to two washes in ethanol.  First, tissue was incubated with 100% ethanol for 
15 min at RT followed by centrifuging for 2 min at full speed.  This step was repeated 
with 75% ethanol.  A proteinase k digestion (1mg/ml in TE buffer, 0.5% Tween-20) step 
was carried out for 24 h at 55 oC.  500 µl of phenol:chloroform:isopropanol (25:24:1) was 
added to the tissue and the sample was mixed by vortexing.  The suspension was then 
centrifuged at 12,000 x g for 5 min and the upper layer of fluid was transferred to a sterile 
centrifuge tube.  One volume of chloroform was added to the sample and mixed by 
vortexing.  The sample was then centrifuged once more at 12,000 x g for 5 min and the 
upper layer transferred to a clean centrifuge tube.  0.3 M sodium acetate was added at 
a 0.1 of the volume of sample and mixed by vortexing.  1 volume of isopropanol was 
added to the sample and incubated at -20 oC overnight.  The sample was then centrifuge 
at 12,000 x g at 4 oC to pellet the precipitated DNA and then washed with 75% ethanol.  
DNA was left to dry in a hood and then dissolved in 50 µl of distilled water. 
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3.1.12 ctDNA extraction from HCC plasma samples 
HCC patient plasma samples were collected with ethical approval obtained through the 
Newcastle Hepatopancreatobiliary Tissue Biobank.  DNA was extracted from HCC 
plasma samples using the DNA Blood Mini kit (Qiagen®) as per protocol.  Briefly, plasma 
samples were thawed and 200 µl aliquots were subjected to a proteinase K digest for 10 
min at 56 oC.  Samples were then vortexed with an equal volume of ethanol to enable 
DNA to bind to the spin column.  The sample was then loaded onto a QIAmp Mini spin 
column and spun at full speed for 1 min.  The eluate was collected and discarded.  
Subsequent washes were carried out with buffers AW1 for 1 min at 6000 x g and AW2 
for 3min at full speed.  The DNA was then eluted by loading 50 µl DNAse free water onto 
the column, incubating for 5 min and then centrifuging at 6000 x g for 1 min.  The eluate 
was added back on to the column and spun again at 6000 x g for 1 min. 
3.1.13 Determination of DNA concentration 
DNA extracted using the above described methods 1.3.1-1.3.3 was stored at -80oC.  
Concentration (ng/µl) was determined using the NanoDrop® ND-1000 
spectrophotometer (Nanodrop technologies, USA).  A260/A280 ratios were recorded to 
assess purity. 
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3.1.14 KRAS Sequenom MassARRAY iPLEX  
DNA samples extracted from HCC plasma samples were sent to NewGene Ltd, 
Newcastle-upon-Tyne, UK.  The KRAS assay was performed using the Sequenom 
MassARRAY iPLEX platform.  This method is a high throughput single nucleotide 
polymorphism (SNP) platform that utilises matrix-assisted laser desorption/ionization-
time of flight (MALDI-TOF) mass spectrometry to resolve. 
Gene Mutation  Gene Mutation 
KRAS G12R   KRAS Q61X 
KRAS G12S  KRAS Q61P 
KRAS G12C  KRAS Q61R 
KRAS G12A  KRAS Q61L 
KRAS G12D  KRAS Q61H 
KRAS G12V  KRAS Q61Q 
KRAS G13R  KRAS Q61H 
KRAS G13S  KRAS A146P 
KRAS G13C  KRAS A146T 
KRAS G13A  KRAS A146S 
KRAS G13D  KRAS A146G 
KRAS G13V  KRAS A146E 
KRAS Q61E  KRAS A146V 
KRAS Q61K  BRAF V600E 
Table 3.1 List of mutations explored using the Sequenom MassARRAY iPLEX platform. 
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3.2 Aims 
 To explore the presence and characteristics of CTCs in HCC patient blood 
samples using the Imagestream using an optimised biomarker panel. 
 To explore correlations between the presence of CTCs with clinical parameters; 
including tumour characteristics, time to progression and survival.  
 To develop an assay to detect ctDNA in HCC patient blood samples and 
determine KRAS mutational status. 
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3.3 Results 
3.3.1 Newcastle CTC cohort 
Blood samples were collected from 69 HCC patients and processed and assessed for 
CTCs as outlined in Chapter 2.  The patient set from which blood samples were collected 
included a range of patients at different stages of disease progression Table 3.2.  The 
median patient age for the cohort was 73 years and approximately two thirds of patients 
(66.7%) had HCC developed on an aetiology of ALD (31.9%) or NAFLD (34.8%).  The 
majority of patients (71%) had liver cirrhosis, with a mean of 1.9 SEM±0.2 nodules and 
a mean tumour size of 58 SEM±6mm.  Few patients had known extra-hepatic disease 
(13%) and 18.8% had PVT.  Most patients had underlying liver disease that was 
categorised as Child-Pugh A but HCC that was defined as BCLC stage C, attributed to 
portal vein invasion (18.8% of all patients), the presence of EHD (13% of all patients) or 
a performance status of >0 (69.6% of all patients).  Most samples - 40/69 (58%) - were 
taken prior to the commencement of treatment but in the post-treatment cases, the 
majority received loco-regional arterial therapy (with DEB-TACE or SIRT). Supportive 
care was the second most common HCC management decision. 
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Cases All At diagnosis Post-treatment 
Number of cases 69 40 29 
Age (median) 73 74 69 
Liver disease 
None 
ALD 
NAFLD 
PBC/AIH 
Haemochromatosis 
Cryptogenic 
8 
22 
24 
9 
4 
2 
6 
13 
12 
3 
4 
2 
2 
9 
12 
6 
0 
0 
Cirrhosis (present) 49 25 24 
Tumour number  1.9±0.2 1.9±0.2 1.8±03 
Tumour size (mm)  58±6 72±9 38±5 
PVT (present) 14 9 5 
EHD (present) 9 4 5 
Childs Pugh A/B/C 58/8/3 31/6/3 27/2/0 
BCLC A/B/C/D 11/5/50/3 4/1/32/3 7/4/18/0 
PST 0/1/2/3 21/17/27/4 8/9/1/9/4 13/8/8/0 
AFP (median kU/L) 14 (≤1-≥50000) 14 (≤1-≥50000) 18.5 (≤1-≥50000) 
Albumin (g/l) 38.9±5.4 38.5±5.3 39.5±5.6 
Bilirubin (µmol/l) 18.2±15.4 19.0±15.3 17.2±15.8 
Prothrombin time (s) 12.6±2.5 12.9±2.7 12.3±2.3 
Encephalopathy 
(present) 
4 2 2 
Ascites (present) 6 5 1 
Primary Treatment 
Liver transplant 
Resection 
Ablation 
Arterial treatment 
Sorafenib 
Supportive care 
4 
3 
7 
27 
9 
19 
2 
2 
3 
7 
7 
19 
2 
1 
4 
20 
2 
0 
Table 3.2 Demographics of patients in the CTC HCC cohort (n=69).  Blood samples were 
collected from patients during diagnosis, staging and pre- and post-treatment.  Ablation 
treatment was using microwave and aterial treatment was using drug eluting bead-
transarterial chemoembolisation (DEB-TACE) or selective internal radiotherapy(SIRT). 
ALD=alcoholic liver disease; NAFLD=non-alcholic fatty liver disease; PBC=primary biliary 
cirrhosis; AIH=autoimmune hepatitis; PVT=portal vein thrombosis; EHD=extra-hepatic 
disease; BCLC=Barcelona Clinic for Liver Cancer; PST=performance status; 
AFP=alphafetoprotein. ±SEM. 
  
 94 
 
3.3.2 Between 1-1642 CTCs were detected in 65% of HCC patient samples using 
the Imagestream and CTCs could be detected on the basis of size  
Based on data generated during development and optimisation of the CTC assay 
(Chapter 2), since the expression of HCC biomarkers was heterogeneous amongst HCC 
cell lines, CTCs were initially identified on the basis of one of a panel of positive 
biomarker expression (CK, EpCAM, GPC3, SULF2, DNA-PK) in combination with a 
positive nuclear stain and CD45 negativity.  Subsequent analyses confirmed that the size 
of HCC CTCs was considerably larger than WBCs and consistent in size with HCC cell 
lines Figure 3.1B.  The mean surface area of biomarker positive CTCs was 362.2 µm2 
SEM±55.5; which was similar to the area of biomarker negative CTCs (345.2 µm2 
SEM±38.4) and HCC cell lines which ranged from the smallest being HepG2 (219.5 µm2 
SEM±2.1) to SNU475 (402.7 µm2 SEM±2.9).  The area of CTCs detected and HCC cell 
lines was in contrast to the area of WBCs of which the mean was 88.3 µm2 SEM±0.2.  
Therefore, by selecting a sub-population of cells on the basis of brightfield area a smaller 
final population of cells to analyse by eye was selected Figure 3.1A.  Observers were 
not blinded to patient status and were aware of whether the sample was a control or from 
a patient with HCC. 
In the Newcastle HCC CTC patient cohort Table 3.2, CTCs were detected in 45/69 (65%) 
of HCC patients.  In the control samples, which consisted of 15 healthy volunteers and 
16 cirrhotic patients, 0 CTCs were detected.  The number of CTCs in HCC patient 
samples was highly variable with CTC counts ranging from 1-1642 CTCs per 4ml of 
blood Figure 3.1C.  In 38 out of the 45 patients that had CTC-positive samples, ≤10 
CTCs were detected per 4 ml of blood.  A further 5/45 patients had a CTC count between 
10 and 50 CTCs per 4 ml of blood.  Two patients that had CTC-positive samples had 
high CTC counts of 197 and 1642 CTCs per 4 ml.   
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Figure 3.1 A. CTCs could be discriminated from WBCs on the property of brightfield area.  
C. Area of CTCs was greater than that of WBCs and comparable to HCC cell lines.  D. CTC 
count in HCC patient samples was highly variable with a range of 1-1642 CTCs per 4ml of 
blood.   
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3.3.3 Heterogeneity in biomarker expression in HCC CTCs 
The biomarker panel for the characterisation of HCC CTCs was initially performed using 
cell lines.  Antibodies and fluorophores were chosen based on the localisation of the 
protein and to minimise spectral overlap.  The final antibody panel included epithelial 
biomarkers CK and EpCAM to enable comparisons to be made with the CellSearch 
system reported data.  AFP was included since it is the only clinically validated biomarker 
in HCC.  Furthermore, one of the aims of the project was to include biomarkers that had 
potential clinical relevance.  GPC3, SULF2 and DNA-PK were also included since 
evidence suggest that these biomarkers may be useful in terms of diagnosis and 
treatment stratification. 
Preliminary experiments in HCC cell lines demonstrated the heterogeneity in biomarker 
expression suggesting that an optimal biomarker panel would include a combination of 
biomarkers in order to detect and characterise CTCs in HCC patient samples.  Although 
it was later observed that CTCs were larger in size in comparison to WBCs it was noted 
that there was heterogeneity amongst biomarker expression in HCC CTCs.  In cases 
where CTCs were detected, 37% demonstrated positive expression of one or more 
biomarkers included in the panel; whereas in a further 28% of cases, the presence of 
cells that were nucleated, larger in size to WBCs, CD45 negative and did not stain 
positively for any of the biomarkers included in the panel were noted.  This may indicate 
that these cells may be a sub-type of CTCs that had a different phenotype compared to 
other CTCs that did positively express the biomarkers of interest; for example cells that 
had undergone EMT, although this is only speculation.  In CTCs that did positively 
express biomarkers of interest, CK was the most frequently expressed biomarker (29%), 
followed by DNA-PK (24%), AFP (20%), EpCAM (18%) and GPC3 (12.5%).  SULF2 was 
not detected in any CTCs found in HCC patient samples.  
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Figure 3.2 Heterogeneity amongst biomarker expression in HCC CTCs.  A. CTCs 
expressing either EpCAM or CK with CD45-posiitve WBCs in the same frame indicating 
size difference.  B. CTCs expressing CK in addition to AFP and DNA-PK.  C. Doublets of 
CTCs expressing DNA-PK or AFP and CK or DNA-PK and EpCAM.  D. GPC3-positive CTCs 
displaying cytoplasmic and membranous expression.  E. A triplet of biomarker-negative 
CTCs, distinguished on cellular morphology, size and DNA content. 
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3.3.4 CTCs observed travel in the peripheral blood individually and as 
aggregates with CTCs and leucocytes 
In addition to CTCs travelling singularly in the blood, it was also observed that in 14/45 
(31%) of CTC-positive patients CTCs travelled together as doublets or aggregates 
Figure 3.3A-B. In 11/14 of cases where CTCs were observed travelling together, CTCs 
were observed as doublets, while in 5/14 cases, CTCs were observed as aggregates 
(>2 CTCs per cluster).   
Another rare observation made was that of white blood cell interaction with CTCs Figure 
3.3C.  The clinical significance of this observation is not known but in one case where 
this observation was made in a pre-transplant patient, follow-up data showed that the 
patient did not have disease recurrence during the follow up period of 33 months post- 
transplant. 
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Figure 3.3 A. Doublets of CTCs were observed in 11/45 CTC-positive samples.  B. 
Aggregates of CTCs (>2 CTCs per cluster) were observed in 5/45 CTC positive samples.  
C. Leucocyte interaction with CTCs was also observed. 
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3.3.5 Other observations in HCC patient samples included dividing cells and 
cells with a macrophage phenotype 
One of the points up for discussion in CTC research is whether or not the CTCs are 
viable are capable of forming metastatic lesions.  Instances of cells that appeared to be 
dividing were apparent Figure 3.4A.  Once again, the clinical significance of this 
phenomena is not known due to the low number of instances. 
A frequent observation in both control samples and HCC patient samples was that of 
cells with a macrophage-like morphology Figure 3.1B.  These cells often stained 
positively for the biomarkers of interest, sometimes being CD45 negative and sometimes 
appearing CD45 positive.  It is unclear whether or not these are definitely macrophages 
or damaged cells but they were certainly larger in size compared to WBCs and CTCs. 
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Figure 3.4 A. EpCAM-positive CTCs that appeared to be dividing.  B. Cells that were 
nucleated, large in size and picked up multiple dyes had a morphology consistent with 
macrophages. 
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3.3.6 Imagestream CTC count was associated with advanced HCC stage 
Samples were collected from 69 HCC patients at varying stages of disease and 
treatments.  Exploration of correlations between CTC number and clinical parameters 
were explored using bivariate correlations.  CTC number positively correlated weakly 
with features identified with a worse prognosis; including size of the largest tumour 
(0.291, p=0.015) and presence of hepatic encephalopathy (0.336, p=0.005) Spearman’s 
Rho test.  41/65 HCC patients without hepatic encephalopathy had a median number of 
1 CTC per 4ml; compared to the 4/4 patients with encephalopathy where the median 
number of CTCs detected was 10. 
Regarding the biomarker positivity of CTCs detected, correlations were also explored.  
EpCAM expressing CTCs positively correlated with CK expressing CTCs (0.497, 
p<0.0001), AFP expressing cells (0.463, p<0.0001) and GPC3 positive cells (0.405, 
p=0.024).  The strongest correlation was observed between CK and AFP positivity on 
HCC CTCs (0.786, p<0.0001).  Correlations between individual biomarkers and HCC 
disease stage were not significant – possibly due to the small number of cases. 
Collectively, numbers of biomarker-positive CTCs had a weak, positive correlation with 
encephalopathy (0.331, p=0.005) and there was a trend towards association with tumour 
size (0.236, p=0.05).  There was also a weak inverse correlation between the presence 
of biomarker positive CTCs and serum albumin (-0.354, p=0.003).  Biomarker negative 
cells were weakly associated with the presence of PVT (0.348, p=0.004) Spearman’s 
Rho.  Also, there was an indication of an association between biomarker negative CTCs 
and neutrophils (0.240, p=0.049) in blood counts taken on the same day that the CTC 
blood sample was collected. 
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3.3.7 The presence of CTCs in HCC patients is indicative of a shorter survival 
time  
Follow-up data from the Newcastle HCC CTC cohort was collected where possible, 
including time to radiological or clinical progression and survival.  Initially, variable 
affecting survival were identified in a univariate Cox regression analysis Table 3.3A.  
Factors that were identified as being significantly associated with survival included: 
number of CTCs per 4ml (p=0.043); tumour size (p<0.0001); presence of PVT 
(p=0.0002) and presence of EHD (p<0.0001).   
In multivariate analyses Table 3.3B-C, CTCs, presence of PVT/EHD were independent 
of each other.  The presence or absence of CTCs was not significantly associated with 
survival (p=0.127).  However, when patients were divided into groups based in whether 
they had ≤1 CTC per 4 ml (n=37), compared to those that had >1 CTC per 4 ml (n=32) 
notable differences in survival were observed.  Receiver operating characteristic (ROC) 
curve analysis was performed to determine a threshold of >1 (optimal cut-off 1.250, 
sensitivity 68.75%, specificity 72.97%, likelihood ratio 2.544).  Kaplan-Meier regression 
analysis and the Log-rank test were performed Figure 3.5.  The presence of >1 CTC/4ml 
was a significant, independent predictor of survival in the cohort of 69 HCC patients with 
patients with >1 CTC/4 ml having a median overall survival of 7.5 months compared to 
those with a CTC count of ≤1 CTC/4 ml who had a median overall survival of 34 months 
(p<0.0001) Figure 3.5A.  The threshold of ≤1 CTC per 4 ml remained significant in a 
multivariate analysis (p=0.049, HR 2.34, 95% CI 1.005-5.425) Table 3.3C.  Looking at 
only the patients that had received prior treatment (n=29), median survival was also 
different when comparing groups of patients that had ≤1 CTC/ 4 ml and those that had 
>1 CTC/ 4 ml (21.6 months vs 7.5 months respectively), p<0.0001 Figure 3.5C.  Time 
to progression was also longer in patients that had ≤1 CTC per 4 ml compared to those 
that had >1 CTC per 4 ml detected (median 5.3 months vs 1.9 months) Kaplan-Meier 
with Log-Rank p=0.006 Figure 3.5B.  This was also true in the post-treatment group (8.4 
months vs 1.6 months) p=0.002 Figure 3.5D. 
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Figure 3.5 Kaplan-Meier survival curves of patients with ≤1 CTC/4ml or >1 CTC/4ml in A. 
the full cohort of 69 HCC patients and C. Patients that had received any form of treatment 
(n=29) after which a sample was assessed for the number of CTCs.  Time to progressions 
(TTP) first documented radiological or clinical is shown for the full cohort of patients in B. 
and for the subset of patients that had received prior treatment in D. 
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Table 3.3 Variables that were significant in the univariate analysis (p<0.05) were entered into the multivariate analysis. Where variables were categorical 
(cat) the comparator variable was that with the best outcome.   
A. Univariate 
Analysis 
B. Multivariate Analysis   C. Multivariate Analysis 
 95% CI  95% CI 
  p HR Lower Upper  p HR Lower Upper 
CTC number/ 4ml  0.043 0.025 1.002 1.000 1.003  (Not included) 
CTC >1 / 4ml <0.0001 (Not included)  0.049 2.335 1.005 5.425 
Age (median year) 0.217       
BMI 0.474          
T2DM 0.939          
Cirrhosis 0.643          
No of tumours 0.071          
Size of largest (cm) <0.0001 0.174 1.005 0.998 1.013  0.065 1.007 1.000 1.014 
PVT (cat) 0.002 0.005 3.568 1.467 8.679  0.023 2.575 1.140 5.818 
EHD (cat) 0.001 0.003 4.163 1.634 10.605  0.122 1.999 0.831 4.807 
Ascites   0.061          
Encephalopathy 0.183          
AFP (median) 0.065          
Albumin (g/l) 0.120          
Bilirubin (µmol/l) 0.582          
Prothrombin time 0.566          
PST (cat) 0.127          
Treatment (cat) 0.072          
BCLC stage 0.187          
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3.3.8 pERK and c-MET expression in CTCs in HCC 
A small cohort of HCC patients (n=14) were assessed for the presence of CTCs and the 
expression of the biomarkers pERK and c-Met (M. McCain, Unpublished data).  In this cohort, 
3/14 patients provided blood samples that tested positive for CTCs – the lower number 
perhaps partly attributed to the learning curve associated with sample preparation by our 
MRes student.  Out of the three patients that were CTC-positive, one patient had 3 CTCs that 
were negative for both pERK and c-Met, one patient had 13 CTCs one of which one was c-
Met positive and the final patient provided two samples – one pre-TACE and one 24h post-
TACE.  In the pre-TACE sample, 46 CTCs were counted; 14 of which were pERK positive and 
2 of which were c-Met positive.  In the post-TACE sample, twice as many CTCs were counted; 
however none were pERK positive and only one was c-Met positive.  This cohort of patients 
was too small to infer clinical correlations and was not included in the main cohort analysis of 
HCC patients. 
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3.4 Development of an assay for the detection of ctDNA in HCC 
Although it was possible to detect CTCs in 65% of HCC patients, often the number of CTCs 
per 4 ml was low.  Methods of ctDNA detection have become more sensitive and specificity 
has improved through the detection of mutational status.  Although the key genetic drivers of 
hepatocarinogenesis remain to be fully defined, activation of the RAS signalling pathway has 
been identified in patients with HCC developed on a background of HBV, HCV and ALD 
(Newell et al., 2009).  Previous work within the Newcastle Hepatology research group 
demonstrated that there was increased activation of the RAS signalling pathway in a 
NAFLD/NASH murine model of hepatocarcinogenesis; leading to the hypothesis that this may 
be mirrored in HCC patient samples with a NAFLD/NASH aetiology.  Additionally, Refametinib 
(BAY86-9766), a MEK1/2 inhibitor is currently in clinical trials (trial identifier: NCT01915589) 
for the treatment of HCC patients with unresectable or metastatic disease with a known KRAS 
or NRAS mutation. 
The KRAS iPLEX method has the ability to detect mutant DNA in a background of wt DNA 
when it is present at a percentage of 5-10%.  This assay is more sensitive than Sanger 
sequencing which is able to detect mutant DNA if it is present in quantities ~20-30%.  
Currently, the KRAS iPLEX assay is clinically validated to determine the mutational status of 
KRAS in patients with colorectal cancer using FFPE sections.  Mutations in KRAS can lead to 
its constitutive activation leading to resistance to the EGFR inhibitor Cetuximab which is a first 
line therapy in patients with colorectal cancer.  Our aim was to determine whether or not it 
would be possible to translate this assay into a blood-based assay in patients with HCC to 
determine KRAS mutational status using ctDNA.   
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3.4.1 Extraction of ctDNA from frozen plasma samples 
In order to determine the suitability of the iPLEX KRAS assay for use with ctDNA extracted 
from blood, DNA was extracted from three different sample types: FFPE sections, plasma and 
cell lines.  DNA from a colorectal cell line (SW480) - with a known KRAS mutation in codon 
12 - was included as a positive control; DNA extracted from FFPE section slides from a 
colorectal cancer patient and plasma from both a healthy volunteer (negative control) and a 
HCC patient with a large (4.2cm) tumour were tested.  DNA concentrations from the 
aforementioned samples varied.  All samples were tested using the KRAS iPLEX assay 
whereby the tester was blinded to the sample type.  Results confirmed the presence of the 
G12V mutation in the SW480 cell line and all other samples were negative for KRAS mutations 
included in the assay. 
3.4.2 KRAS mutations ~5% HCC patient samples with HCC developed on a 
background of NASH/NAFLD 
In the initial testing, DNA extracted from FFPE sections was used as a comparator to 
determine if DNA obtained from plasma samples was of a similar quantity and would perform 
similarly to DNA extracted from FFPE sections in the KRAS assay.  In total, 38 HCC patient 
plasma samples were tested.  KRAS mutations were detected in 2/38 (5.26%) HCC patient 
plasma samples.  Both of these mutations were at the same codon (KRAS codon 12A) 
involving the same base change (G>T), resulting in an amino acid change from glycine to 
cysteine.  To test the specificity of the assay, one of the samples that had a mutation was re-
tested.  A mutation in the same codon was detected however this time the base change was 
detected as G>C as opposed to G>T Figure 3.6.   
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Figure 3.6 DNA extracted from plasma was assessed for the presence of KRAS mutations 
Table 3.1. A. Wild-type DNA.  B. Example showing a mutation of glycine > cysteine in KRAS 
codon 12. 
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3.5 Discussion 
In the previous chapter, the method of patient sample CTC enrichment and detection was 
discussed.  This was worked up using a panel of 6 HCC cell lines that were heterogeneous 
for the biomarkers of interest leading in the creation of a panel containing multiple biomarkers.  
Also, in our patient cohort we were interested to investigate the expression of additional 
biomarkers including: DNA-PK, GPC3 and SULF2.  Overall detection of CTCs in this HCC 
patient cohort was 65% compared to 0% in the control samples.  Taking into account only 
epithelial-positive CTCs, results were comparable with other studies (Schulze et al., 2013, 
Morris et al., 2014).  Application of a size criterion also identified CTCs that were positive for 
other biomarkers included in the panel and also identified a population of CD45-negative, 
nucleated cells that were negative for all biomarkers included in the panel.  This suggests that 
CTC detection platforms that are reliant on epithelial markers may be under-detecting a 
proportion of CTCs that are epithelial marker negative – possibly as a result of undergoing 
EMT.  Unfortunately, one of the limitations of the method described above is that cells are not 
viable at the end of the process so it is not possible to perform further downstream analysis 
on these cells.   
Using the Imagestream as a method of CTC detection also led to the observation of some 
other interesting objects that would have been likely to have gone unnoticed using other forms 
of CTC detection.  In several HCC patients, CTCs appeared to be travelling in clusters.  This 
phenomenon has already been reported by researchers using the ISET technique and it has 
been suggested that clusters of cells may be more likely to be able to form metastases at 
distant sites (Vona et al., 2000).  It is still not known as to whether this is a true phenomenon 
or if it is an artefact of the methods used.  CTCs with leucocyte interaction were also observed 
which may be indicative of an immune response towards CTCs, eradicating them from the 
blood resulting in such CTCs being unable to form metastatic lesions.  However, a counter 
argument to this is that CTCs may use leucocytes as a protective mechanism to prevent 
immune evasion (Alix-Panabieres and Pantel, 2014).  Larger cohort studies would be required 
in order to infer clinical relevance of these observations. 
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The clinical utility of CTCs in HCC still remains to be determined but results of this study 
suggest that CTCs may have a prognostic role in HCC management.  Factors that were 
significant predictors of prognosis included size of largest tumour, EHD and PVT as well as 
CTC count >1/ 4 ml.  In this cohort of HCC patients, the data presented in this chapter 
demonstrated that the presence of >1 CTC/4ml was an independent predictor of survival and 
TTP in the whole cohort of patients and in the sub-cohort of patients that had samples 
assessed following treatment.  Although in this cohort of patients, none of the control samples 
were CTC-positive; previous studies that have looked into the presence of CTCs in HCC using 
the CellSearch system have classified a level of ≥1 CTC as being a positive result.   
Biomarker positive CTCs weakly correlated positively with the size of the largest tumour and 
hepatic encephalopathy and inversely correlated with serum albumin levels; all of which are 
associated with worsening HCC stage.  In terms of biomarker expression on CTCs, there was 
strongest correlation between cytokeratin and AFP positive cells but there were also trends 
between epithelial biomarkers EpCAM and CK as well as EpCAM with AFP and GPC3.  
Biomarker negative CTCs correlated with neutrophil and platelet counts from blood samples 
taken on the same day.  Studies have indicated that neutrophils have a tumourigenic role in 
HCC (Piccard et al., 2012, Sionov et al., 2015, Xu et al., 2014).  Platelets may also have a 
tumorigenic role with studies suggesting that they may facilitate EMT and form a “protective 
cloak” around CTCs enabling them to evade the immune system (Plaks et al., 2013, Labelle 
et al., 2011). 
Isolation of cfDNA from HCC plasma samples was briefly investigated to determine if this may 
be a suitable method to obtain molecular information from the tumour and potentially have a 
role in stratifying patients for therapy.  The method employed to detect KRAS mutations in 
ctDNA from HCC samples is currently a clinically validated method for use with FFPE sections 
from patients with CRCa.  The KRAS iPLEX method has the ability to detect mutant DNA in a 
background of wt DNA when it is present at a percentage of 5-10%.  This means that it is more 
sensitive than Sanger sequencing which is able to detect mutant DNA if it is present in 
quantities ~20-30%.  Although initial testing showed that it was suitable for use on patient 
plasma samples, in the samples that were tested for the presence of KRAS mutations, in some 
cases single SNPs failed and in one of the patients where a mutation was detected, on re-
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testing the base had changed raising issues about specificity despite this being a clinically 
validated assay for patients with colorectal cancer. 
Ideally, this assay would have been developed using a mutation that was highly prevalent in 
patients with HCC.  For example, mutations in the TERT promoter region have been 
recognised in ~59% of patients with HCC (Nault et al., 2013).  Attempts were made to 
implement the detection of mutations in this region into a blood-based assay; however due to 
the high GC content of the promoter region attempts at primer design and assay optimisation 
failed.  Another option could be to use the Ultraseek which is a more sensitive method than 
the iPLEX method, with the ability to detect ≤1% of mutant DNA in a background of wtDNA.  
Furthermore, the Ultraseek provides the options of testing for a panel of oncogene mutations.  
However, this method is much more costly.  An alternative method to improve the detection of 
KRAS mutations in patient plasma samples may be to enrich the DNA prior to running the 
KRAS iPLEX.  
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3.6 Conclusions 
 1-1642 CTCs were detected in 65% of HCC patients using the Imagestream.  
Biomarker expression on patient CTCs was heterogeneous, with some cells negative 
for all biomarkers included in the panel.   
 The presence of >1 CTCs per 4 ml of blood compared to ≤1 CTC per 4 ml of blood 
indicated a worse median survival time in HCC patients (7.5 months vs 34 months, 
p>0.0001) and shorter TTP (1.9 months vs 5.3 months, p=0.006).  These differences 
were also observed in the post-treatment group; patients with >1 CTC had shorter 
median survival compared to those with patients who had ≤1 CTC per 4 ml (7.5 months 
vs 21.6 months, p<0.0001) and TTP (1.6 months vs 8.4 months, p=0.0002). 
 CTC detection using the Imagestream also enables observation of leucocyte-CTC 
interactions, tumour-associated macrophages and CTC clusters although the clinical 
significance of these phenomena is unknown. 
 It is possible to isolate ctDNA from HCC plasma samples but in order to improve this 
assay it would be necessary to test for a mutation that is more prevalent in human 
HCC, use a pre-enrichment step for ctDNA or use a more sensitive method of mutant 
DNA detection. 
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Chapter 4. Circulating immune cells and Hepatocellular Carcinoma 
4.1 Introduction 
Innate immune cells contribute to inflammation, which is recognised as an enabling 
characteristic for the other hallmarks of cancer (Hanahan and Weinberg, 2011).  In 
hepatocellular carcinoma (HCC), it is estimated that approximately 90% of cases develop 
within an environment characterised by chronic inflammation (Nikolaou et al., 2013). 
Furthermore, inflammatory cells are common in the tumour microenvironment, which is 
comprised of numerous non-malignant cells with tumour-promoting properties, with signalling 
and communication recognised between the malignant and non-malignant components 
(Balkwill et al., 2012, Hanahan and Coussens, 2012).  Remarkably, it has been estimated that 
over 50% of the total tumour mass may be comprised of non-tumour cells and stromal tissues 
(Balkwill et al., 2012).  Presently, although inflammatory cells exist in pre-malignant tissues 
and tumour masses, and the tumorigenic potential of inflammation has been established, the 
individual roles of inflammatory cells and crosstalk between these cells and the tumour cells 
in the tumour microenvironment remains to be fully understood. It is suspected, however, that 
the tumour microenvironment could be an important factor to consider in patients with cancer, 
possibly associated with progression and prognosis, but also response to treatment (Balkwill 
et al., 2012).  
4.1.1 Neutrophils  
Circulating immune cells are commonly called ‘white cells’, as opposed to red blood cells 
carrying haemoglobin, with the most abundant being the neutrophil. Neutrophils play an 
important role in the activation and regulation of both innate and adaptive immune responses 
(Mantovani et al., 2011).  Although neutrophils have an important role in the immune response 
to infection, they can be retained in tissues such as the liver, where their excessive activation, 
characterised by the release of ROS, has the potential to induce liver damage (Jaeschke, 
2006).  Associations with viral hepatitis, ALD and NAFLD have been reported, as have 
associations with progression to fibrosis and cirrhosis. Attempts to reduce the number of 
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neutrophils has been considered as an immunotherapy, presently limited to patients with HBV 
and HCV (Xu et al., 2014).  
Notably, emerging literature supports paradoxical roles for neutrophils in patients with cancer, 
possibly related to their phenotype rather than actual numbers in either tissues or the 
circulation.  Akin to tumour associated macrophages (TAMs), tumour associated neutrophils 
(TANs) have been recently described as potentially having either an anti-tumorigenic (N1) 
phenotype or a pro-tumorigenic (N2) phenotype. While neutrophils attraction or retention in 
the liver may be chemokine driven e.g. CXCR2, their phenotype is thought to be further 
influenced by the tumour microenvironment, where TGF-β is an important effector molecule 
leading to the switch of neutrophils to a pro-tumorigenic (N2) phenotype (Xu et al., 2014). This 
switch is not necessarily restricted to the liver.  In a study performed by Sagiv and colleagues, 
distinct populations of circulating neutrophils were described, differentiated on the basis of cell 
density with cancer patients having a significant increase in the number of low-density 
neutrophils (Sagiv et al., 2015).  N2 neutrophils may have multi-faceted tumorigenic roles, 
including promotion of tumour growth; evasion of apoptosis; promotion of genetic instability; 
angiogenesis; invasion, and metastasis, (Piccard et al., 2012, Sionov et al., 2015).  
4.1.2 Lymphocytes 
The roles of circulating and tissue lymphocytes is an active area of research, but the 
complexities remain poorly understood.  Contrary to neutrophil studies, an increased number 
of TILs – although rare in HCC - is considered a good prognostic indicator and associated with 
decreased risk of recurrence in resection patients (Shirabe et al., 2010, Wada et al., 1998).  
Furthermore, in a randomised trial where 76/150 patients were subjected to immunotherapy 
in the form of activated lymphocyte infusions post-operatively, their time to recurrence was 
longer and recurrence frequency decreased by 18% (Takayama et al., 2000).  Although there 
was no significant difference in overall survival of the treated group compared to the control 
group, recurrences were actively treated, confounding subsequent follow-up.  Thus the 
importance of delayed recurrence should not be lightly dismissed. However, presently we are 
a long way off assuming all increases in lymphocytes are ‘good'. Increased number of 
circulating T-regulatory (Treg) cells in the blood of HCC patients compared to controls has 
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been reported (Ormandy et al., 2005).  In another study, the proportion of the Treg population 
that were TGFβ-positive was increased in HCC patients, rather than total numbers (Unitt et 
al., 2005).  These are small studies and associations with outcome unreported. In a mouse 
model of inflammation-associated epithelial carcinogenesis, B-cells are required for malignant 
transformation (de Visser et al., 2005) and there have been reports of an increased number 
of circulating B-regulatory (Breg) cells in patients with HCC, with higher counts being 
associated with more advanced disease (Shao et al., 2014). Thus, as in the case of 
neutrophils, it is likely that lymphocytes can play protective and promoting roles in both tumour 
initiation and progression.  
4.1.3 Platelets 
The role of circulating platelets or platelets within tissues in HCC is less well studied and 
potentially difficult to interpret in patients with liver disease. Circulating platelet counts are 
often seen to rise in association with inflammation.  In patients with cirrhosis and portal 
hypertension, characterised by hypersplenism and a shorter platelet life expectancy, platelet 
counts are typically lower, and any relative increase potentially masked. Generally, however, 
platelets are proposed to have tumour promoting roles. A study carried out by Hynes and 
colleagues indicated that platelet-activation of both the TGFβ and NFB-signalling pathways 
resulted in EMT, increasing invasiveness and metastatic potential of tumour cells (Labelle et 
al., 2011). Furthermore, it has been suggested that platelets may play a role in cancer 
metastasis by providing a protective role to circulating tumour cells (CTCs) - shielding them 
from physical damage and enabling immune system evasion (Plaks et al., 2013).   
4.1.4 Circulating inflammatory cells prognostic scores  
The ratios of circulating immune cells have been shown to be indicative of prognosis in 
patients in a range of different cancer types.  In HCC, an increased number of neutrophils 
combined with a decreased number of lymphocytes has often been proposed as the biomarker 
most indicative of the level of inflammation in patients (Xu et al., 2014).  The neutrophil to 
lymphocyte ratio (NLR) has been shown to have prognostic value in HCC patients undergoing 
 117 
 
a range of different treatment regimens.  A NLR or ≥5 versus <5 was shown to be a poor 
prognostic indicator in a cohort of 96 patients undergoing resection (Gomez et al., 2008), as 
well as in a cohort of 160 patients treated with liver transplantation (Limaye et al., 2013).  Chen 
and colleagues demonstrated that a post-operative increase in NLR was associated with 
significantly different PFS, as well as OS at 1-, 3-, and 5-years following treatment with 
radiofrequency ablation (Dan et al., 2013).  Thus far, the studies in transplanted patients have 
been largely limited to those with HCC arising on a background of viral hepatitis (Limaye et 
al., 2013, Yoshizumi et al., 2013).  In the study by Yoshizumi et al, transplanted organs were 
from living donors, treating cases of recurrent HCC without a size restriction, thus including 
more advanced cases beyond ‘Milan Criteria’.  Surgical series also have some limitations, also 
including patients presenting with more advanced symptomatic disease (Yoshizumi et al., 
2013, Gomez et al., 2008).  Furthermore, the NLR is an established predictor of cirrhosis 
irrespective of the presence of cancer (Biyik et al., 2013), and in some studies is not 
necessarily accounted for in multivariate analyses (Gomez et al., 2008).  Thus the true 
prognostic or predictive value of NLR independent of aetiology and severity of underlying liver 
disease, at different stages of disease, remains to be validated.  
A possible step forward was reported in a recent study taking into account platelets as well as 
neutrophils and lymphocytes. The research team used these parameters from a standard 
blood count in a retrospective cohort of 133 resection patients to create the systemic immune-
inflammation index (SII) (Hu et al., 2014).   X-tile analysis was carried out to determine optimal 
cut-off values resulting in a group of patients with a low SII (<330 x 109) and patients with a 
high SII (≥330 x 109) (Hu et al., 2014).  A prospective cohort of 123 patients was used to 
validate the SII. Additional blood samples were also collected from this cohort to assess for 
the presence of EpCAM and CK-positive CTCs using the CellSearch method.  The SII score 
was compared to both the NLR and platelet to lymphocyte ratio (PLR).  In a multivariate Cox 
regression analysis, the SII was deemed to be a highly significant predictor of OS and relapse-
free survival.  Correlations with clinical parameters showed that a high SII was significantly 
associated with large tumours, vascular invasion and the number of CTCs (Hu et al., 2014). 
In this chapter, inflammation status in a much larger and heterogeneous cohort of HCC 
patients has been explored, attempting to validate prognostic scores across all stages of 
disease, as well as to pinpoint key associations or roles for individual cell types.  The patients 
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included those presenting to our own tertiary referral centre in Newcastle, but also a cohort 
presenting in Hong Kong.  These combined patient cohorts comprised 1168 patients, with the 
opportunity to assess the impact of different aetiologies, clinical factors and treatment 
regimens.  We have explored the inflammatory status in HCC patients by investigating 
relationships between circulating inflammatory cells and clinical parameters.  Furthermore we 
have investigated the prognostic value of previously described immune cell ratios in this large 
patient dataset.  
 119 
 
4.2 Aims 
 To define the association between the counts and ratios of circulating inflammatory 
cells and clinical parameters, including tumour stage and markers of liver function, in 
a test patient cohort. 
 To explore the associations of circulating inflammatory cells and scores with survival 
in the test cohort. 
 To investigate if the circulating inflammatory biomarkers retained prognostic value in 
an independent cohort of patients, with a different predominant aetiology undergoing 
different treatment regimens 
 To explore in a single, combined, larger cohort the value of the candidate inflammatory 
biomarkers of predicting outcome overall as well as within defined stages or treatment 
categories  
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4.3 Materials and Methods 
4.3.1 HCC Patient Blood Count Data - Newcastle Cohort 
Blood count data was retrospectively collected from a cohort of HCC patients (n=583) 
presenting at the Newcastle-upon-Tyne Foundation Trust between 2000 and 2010 Table 4.1.  
Laboratory blood data included total white cell count (WCC), neutrophils, lymphocytes and 
platelets.  Serum measurements of AFP, albumin, bilirubin, INR, sodium and creatinine were 
also recorded.  The blood count data used was that collected closest to the date of diagnosis.  
Clinical parameters collected alongside included patient demographics (age, sex); aetiology; 
mode of presentation; assessment of underlying liver disease (presence/absence of cirrhosis, 
Child-Pugh score and grade); tumour characteristics (number of nodules, size, extra-hepatic 
metastases, PVT, lymph node involvement, ascites, encephalopathy); staging information 
(TNM, BCLC classification, Okuda, CLIP, ECOG Performance Status) and primary treatment.  
Current survival status was recorded and overall survival was calculated in months from the 
date of diagnosis to the date of death (Dyson et al., 2014). 
This dataset was used as a training cohort to explore the relationships between circulating 
immune cells and clinical parameters as well as to determine categorical grouping cut-off 
values. 
4.3.2 Hong Kong Validation Cohort   
In order to explore whether or not observed relationships were reproducible in a non-UK based 
cohort, data from HCC patients with a predominant HBV/HCV aetiology were collected from a 
consecutive cohort of HCC patients (n=585) presenting to Dr Stephen Chan and colleagues 
at the Prince of Wales Hospital, Hong Kong, between 1st January 2007 and 31st July 2013.   
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4.3.3 Combined cohort 
Patient data from all three cohorts was re-coded appropriately to form a combined cohort 
consisting of a total of 1168 HCC patients. 
4.3.4 Neutrophil to lymphocyte ratio and SII score 
The neutrophil to lymphocyte ratio was calculated by dividing the total number of neutrophils 
by the total number of lymphocytes. 
The SII was calculated as outlined by Hu and colleagues (Hu et al., 2014). 
SII = 𝑃𝑙𝑎𝑡𝑒𝑙𝑒𝑡𝑠 (
𝑁𝑒𝑢𝑡𝑟𝑜𝑝ℎ𝑖𝑙𝑠
𝐿𝑦𝑚𝑝ℎ𝑜𝑐𝑦𝑡𝑒𝑠
) 
4.3.5 Statistical analysis 
All statistical analyses were performed using IBM® SPSS® Satistics for Windows, Version 
22.0, IBM® Corporation, Armonk, New York, USA).  Comparisons were performed using the 
Kruskal-Wallis test.  Associations with defined parameters  were using univariate Cox 
regression analysis. Variables that were significant (p<0.01) in a univariate Cox regression 
analysis were included in multivariate Cox regression analyses.  When including categorical 
variables in the multivariate analysis, those with the best outcome or lowest stage were used 
as comparator values denoted by ‘(first)’ unless otherwise stated.  Additional survival analyses 
for plotting daya were performed using the Kaplan-Meier method and Log-Rank test.  Bivariate 
correlation analyses were carried out using Pearson’s correlation coefficient for normally 
distributed parametric data and Spearman’s rho for non-parametric data or data that was not 
normally distributed.  Statistical significance was denoted by the following: ns = not significant; 
*p<0.05, **p<0.01, ***p<0.001.  Subsequently, the Bonferroni correction was also performed 
to account for multiple comparison.  Results are displayed in a table following the initial 
association testing.  For the Bonferroni correction, the p-value (α=0.05) was adjusted based 
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on the number of associations that were tested (n=45).  The adjusted p-value = α/45 = 0.001; 
therefore associations that were significant at the p≤0.001 level were identified.   
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4.4 Results – Newcastle training cohort 
4.4.1 Newcastle cohort description 
The Newcastle cohort consisted of mostly males (81%) of which the median age was 69 years 
old.  The commonest aetiologies for CLD were alcohol-related and NAFLD.  Nearly three 
quarters of patients (73%) had underlying cirrhosis and assessment of underlying liver disease 
scored most patients as Child-Pugh A.  On average patients had 2.55 nodules measuring 6.17 
mm SEM±0.19, with PVT present in approximately a quarter of patients.  EHD was present in 
a small proportion of patients (16%).  Using the BCLC classification, the majority of patients 
(69%) were classed as BCLC C-D.  Most patients received arterial treatment or best 
supportive care. 
4.4.2 Relationship between circulating inflammatory cells, tumour stage and liver 
function 
The classical cancer staging system is the TNM stage, based on tumour number and size, but 
also invasive characteristics including lymph node invasion and extrahepatic metastases. The 
details of the HCC TNM staging system are previously described Section 1.1.9, as are its 
shortcomings in patients with underlying CLD and impaired liver function.  The BCLC staging 
system incorporates an estimate of liver function in the form of the Child-Pugh grade, 
alongside tumour number, size, portal vein invasion and EHD. The numbers of circulating 
inflammatory cells in each of these systems (TNM, Child-Pugh, and BCLC) were compared.   
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Patient demographics 
Male/Female (number) 473/110 
Age (median) 69 (range 18 - 93) 
Aetiology 
Unknown/None 
Alcohol related 
Non-alcoholic fatty liver 
HBV/HCV 
HBV & HCV 
PBC/AIH 
Haemochromatosis 
Cryptogenic 
Other 
114 
168 
127 
28/60 
- 
19/7 
31 
24 
5 
Cirrhosis (Absent/Present) 157/426 
Tumour characteristics 
Number of tumours 2.55 ±0.11 
Size of largest tumour (mm) 6.17 ±0.19 
Portal vein thrombosis (Absent/Present) 430/153 
Extrahepatic disease (Absent/Present) 489/94 
Laboratory blood data 
Median AFP (median; kU/L) 
White cell count (x109) 
Neutrophils (x109) 
Lymphocytes (x109) 
Platelets (x109) 
Neutrophil to lymphocyte ratio 
SII  
Albumin (g/L) 
Bilirubin (µmol/L) 
INR 
Sodium (mmol/L) 
Creatinine (µmol/L) 
27.5 (range 1 – 640,000) 
7.41 ±0.21 
4.82 ±0.12 
1.71 ±0.15 
198.87 ±5.32 
4.11 ±0.19 
855.11 ±46.34 
35.70 ±0.24 
29.16 ±1.61 
1.09 ±0.01 
138.9 ±2.07 
102.64 ±1.74 
Staging 
ECOG Performance Status  Child-Pugh 
0 
1 
2 
3 
4 
217 
160 
115 
78 
13 
A 
B 
C 
369 
132 
80 
BCLC Stage TNM Stage 
0/A 
B 
C 
D 
88 
94 
268 
133 
1 
2 
3 
4 
214 
106 
168 
95 
Primary Treatment 
Liver transplant 
Resection 
Ablation 
Arterial treatment 
Sorafenib 
Supportive care 
53 
31 
65 
188 
9 
237 
Table 4.1 Newcastle cohort patient demographics (n=583). Values are shown as number or mean 
± standard error unless otherwise stated. HBV=hepatitis B virus; HCV=hepatitis C virus; 
PBC=primary biliary cirrhosis; AIH=autoimmune hepatitis; AFP=alphafetoprotein; SII=systemic 
immune-inflammation index; INR=international normalised ratio; ECOG=Eastern Cooperative 
Oncology Group; BCLC=Barcelona Clinic for Liver Cancer; TNM=tumour, node, metastases. 
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4.4.3 Circulating neutrophils and platelets increase with HCC TNM stage 
The mean total WCCs, neutrophils and platelets increased significantly in association with 
more advanced tumour stage as determined by the TNM system Figure 4.1. Similarly, the 
NLR and SII increased, although the significance of these associations were driven largely by 
neutrophils and platelets, as there was no clear difference in lymphocyte numbers based on 
TNM. 
4.4.4 Circulating lymphocytes fall in association with deteriorating liver function 
In contrast to tumour stage, study of circulating cells in association with the Child-Pugh grade 
showed no significant changes in WCC or neutrophil numbers Figure 4.2.  On the other hand, 
there were significant decreases in numbers of lymphocytes and platelets with poorer liver 
function.  The increase in the NLR was driven in this circumstance by reduced lymphocytes 
rather than elevated neutrophils.  There was no significant difference between the SII score of 
the three different Child-Pugh grades in this cohort. 
4.4.5 Stepwise increases in circulating neutrophils with BCLC stage, while 
lymphocytes fall 
Total white cells increased stepwise in association with the composite BCLC staging system, 
Figure 4.3, incorporating both associations with tumour stage and liver function.  The BCLC 
staging system also incorporates an assessment of performance status, the ECOG PST.  The 
striking inverse associations – increases for neutrophils and decreases for lymphocytes – 
reflect similar changes seen in association with ECOG PST, as shown in Figure 4.4. 
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Figure 4.1 Newcastle cohort – mean number of circulating inflammatory cells across TNM stages 
A. Mean white cell count; B. Neutrophils; C. Lymphocytes; D. Platelets; E. NLR; F. SII.  Kruskal-
Wallis test (ns = not significant; *p<0.05, **p<0.01, ***p<0.001). WCC=white cell count.   
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Figure 4.2 Newcastle cohort – mean number of circulating inflammatory cells across Child-Pugh 
grades A. Median white cell count; B. Neutrophils; C. Lymphocytes; D. Platelets; E. NLR; F. SII. 
Kruskal-Wallis test (ns = not significant; *p<0.05, **p<0.01, ***p<0.001). WCC=white cell count; 
NLR=neutrophil to lymphocyte ratio; SII= systemic immune-inflammation index.  
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Figure 4.3 Newcastle cohort – mean number of circulating inflammatory cells across BCLC 
stages A. Median white cell count; B. Neutrophils; C. Lymphocytes; D. Platelets; E. NLR; F. SII.  
Kruskal-Wallis test (ns = not significant; *p<0.05, **p<0.01, ***p<0.001). WCC=white cell count; 
NLR=neutrophil to lymphocyte ratio; SII= systemic immune-inflammation index; 
BCLC=Barcelona Clinic for Liver Cancer.  
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Figure 4.4 Newcastle cohort – mean number of circulating inflammatory cells and ECOG 
performance status A. Median white cell count; B. Neutrophils; C. Lymphocytes; D. Platelets; E. 
NLR; F. SII.  Kruskal-Wallis test (ns = not significant; *p<0.05, **p<0.01, ***p<0.001). WCC=white 
cell count; NLR=neutrophil to lymphocyte ratio; SII= systemic immune-inflammation index; 
ECOG= Eastern Cooperative Oncology Group.  
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4.4.6 Newcastle cohort - associations with prognostic factors in patients with HCC 
Exploration of bivariate associations between the combination prognostic tools, NLR and SII, 
performed largely as expected in this cohort Table 4.2, showing positive associations with 
poor prognostic factors (tumour size, extrahepatic disease, vascular invasion, AFP), as well 
as negative associations with albumin – a biomarker of preserved liver function and a better 
prognosis. These findings are in keeping with falling numbers of lymphocytes and/or rising 
numbers of neutrophils and/or platelets being associated with a poorer prognosis. The value 
of this large cohort, however, is the potential to study the contributions of individual cell types, 
with the hope of gaining a clearer understanding of the driving changes underlying the biology 
of progressive disease.  It is clear that all cell types Table 4.2 (neutrophils, lymphocytes and 
platelets) show declining numbers in association with cirrhosis, in keeping with the presence 
of portal hypertension and hypersplenism reducing numbers of these cells.  Within that 
environment however, both neutrophils and platelet numbers, but not lymphocyte numbers, 
associated positively and highly significantly with tumour size. Data were similar for extra 
hepatic disease, vascular invasion, and constitutional symptoms, although in the latter two 
cases (vascular invasion and constitutional symptoms) there was a weak but significant 
negative association with lymphocyte number – in keeping with a protective association with 
increased circulating lymphocytes. A positive association between lymphocyte number and 
serum albumin was supportive of this, although may simply reflect less severe portal 
hypertension/hypersplenism, as there was a similar positive association with platelet number. 
On a similar note, rising bilirubin is a strong predictor of declining liver function and all 
inflammatory cells correlated negatively with this factor, perhaps highlighting the difficulties 
associated with understanding the immune system dysregulation in the presence of end stage 
liver disease and portal hypertension. 
While exploring bivariate associations of staging parameters at diagnosis is interesting, the 
biological significance of weak bivariate associations when a number of different parameters 
can contribute to progression should be interpreted cautiously. Interpreting these data 
alongside the staging data (TNM, Child Pugh, BCLC, ECOG PST), however, suggests that 
advanced tumour stage is associated with rising numbers of neutrophils and platelets, rather 
than falling numbers of lymphocytes – the latter associated with or perhaps a consequence of 
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deteriorating liver function. Ideally, these studies should be supported with longitudinal 
assessments, such time to progression or survival, where multivariate analyses can be used 
to identify independent predictors of outcome.  
Following Bonferroni adjustment of the p-value to correct for the number of correlations being 
tested, the association between vascular invasion and lymphocytes/platelets was no longer 
significant.  The same was true for the association between lymphocytes and constitutional 
symptoms and the association between SII with albumin and bilirubin Table 4.3.  
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Variable Neutrophils Lymphocytes Platelets NLR SII 
Number of 
HCC 
0.070, 
p=0.098 
-0.048, 
p=0.254 
-0.017, 
p=0.688 
0.105, 
p=0.012* 
0.070,      
p= 0.097 
Size of HCC 0.302, 
p<0.001** 
-0.024, 
p=0.573 
0.432. 
p<0.001** 
0.255, 
p<0.001** 
0.428, 
p<0.001** 
EHD 0.222, 
p<0.001** 
-0.009, 
p=0.832 
0.260, 
p<0.001** 
0.165, 
p<0.001** 
0.272, 
p<0.001** 
Vascular 
invasion 
0.171, 
p<0.001** 
-0.106, 
p=0.010* 
0.113, 
p=0.006** 
0.210, 
p<0.001** 
0.197, 
p<0.001** 
Constitutional 
symptoms 
0.226, 
p<0.001** 
-0.117, 
p=0.005** 
0.220, 
p<0.001** 
0.253, 
p<0.001** 
0.309, 
p<0.001** 
Cirrhosis -0.267, 
p<0.001** 
-0.172, 
p<0.001** 
-0.487, 
p<0.001** 
-0.072, 
p=0.080 
-0.337 
p<0.001** 
AFP 0.186, 
p<0.001** 
-0.059, 
p=0.156 
0.164, 
p<0.001** 
0.184, 
p<0.001** 
0.227, 
p<0.001** 
Albumin -0.034, 
p=0.416 
0.179, 
p<0.001** 
0.178, 
p<0.001** 
-0.107, 
p=0.010** 
0.024, 
p=0.561 
Bilirubin -0.147, 
p<0.001** 
-0.252, 
p<0.001** 
-0.397, 
p<0.001** 
0.095, 
p=0.021* 
-0.177, 
p<0.001** 
Table 4.2 Newcastle cohort – bivariate associations between prognostic factors and circulating 
inflammatory cells. HCC=hepatocellular cancer; EHD=extra-hepatic disease; 
AFP=alphafetoprotein; NLR=neutrophil to lymphocyte ratio; SII=systemic immune-inflammation 
index. 
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Variable Neutrophils Lymphocytes Platelets NLR SII 
Number of 
HCC 
0.070, 
p=0.098 
-0.048, 
p=0.254 
-0.017, 
p=0.688 
0.105, 
p=0.012 
0.070,      
p= 0.097 
Size of HCC 0.302, 
p<0.001* 
-0.024, 
p=0.573 
0.432. 
p<0.001* 
0.255, 
p<0.001* 
0.428, 
p<0.001* 
EHD 0.222, 
p<0.001* 
-0.009, 
p=0.832 
0.260, 
p<0.001* 
0.165, 
p<0.001* 
0.272, 
p<0.001* 
Vascular 
invasion 
0.171, 
p<0.001* 
-0.106, 
p=0.010 
0.113, 
p=0.006 
0.210, 
p<0.001* 
0.197, 
p<0.001* 
Constitutional 
symptoms 
0.226, 
p<0.001* 
-0.117, 
p=0.005 
0.220, 
p<0.001* 
0.253, 
p<0.001* 
0.309, 
p<0.001* 
Cirrhosis -0.267, 
p<0.001* 
-0.172, 
p<0.001* 
-0.487, 
p<0.001* 
-0.072, 
p=0.080 
-0.337 
p<0.001* 
AFP 0.186, 
p<0.001* 
-0.059, 
p=0.156 
0.164, 
p<0.001* 
0.184, 
p<0.001* 
0.227, 
p<0.001* 
Albumin -0.034, 
p=0.416 
0.179, 
p<0.001* 
0.178, 
p<0.001* 
-0.107, 
p=0.010 
0.024, 
p=0.561 
Bilirubin -0.147, 
p<0.001* 
-0.252, 
p<0.001* 
-0.397, 
p<0.001* 
0.095, 
p=0.021 
-0.177, 
p<0.001* 
Table 4.3 Newcastle cohort – bivariate associations between prognostic factors and circulating 
inflammatory cells with p-value adjusted following Bonferroni correction. HCC=hepatocellular 
cancer; EHD=extra-hepatic disease; AFP=alphafetoprotein; NLR=neutrophil to lymphocyte 
ratio; SII=systemic immune-inflammation index. 
  
 134 
 
4.4.7 Newcastle cohort – survival analyses  
Univariate Cox regression analysis was performed to identify variables significantly associated 
with survival. Those explored included patient factors (sex, metabolic risk factors, aetiology of 
chronic liver disease, presence of cirrhosis), tumour factors (number of HCC, size -diameter 
of largest HCC, PVT, EHD), clinical assessment of liver function (ascites, encephalopathy), 
serum biomarkers of tumour or liver function (AFP, albumin, bilirubin, INR), other serum 
biochemical parameters (creatinine, sodium).  Full blood count data (WCC, neutrophils, 
lymphocytes, platelets), the NLR and SII prognostic scores, clinical assessment of 
constitutional symptoms and finally, the treatment received were also explored.  Data are 
shown in Table 4.4A. 
Variables that demonstrated significance of <0.01 were entered into a multivariate Cox 
regression model, as shown in Table 4.4B.  As the NLR and SII include single variables 
entered into the multivariate analysis within their component parts, distinct multivariate 
analyses to assess the impact of the combined scores were performed, as shown in 
Table 4.4C.  Considering the inflammatory cells in the univariate survival analyses, both 
numbers of circulating neutrophils and platelets were significantly associated with survival, 
while circulating lymphocytes were not.  In the multivariate study, neutrophils were 
independently associated with survival (p=0.015, HR 1.052, 95% CI 1.010-1.097), but platelets 
were not Table 4.4B.  The SII and NLR were also significant in both univariate (p<0.001) and 
multivariate survival analyses (p<0.001) and associations with those key biomarkers 
predicting survival shown in Table 4.2.  
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A. Univariate 
analysis 
Variable 
Signific-
ance 
 
B. Multivariate 
analysis 
Variable 
Signific
-ance 
HR 95% Confidence 
Interval 
Lower Upper 
BMI 0.325 
 
Number of HCC 0.022 1.040 1.006 1.076 
Gender 0.626 
 
Size of HCC 0.001 1.046 1.019 1.073 
Aetiology 0.154 
 
EHD 0.059 1.314 0.990 1.745 
Cirrhosis 0.936 
 
PVT 0.001 1.495 1.173 1.907 
T2DM 0.208 
 
Ascites 0.092 1.247 0.965 1.612 
Number of HCC <0.001 
 
Albumin <0.001 0.944 0.925 0.964 
Size of largest HCC <0.001 
 
Bilirubin 0.143 1.002 0.999 1.004 
EHD <0.001 
 
Neutrophils (cont.) 0.015 1.052 1.010 1.097 
PVT <0.001 
 
Platelets (cont.) 0.463 1.000 0.999 1.001 
Ascites <0.001 
 
Const. symptoms <0.001 2.089 1.664 2.621 
Encephalopathy 0.371  Rx (OLTx) <0.001    
AFP 0.013
  
 Rx (resection) 0.228 1.526 0.768 3.032 
Albumin <0.001  Rx (RFA) <0.001 4.490 2.674 7.541 
Bilirubin <0.001  Rx (HAT) <0.001 8.034 4.932 13.088 
INR 0.084  Rx (Medical) <0.001 6.101 2.413 15.425 
Sodium 0.528  Rx (BSC) <0.001 12.74 7.769 20.888 
Creatinine 0.549       
WCC <0.001       
 
Neutrophils (cont.) 
 
<0.001 
 
C. Multivariate analyses - assessing the association of 
either NLR or SII (other parameters not shown – data very 
similar to above, in both analyses) 
Lymphocytes 
(cont.) 
0.674 
 
WCC 0.867 1.002 0.982 1.022 
Platelets (cont.) <0.001 
 
NLR <0.001 1.042 1.019 1.066 
Constitutional 
symptoms 
<0.001  SII <0.001 1.000 1.000 1.000 
Treatment <0.001       
NLR <0.001       
SII <0.001       
Table 4.4 Newcastle cohort survival analyses where all inflammatory cell data were analysed as 
continuous variables. A. univariate cox regression analyses. B. multivariate analysis including 
variables that were significant at a p-value<0.01). C. multivariate analysis assessing NLR and SII 
combination tools without confounding by inclusion of individual components of scores. Data 
for other factors entered into the multivariate analyses were as for Table 1.3B. HR= Hazard Ratio; 
BMI=body mass index; T2DM=type 2 diabetes mellitus; HCC=hepatocellular cancer; EHD=extra-
hepatic disease; PVT=portal vein thrombus; AFP=alphafetoprotein; INR=international 
normalised ratio; WCC=white cell count; NLR=neutrophil to lymphocyte ratio; SII=systemic 
immune-inflammation index; Rx = treatment; OLTx=orthotopic liver transplant; 
RFA=radiofrequency ablation; HAT=hepatic arterial therapy; BSC=best supportive care. 
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4.4.8 Newcastle cohort – exploring clinical relevance of predictive value of circulating 
inflammatory cells, the NLR and the SII 
While there may be value in cohort studies exploring the relationships of inflammatory cells as 
continuous variables with patient parameters and clinical outcomes, the clinical impact of a 
single circulating cell count may be small. Here we have explored the value of grouping 
patients categorically on the basis of whether their cell counts were above or below median 
value.  There is the possibility that studied in large enough cohorts, these data could have 
value – supporting the development of biological hypotheses of progression, but also as either 
independent or contributory to biomarker scores (such as the NLR or SII) that have clinical 
utility.  There may be value not just in predicting survival, but in predicting those patients who 
might be best served by one therapy over another – i.e. as predictive biomarkers.  
The group’s overall survival (OS) data, above and below the median for circulating neutrophils, 
lymphocytes, platelets and NLR or as three groups based on an SII <500, >500 but <2000 or 
>2000 are shown as Kaplan-Meier plots in Figure 4.5. In the Newcastle cohort, all groupings 
based on inflammatory cell count or ratio showed significant differences in survival times.  
Patients with high WCC, neutrophil, platelet, NLR and SII scores had shorter median OS (Log-
Rank p<0.001) Table 4.5 and Figure 4.5.  A high lymphocyte count was associated with a 
longer median OS (Log-Rank, p<0.001) Table 4.5 and Figure 4.5.   
The median OS for patients with an NLR above the median for the Newcastle cohort was 6.5 
months (95% CI 4.8-8.2) compared to those with an NLR below median which was 17.5 
months (95% CI 14.3-20.7) Table 4.5.  Differences in median OS were also observed when 
the cohort was divided into three categories based on SII score.  Patients with a high SII score 
(>2000) had the lowest median OS - 2.0 months (95% CI 0.8-3.2) - compared to those with a 
medium (SII>500 but <2000) or low SII score (<500) where survival was 7.7 months (95% CI 
5.1-10.3) and 19.7 months (95% CI 15.8-23.6) respectively (Log-Rank, p<0.001) Table 4.5.  
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Circulating 
immune 
cell/score 
Months 
< median 
95% CI Months 
> median 
95% CI 
 
p-value 
Lower Upper 
 
Lower Upper 
 
WCC 15.1 11.8 18.4 8.1 5.8 10.5 <0.001 
Neutrophils 16.9 13.6 20.2 7.6 5.3 9.9 <0.001 
Lymphocytes 8.5 5.8 11.3 14.7 11.9 17.5 <0.001 
Platelets 15.6 11.9 19.3 7.2 4.7 9.7 <0.001 
NLR 17.5 14.3 20.7 6.5 4.8 8.2 <0.001 
SII Months 
survival  
 
p-value 
SII<500 19.7 15.8 23.6 
<0.001 
SII>500<2000 7.7 5.1 10.3 
SII>2000 2.0 0.8 3.2 
Table 4.5 Newcastle cohort – Kaplan-Meier survival analysis showing median survival in months 
in patients with above or below median circulating inflammatory cell counts or scores (median 
WCC = 6.7; median neutrophil count = 4.1; median lymphocyte count = 1.4; median platelet count 
= 169; median NLR = 2.9; SII was divided into three categories: SII<500, SII>500 but <2000, 
SII>2000).  Upper and lower 95% confidence intervals are shown along with Log-Rank p-value. 
WCC=white cell count; NLR=neutrophil to lymphocyte ratio; SII=systemic immune-inflammation 
index; CI=confidence interval.  
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Figure 4.5 Newcastle cohort - Kaplan-Meier survival curves to show to differences between 
patients with above or below median A. white cell count B. neutrophil count C. lymphocyte count 
D. platelet count E. neutrophil to lymphocyte ratio.  F. Patients were divided into three groups 
on the basis of having a low (<500), medium (SII>500 but <2000) or high (>2000) SII. 
NLR=neutrophil to lymphocyte ratio; SII=systemic immune-inflammation index. 
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When cell counts were considered as categorical values in the multivariate analysis, 
neutrophils above or below the median (4.1) was independently associated with a poorer 
survival, with a hazard ratio of 1.33 Table 4.6. The NLR and SII were also independently 
associated with survival Table 4.6. SII >2000 had the greater hazard ratio (2.83), identifying 
a sub-group of 48 patients with an almost 3 fold greater likelihood of hazard (death) compared 
to patients with an SII <2000. 
A. Univariate 
analysis 
Variable 
 p-value 
 
B. Multivariate 
analysis 
Variable 
p-value HR 95% Confidence 
Interval 
    
Lower Upper 
WCC  <0.001  WCC  0.034 1.255 1.017 1.549 
Neutrophils  <0.001 
 
Platelets  0.977 1.003 0.800 1.259  
Lymphocytes  0.017 
  
Platelets  <0.001 
 
Neutrophils  0.007 1.333 1.083 1.641 
NLR  <0.001  NLR  0.002 1.360 1.118 1.654 
SII  <0.001  SII  <500 <0.001    
   SII>500 but <2000 0.035 1.258 1.017 1.556 
   SII>2000 <0.001 2.830 1.906 4.201 
 
Table 4.6 Newcastle cohort - Cox regression analysis of cell counts as categorical variables 
were also analysed. Data were categorised into above or below median values (median WCC = 
6.7; median neutrophil count = 4.1; median lymphocyte count = 1.4; median platelet count = 169; 
median NLR = 2.9; SII was divided into three categories: SII<500, SII>500 but <2000, SII>2000).  
A. Univariate analyses.  Variables that were significant <0.01 were entered into a multivariate 
analysis. B. Multivariate analysis containing cell counts/scores as categorical variables and the 
variables that were significant <0.01 in univariate analyses in Table 4.4A. 
These data support the roles of the combination NLR or SII scores as tools predicting 
prognosis in a large heterogeneous consecutive cohort of patients with HCC presenting to a 
single centre (Newcastle).  In this cohort, however, it appeared that the key component of the 
tools was in fact an elevated neutrophil count, rather than elevated platelet count or falling 
lymphocyte count.  We sought to validate this finding in a large centre in Hong Kong.  
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4.5 Hong Kong cohort 
4.5.1 Hong Kong cohort description 
As previously considered, the aetiology of HCC in Asia is largely HBV.  This was reflected in 
the large patient cohort describing consecutive patients presenting to the Prince of Wales 
Hospital, Sha Tin, Hong Kong between 1st January 2007 and 31st July 2013, as shown in Table 
4.7.  As expected, HBV was the most common aetiology underlying HCC (79%).  In this cohort, 
there was a larger proportion of males to females (88% vs 12%).  The median age of patients 
was slightly lower than the Newcastle cohort (60 years).  Patients had the presence of cirrhosis 
in over half of cases and a third had PVT.  The mean size of the largest tumour was 8.55 mm 
SEM±0.21, the mean tumour number was 1.63 SEM±0.02.  EHD was present in less than one 
quarter (~23%) of cases.  In this patient cohort, patient performance status was 0-1 in 94% of 
patients.  Most patients’ (69%) underlying liver disease was classified as Child-Pugh A.  More 
than three quarters (78%) of the cohort had HCC that was classified as BCLC B/C and using 
the TNM system, 58% of HCC in the cohort were deemed to be TNM stage IV.  In terms of 
treatment, despite the majority of patients presenting with underlying liver disease classed as 
Child-Pugh A with good ECOG performance status, the majority had advanced diseased 
classed as TNM IV or BCLC C/D and the most common form of treatment reported was best 
supportive care (BSC).  
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Patient demographics 
Male/Female 516/69 
Age (median) 60 
Aetiology 
HBV 
HVC 
HBV & HCV 
Other 
463 
41 
6 
75 
Cirrhosis (Absent/Present) 246/339 
Tumour characteristics 
Number of tumours 1.63 ±0.02 
Size of largest tumour (mm) 8.55 ±0.21 
Portal vein thrombosis (Absent/Present) 390/195 
Extrahepatic disease (Absent/Present) 452/133 
Laboratory blood data 
Median AFP (median; kU/L) 
White cell count (x109) 
Neutrophils (x109) 
Lymphocytes (x109) 
Platelets (x109) 
Neutrophil to lymphocyte ratio 
SII  
Albumin (g/L) 
Bilirubin (µmol/L) 
INR 
Sodium (mmol/L) 
Creatinine (µmol/L) 
265 (range 1-3,637,000) 
7.01 ±0.12 
4.93 ±0.11 
1.31 ±0.03 
206.55 ±5.51 
4.94 ±0.21 
1113.63 ±63.69 
36.76 ±0.24 
33.35 ±2.42 
1.15 ±0.01 
- 
90.37 ±2.98 
Staging 
ECOG Performance Status  Child-Pugh 
0 
1 
2 
3 
4 
186 
365 
25 
9 
- 
A 
B 
C 
402 
156 
27 
BCLC Stage TNM Stage 
0/A 
B 
C 
D 
94 
140 
316 
35 
1 
2 
3 
4 
24 
140 
82 
339 
Primary Treatment 
Resection 
Ablation 
Arterial treatment 
Systemic/sorafenib 
Supportive care 
68 
39 
129 
128 
221 
Table 4.7 Hong Kong cohort patient demographics (n=585). HBV=hepatitis B virus; 
HCV=hepatitis C virus; PBC=primary biliary cirrhosis; AIH=autoimmune hepatitis; 
AFP=alphafetoprotein; SII=systemic immune-inflammation index; INR=international normalised 
ratio; ECOG=Eastern Cooperative Oncology Group; BCLC=Barcelona Clinic for Liver Cancer; 
TNM=tumour, node metastases.  
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4.5.2 Increasing tumour stage, more extensive underlying liver disease and 
performance status was associated with increasing neutrophils and 
inflammatory scores as well as decreasing lymphocyte counts 
As TNM stage, Child-Pugh scores and BCLC classification increased, so did the WCC, 
circulating neutrophils and both of the inflammatory scores – NLR and SII Figure 4.6-Figure 
4.9.  In all cases, there were highly statistically significant differences between the groups; 
tested using the Kruskal-Wallis test (p<0.001).  Platelet counts also increased with increasing 
TNM stage and BCLC classification Figure 4.6 and Figure 4.8; however the relationship 
between platelets and Child-Pugh score was less well-defined with little difference seen 
between the groups Figure 4.7.  Platelets increased with ECOG performance status 0-2 in a 
stepwise manner but although there were significant differences between the groups, platelet 
counts fell in patients with PST 3 Figure 4.9.  Conversely, the number of lymphocytes 
decreased with increased TNM stage (p=0.020); worsening Child-Pugh (p=0.009); BCLC 
(p<0.001) and ECOG performance status (p=0.001) Figure 4.6-Figure 4.9.  
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Figure 4.6 Hong Kong cohort – mean numbers of circulating inflammatory cells across TNM 
stages A. Neutrophils; B. Lymphocytes; C. Platelets; D. NLR; E. SII.  Kruskal-Wallis test (ns = 
not significant; *p<0.05, **p<0.01, ***p<0.001). NLR=neutrophil to lymphocyte ratio; SII= systemic 
immune-inflammation index; TNM=tumour, node, metastases.   
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Figure 4.7 Hong Kong cohort – mean numbers of circulating inflammatory cells across Child-
Pugh scores A. Neutrophils; B. Lymphocytes; C. Platelets; D. NLR; E. SII.  Kruskal-Wallis test 
(ns = not significant; *p<0.05, **p<0.01, ***p<0.001). NLR=neutrophil to lymphocyte ratio; SII= 
systemic immune-inflammation index.  
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Figure 4.8 Hong Kong cohort – mean numbers of circulating inflammatory cells across BCLC 
stages. A. Neutrophils; B. Lymphocytes; C. Platelets; D. NLR; E. SII.  Kruskal-Wallis test (ns = 
not significant; *p<0.05, **p<0.01, ***p<0.001). NLR=neutrophil to lymphocyte ratio; SII= systemic 
immune-inflammation index; BCLC=Barcelona Clinic for Liver Cancer.   
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Figure 4.9 Hong Kong cohort – mean circulating inflammatory cell counts and ECOG 
performance status. A. Neutrophils; B. Lymphocytes; C. Platelets; D. NLR; E. SII.  Kruskal-Wallis 
test (ns = not significant; *p<0.05, **p<0.01, ***p<0.001). NLR=neutrophil to lymphocyte ratio; 
SII= systemic immune-inflammation index; ECOG= Eastern Cooperative Oncology Group   
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4.5.3 Hong-Kong cohort - associations with HCC prognostic factors 
Bivariate correlations observed in the Hong-Kong cohort were similar to those observed in the 
Newcastle cohort.  Positive correlations were observed between neutrophils, platelets, the 
NLR, SII with tumour number and diameter, EHD, vascular invasion, constitutional symptoms 
AFP and bilirubin Table 4.8.  Negative correlations were observed between neutrophils, the 
NLR and SII with cirrhosis and albumin Table 4.8.  Lymphocytes correlated inversely with 
tumour size, vascular invasion, constitutional symptoms, AFP and bilirubin Table 4.8.  There 
was a positive association between lymphocytes and serum albumin Table 4.8. 
As for the Newcastle cohort, when the Bonferroni correction was applied to account for 
multiple associations, the association between lymphocytes and constitutional symptoms was 
no longer significant.  Also, Bonferroni adjustment of the p-value meant to the associations 
between neutrophils and serum bilirubin; and the NLR and cirrhosis were no longer statistically 
significant Table 4.9.  
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Variable Neutrophils Lymphocytes Platelets NLR SII 
Number of 
HCC 
0.176, 
p<0.001** 
-0.022, 
p=0.600 
0.154, 
p<0.001** 
0.145, 
p<0.001** 
0.200, 
p<0.001** 
Size of HCC 0.358, 
p<0.001** 
-0.141, 
p<0.001** 
0.453, 
p<0.001** 
0.382, 
p<0.001** 
0.526, 
p<0.001** 
EHD 0.259, 
p<0.001** 
-0.079, 
p=0.057 
0.197, 
p<0.001** 
0.258, 
p<0.001** 
0.293, 
p<0.001** 
Vascular 
invasion 
0.268, 
p<0.001** 
-0.142, 
p=0.001** 
0.169, 
p<0.001** 
0.305, 
p<0.001** 
0.300, 
p<0.001** 
Constitutional 
symptoms 
0.287, 
p<0.001** 
-0.118, 
p=0.004** 
0.253, 
p<0.001** 
0.301, 
p<0.001** 
0.349, 
p<0.001** 
Cirrhosis -0.215, 
p<0.001** 
-0.068, 
p=0.098 
-0.368, 
p<0.001** 
-0.108, 
p=0.009** 
-0.278, 
p<0.001** 
AFP 0.259, 
p<0.001** 
-0.156, 
p<0.001** 
0.221, 
p<0.001** 
0.309, 
p<0.001** 
0.342, 
p<0.001** 
Albumin -0.176, 
p<0.001** 
0.284, 
p<0.001** 
0.067, 
p=0.104 
-0.310, 
p<0.001** 
-0.189, 
p<0.001** 
Bilirubin 0.088, 
p=0.034* 
-0.314, 
p<0.001** 
-0.222, 
p<0.001** 
0.271, 
p<0.001** 
0.061, 
p=0.143 
Table 4.8 Hong Kong cohort – bivariate associations between significant factors affecting 
survival and circulating inflammation cells. HCC=hepatocellular cancer; EHD=extra-hepatic 
disease; AFP=alphafetoprotein; NLR=neutrophil to lymphocyte ratio; SII=systemic immune-
inflammation index. 
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Variable Neutrophils Lymphocytes Platelets NLR SII 
Number of 
HCC 
0.176, 
p<0.001* 
-0.022, 
p=0.600 
0.154, 
p<0.001* 
0.145, 
p<0.001* 
0.200, 
p<0.001* 
Size of HCC 0.358, 
p<0.001* 
-0.141, 
p<0.001* 
0.453, 
p<0.001* 
0.382, 
p<0.001* 
0.526, 
p<0.001* 
EHD 0.259, 
p<0.001* 
-0.079, 
p=0.057 
0.197, 
p<0.001* 
0.258, 
p<0.001* 
0.293, 
p<0.001* 
Vascular 
invasion 
0.268, 
p<0.001* 
-0.142, 
p=0.001* 
0.169, 
p<0.001* 
0.305, 
p<0.001* 
0.300, 
p<0.001* 
Constitutional 
symptoms 
0.287, 
p<0.001* 
-0.118, 
p=0.004 
0.253, 
p<0.001* 
0.301, 
p<0.001* 
0.349, 
p<0.001* 
Cirrhosis -0.215, 
p<0.001* 
-0.068, 
p=0.098 
-0.368, 
p<0.001* 
-0.108, 
p=0.009 
-0.278, 
p<0.001* 
AFP 0.259, 
p<0.001** 
-0.156, 
p<0.001* 
0.221, 
p<0.001* 
0.309, 
p<0.001* 
0.342, 
p<0.001* 
Albumin -0.176, 
p<0.001* 
0.284, 
p<0.001* 
0.067, 
p=0.104 
-0.310, 
p<0.001* 
-0.189, 
p<0.001* 
Bilirubin 0.088, 
p=0.034 
-0.314, 
p<0.001* 
-0.222, 
p<0.001* 
0.271, 
p<0.001* 
0.061, 
p=0.143 
Table 4.9 Hong Kong cohort – bivariate associations between significant factors affecting 
survival and circulating inflammation cells with Bonferroni adjusted p-value. 
HCC=hepatocellular cancer; EHD=extra-hepatic disease; AFP=alphafetoprotein; 
NLR=neutrophil to lymphocyte ratio; SII=systemic immune-inflammation index. 
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4.5.4 Hong Kong cohort – survival analysis 
The impact of circulating immune cell counts and scores were investigated using survival 
analyses as previosuly described in Section 4.4.6.  Variables that were found to be significant 
in univariate analyses Table 4.10A were entered into multivariate analyses; with separate 
analyses carried out for individual immune cell counts and inflammatory scores.  In this cohort, 
variables that remained siginificant in multivariate analyses included PVT, AFP, treatment and 
neutrophils Table 4.10B-C.   
Additionally, the follwing also remained statistically significant in a multivariate analysis: 
tumour number (p=0.001); tumour size (p=0.002); EHD (p=0.027); bilirubuin (p=0.001); INR 
(p=0.002) and constitutional symptoms (p=0.017) Table 4.10B-C.  The NLR and SII did not 
remain independent prognostic indicators in the multivariate analysis Table 4.10C. 
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A. Univariate 
analysis 
Variable  
Signifi
-cance 
 
B. Multivariate 
analysis 
Variable 
Signifi
-cance 
HR 95% Confidence 
Interval 
Lower Upper 
Gender 0.311 
 
Number of tumours 0.001 1.460 1.174 1.815 
Aetiology 0.354 
 
Size of largest tumour 0.002 1.035 1.012 1.057 
Cirrhosis 0.083 
 
EHD 0.027 1.326 1.033 1.701 
Number of HCC 0.003 
 
PVT <0.001 2.120 1.680 2.676 
Size of largest HCC <0.001 
 
Ascites 0.688 1.052 0.822 1.345 
EHD <0.001 
 
AFP <0.001 1.000 1.000 1.000 
PVT <0.001 
 
Albumin 0.364 0.991 0.971 1.011 
Ascites <0.001 
 
Bilirubin 0.001 1.003 1.001 1.005 
AFP <0.001 
 
INR 0.002 2.487 1.400 4.416 
Albumin <0.001 
 
Neutrophils <0.001 1.113 1.073 1.156 
Bilirubin <0.001 
 
Lymphocytes 0.125 0.873 0.735 1.038 
INR <0.001 
 
Platelets 0.133 0.999 0.999 1.000 
Creatinine 0.565 
 
Constitutional symptoms 0.017 1.362 1.058 1.754 
Neutrophils (cont.) <0.001  Rx (resection) <0.001    
Lymphocytes (cont.) <0.001  Rx (RFA) 0.903 1.039 0.564 1.914 
Platelets (cont.) 0.005  Rx (HAT) 0.324 1.284 0.781 2.112 
Constitutional 
symptoms 
<0.001  Rx (Medical) 0.042 1.700 1.020 2.835 
Treatment <0.001  Rx (palliative) <0.001 2.767 1.685 4.543 
NLR <0.001 
 
     
SII <0.001 
 
     
   C. Multivariate analyses - assessing the association of 
either NLR or SII 
  
 
NLR 0.208 1.009 0.995 1.022 
   SII 0.097 1.000 1.000 1.000 
Table 4.10 Hong Kong cohort –Cox regression survival analyses A. Univariate analysis. B. 
Multivariate analysis. Variables that were significant (p<0.01) in a univariate analysis were 
entered into a multivariate analysis to determine independent variables affecting survival. 
HR=Hazard Ratio; HCC=hepatocellular cancer; EHD=extra-hepatic disease; PVT=portal vein 
thrombus; AFP=alphafetoprotein; INR=international normalised ratio; WCC=white cell count; 
Cont.=continuous; NLR=neutrophil to lymphocyte ratio; SII=systemic immune-inflammation 
index; Rx = treatment; OLTx=orthotopic liver transplant; RFA=radiofrequency ablation; 
HAT=hepatic arterial therapy; BSC=best supportive care. 
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4.5.5 Prognostic implications of circulating neutrophil counts and inflammatory 
scores 
The prognostic implications of circulating immune cell counts and scores were further 
investigated with results indicating that patients with above median counts of neutrophils, 
platelets, NLR; SII; and below median counts of lymphocytes had a shorter median survival 
and these difference were very highly statistically significant (Log-Rank, p<0.001) Table 4.11 
and Figure 4.10.  When circulating cell counts and scores were considered as categorical 
variables - grouped as above/below median for the cohort – neutrophils (p<0.001), the NLR 
(p=0.001) and SII (p<0.001) remained significant independent variables in  separate 
multivariate analyses Table 4.12 containing the variables that were significant in previous 
univariate analyses Table 4.10.  Platelets as a categorical varibale did not remain and 
independent prognostic indicator in multivariate analysis Table 4.12.  In this cohort 
lymphocytes were also a significant independent prognstic indicator (p=0.017) Table 4.14.
Circulating 
immune 
cell/score 
Months < 
median 
95% CI Months > 
median 
95% CI 
 
p-value 
Lower Upper 
 
Lower Upper 
 
Neutrophils 10.2 8.3 12.1 2.8 2.1 3.4 <0.001 
Lymphocytes 3.8 2.9 4.7 8.2 6.0 10.4 <0.001 
Platelets 8.2 6.2 10.2 4.2 3.4 5.0 <0.001 
NLR  11.4 8.6 14.1 2.8 2.2 3.3 <0.001 
SII Months 
survival  
 
p-value 
SII<500 11.9 9.0 14.8 <0.001 
SII>500 but <2000 4.6 3.8 5.5 
SII>2000 1.8 1.2 2.4 
Table 4.11 Hong Kong cohort – Kaplan-Meier survival analysis showing differences in median 
survival in months in patients with above or below median circulating inflammatory cell counts 
or scores.  Median neutrophil count = 4.3; median lymphocyte count = 1.2; median platelet count 
= 176; median NLR = 3.5; SII was divided into three categories: SII<500, SII>500 but <2000, 
SII>2000.  Upper and lower 95% confidence intervals are shown along with Log-Rank p-values. 
NLR=neutrophil to lymphocyte ratio; SII=systemic immune-inflammation index; CI=confidence 
interval.  
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Figure 4.10 Hong Kong cohort - Kaplan-Meier survival curves to show to differences between 
patients with above or below median A. neutrophil count B. lymphocyte count C. platelet count 
D. neutrophil to lymphocyte ratio.  E. Patients were divided into three groups on the basis of 
having a low (<500), medium (SII>500 but <2000) or high (>2000) SII. NLR=neutrophil to 
lymphocyte ratio; SII=systemic immune-inflammation index.  
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A. Univariate 
analysis 
Variable 
 p-value 
 
B. Multivariate 
analysis 
Variable 
p-value HR 95% Confidence 
Interval    
Lower Upper 
Neutrophils (cat.) <0.01  Neutrophils (cat.)  <0.001 1.551 1.253 1.918 
Lymphocytes (cat.) <0.001 
 
Lymphocytes (cat.)  0.017 0.787 0.647 0.957 
Platelets (cat.) 0.001  Platelets (cat.) 0.793 0.970 0.770 1.221 
NLR (cat.) <0.001  NLR (cat.) <0.001 1.683 1.373 2.064 
SII (cat.) <0.001  SII  <500 0.001    
   SII>500 but <2000 0.332 1.120 0.891 1.410 
   SII>2000 <0.001 1.787 1.295 2.466 
Table 4.12 Hong Kong cohort – Cox regression analysis A Univariate analysis. B. Multivariate 
analysis. Cell counts as categorical variables were also analysed.  Data were categorised into 
above or below median values (median neutrophil count = 4.3; median lymphocyte count = 1.2; 
median platelet count = 176; median NLR = 3.5; SII was divided into three categories: SII<500, 
SII>500 but <2000, SII>2000.  All categorical cell counts were significant <0.01 in univariate 
analyses and were entered into a multivariate analysis containing the variables that were 
significant in the univariate analyses in Table 4.10.  In the multivariate analysis neutrophils, NLR 
and SII remained significant independent variable.  
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4.6 Combined cohort 
4.6.1 Combined cohort description 
In order to assess the utility of circulating immune cell counts and inflammatory scores in a 
larger patient cohort, the Newcastle and Hong Kong cohorts were combined.  This resulted in 
a patient cohort of 1168 patients Table 4.13.  The proportion of male:female was 85% vs 15%.  
One of the advanatges of combining the two cohorts was to increase the sample size of 
patients with varying aetiology and undergoing different treatment types.  In the combined 
cohort, the most common aetiology was HBV (42%) with ALD (14%), NAFLD (11%) and HCV 
(9%) being the next most common aetiologies.  The mean number of tumours was 2.08 
SEM±0.05 and the size of the largest tumour was 7.40 SEM±0.15.  PVT was reported in 30% 
of cases and 19% of patients had the presence of EHD.  Most of the patients in the cohort 
(79%) were classified using ECOG as PST 0-1.  66% of assessment of patients’ underlying 
liver disease was scored as Child-Pugh A.  Using the BCLC classification, 50% had BCLC 
stage C compared to BCLC stage A/B or D.  Overall, patients were most often staged as TNM 
IV (37%).  The most commonly regimented treatments were loco-regional and supportive care.   
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Patient demographics 
Male/Female 989/179 
Age (median) 64 
Aetiology 
None/unknown 
Alcohol related 
Non-alcoholic fatty liver 
HBV 
HCV 
HBV & HCV 
PBC 
AIH 
Haemochromatosis 
Cryptogenic 
Other 
114 
168 
127 
491 
101 
6 
19 
7 
31 
24 
80 
Cirrhosis (Absent/Present) 403/765 
Tumour characteristics 
Number of tumours 2.08 ±0.05 
Size of largest tumour (mm) 7.40 ±0.15 
Portal vein thrombosis (Absent/Present) 820/348 
Extrahepatic disease (Absent/Present) 941/227 
Laboratory blood data 
Median AFP (median; kU/L) 
White cell count (x109) 
Neutrophils (x109) 
Lymphocytes (x109) 
Platelets (x109) 
Neutrophil to lymphocyte ratio 
SII  
Albumin (g/L) 
Bilirubin (µmol/L) 
INR 
Sodium (mmol/L) 
Creatinine (µmol/L) 
87.0 
7.21 ±0.12 
4.89 ±0.08 
1.51 ±0.07 
202.72 ±3.83 
4.53 ±0.14 
984.59 ±89.57 
36.23 ±0.17 
31.25 ±1.46 
1.12 ±0.01 
138.90 ±2.07 
96.48 ±1.73 
Staging 
ECOG Performance Status  Child-Pugh 
0 
1 
2 
3 
4 
403 
525 
140 
87 
13 
A 
B 
C 
771 
288 
107 
BCLC Stage TNM Stage 
0/A 
B 
C 
D 
182 
234 
584 
168 
1 
2 
3 
4 
238 
246 
250 
434 
Primary Treatment 
Liver transplant 
Resection 
Ablation 
Arterial treatment 
Systemic medical 
Best supportive care/ no treatment 
53 
99 
104 
317 
137 
458 
Table 4.13 Combined cohort patient demographics n=1491. HBV=hepatitis B virus; 
HCV=hepatitis C virus; PBC=primary biliary cirrhosis; AIH=autoimmune hepatitis; 
AFP=alphafetoprotein; SII=systemic immune-inflammation index; INR=international normalised 
ratio; ECOG=Eastern Cooperative Oncology Group; BCLC=Barcelona Clinic for Liver Cancer; 
TNM=tumour, node metastases.   
 157 
 
4.6.2 Combined cohort- inflammatory cell counts and inflammation scores increased 
with increasing tumour stage and performace status 
Inflammatory cell counts and inflammatory scores showed a general increase as TNM stage, 
BCLC classification and ECOG performance status increased, except for lymphocytes where 
mean counts where variable across the categories Figure 4.11, Figure 4.12, Figure 4.13 and 
Figure 4.14.  In all cases, patients with HCC classified as TNM I had higher counts of all 
inflammation cells and inflammatory scores than patients with TNM II after which there was a 
gradual increase in neutrophils, platelets, NLR and SII Figure 4.11. 
4.6.3 Decreasing numbers of lymphocytes and platelets were associated with 
declining liver function 
An increase in neutrophils, NLR and SII was observed as liver function declined Figure 4.12.  
Interestingly, there was a significant reduction in the number of lymphocytes and platelets 
Figure 4.12.  The combination of increasing neutrophils and falling lymphocytes have led to 
increased NLR being significantly associated with worsening Child-Pugh.  Interestingly, 
although the SII also increase with worsening liver function, the differences between the 
groups were not statistically significant: indicating that the fall in lymphocytes was more 
indicative of deteriorating liver function since the SII calculation places more emphasis on 
increase in neutrophils. 
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Figure 4.11 Combined cohort - - mean number of circulating inflammatory cells across TNM 
stages A. Neutrophils; B. Lymphocytes; C. Platelets; D. NLR; E. SII.  Kruskal-Wallis test (ns = 
not significant; *p<0.05, **p<0.01, ***p<0.001). NLR=neutrophil to lymphocyte ratio; SII= systemic 
immune-inflammation index; TNM=tumour, node, metastases. 
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Figure 4.12 Combined cohort – mean number of circulating inflammatory cells and Child-Pugh 
grade A. Neutrophils; B. Lymphocytes; C. Platelets; D. NLR; E. SII. Kruskal-Wallis test (ns = not 
significant; *p<0.05, **p<0.01, ***p<0.001). NLR=neutrophil to lymphocyte ratio; SII= systemic 
immune-inflammation index.  
 160 
 
 
Figure 4.13 Combined cohort – mean number of circulating inflammatory cells across BCLC 
stages A. Neutrophils; B. Lymphocytes; C. Platelets; D. NLR; E. SII. Kruskal-Wallis test (ns = not 
significant; *p<0.05, **p<0.01, ***p<0.001). NLR=neutrophil to lymphocyte ratio; SII= systemic 
immune-inflammation index; BCLC=Barcelona Clinic for Liver Cancer.  
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Figure 4.14 Combined cohort – mean number of circulating inflammatory cells and ECOG 
performance status score.  A. Neutrophils; B. Lymphocytes; C. Platelets; D. NLR; E. SII. Kruskal-
Wallis test (ns = not significant; *p<0.05, **p<0. 01, ***p<0.001). NLR=neutrophil to lymphocyte 
ratio; SII= systemic immune-inflammation index; ECOG= Eastern Cooperative Oncology Group.  
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4.6.4 Combined cohort – associations with HCC prognostic factors 
In the combined cohort, expectedly bivariate correlations mirror the trends that were observed 
in the individual cohorts.  On the whole, correlations between circulating cell counts and 
tumour characteristics or serum markers of liver function were mostly positive Table 4.14.  
Significant inverse correlations were seen between all circulating cell counts/scores and 
cirrhosis Table 4.14.  Also, lymphocytes negatively correlated with all tumour features and 
serum markers Table 4.14.  With the odd exception, correlations between circulating cell 
counts/ scores with serum albumin/bilirubin now reach statistical significance with bilirubin 
correlating negatively with all cell counts/ scores except NLR and albumin correlating 
negatively with all cell counts/ scores except lymphocytes and platelets Table 4.14. In this 
combined cohort, where the number of cases gave additional statistical power and p values 
for even modest associations were statistically significant, the strength of the associations can 
help when considering which are likely to have biological significance or clinical relevance.  
The strongest associations, all with p values <0.001, are highlighted in yellow. Again it is clear 
that poor prognostic tumour characteristics associate with increasing neutrophil and platelet 
number, while higher lymphocytes correlate with better liver function (higher albumin and lower 
bilirubin).  Following Bonferroni adjustment of the p-value, the only associations that did not 
remain significant at the 0.001 level were those between albumin and neutrophils/SII Table 
4.15.    
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Variable Neutrophils Lymphocytes Platelets NLR SII 
Number of 
HCC 
0.100, 
p=0.001** 
-0.035, 
p=0.231 ns 
0.040, 
p=0.171 
0.112, 
p<0.001** 
0.109, 
p<0.001** 
Size of HCC 0.334, 
p<0.001** 
-0.112, 
p<0.001** 
0.452, 
p<0.001** 
0.340, 
p<0.001** 
0.498, 
p<0.001** 
EHD 0.245, 
p<0.001** 
-0.056, 
p=0.055 ns 
0.230, 
p<0.001** 
0.221, 
p<0.001** 
0.291, 
p<0.001** 
Vascular 
invasion 
0.224, 
p<0.001** 
-0.131, 
p<0.001** 
0.144, 
p<0.001** 
0.267, 
p<0.001** 
0.258, 
p<0.001** 
Constitutional 
symptoms 
0.261, 
p<0.001** 
-0.151, 
p<0.001** 
0.237, 
p<0.001** 
0.305, 
p<0.001** 
0.349, 
p<0.001** 
Cirrhosis -0.244, 
p<0.001** 
-0.093, 
p<0.001** 
-0.426, 
p<0.001** 
-0.109, 
p<0.001** 
-0.320, 
p<0.001** 
AFP 0.231, 
p<0.001** 
-0.136, 
p<0.001** 
0.202, 
p<0.001** 
0.276, 
p<0.001** 
0.311, 
p<0.001** 
Albumin -0.068, 
p=0.020* 
0.215, 
p<0.001** 
0.127, 
p<0.001** 
-0.193, 
p<0.001** 
-0.070, 
p=0.017* 
Bilirubin -0.028, 
p=0.343 ns 
-0.285, 
p<0.001** 
-0.310, 
p<0.001** 
0.187, 
p<0.001** 
-0.053, 
p=0.069 ns 
Table 4.14 Combined cohort – associations of independent variables significantly affecting 
survival. HCC=hepatocellular cancer; EHD=extra-hepatic disease; AFP=alphafetoprotein; 
NLR=neutrophil to lymphocyte ratio; SII=systemic immune-inflammation index. 
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Variable Neutrophils Lymphocytes Platelets NLR SII 
Number of 
HCC 
0.100, 
p=0.001* 
-0.035, 
p=0.231 ns 
0.040, 
p=0.171 
0.112, 
p<0.001* 
0.109, 
p<0.001* 
Size of HCC 0.334, 
p<0.001* 
-0.112, 
p<0.001* 
0.452, 
p<0.001* 
0.340, 
p<0.001* 
0.498, 
p<0.001* 
EHD 0.245, 
p<0.001* 
-0.056, 
p=0.055 ns 
0.230, 
p<0.001* 
0.221, 
p<0.001* 
0.291, 
p<0.001* 
Vascular 
invasion 
0.224, 
p<0.001* 
-0.131, 
p<0.001* 
0.144, 
p<0.001* 
0.267, 
p<0.001* 
0.258, 
p<0.001* 
Constitutional 
symptoms 
0.261, 
p<0.001* 
-0.151, 
p<0.001* 
0.237, 
p<0.001* 
0.305, 
p<0.001* 
0.349, 
p<0.001* 
Cirrhosis -0.244, 
p<0.001* 
-0.093, 
p<0.001* 
-0.426, 
p<0.001* 
-0.109, 
p<0.001* 
-0.320, 
p<0.001* 
AFP 0.231, 
p<0.001* 
-0.136, 
p<0.001* 
0.202, 
p<0.001* 
0.276, 
p<0.001* 
0.311, 
p<0.001* 
Albumin -0.068, 
p=0.020 
0.215, 
p<0.001* 
0.127, 
p<0.001* 
-0.193, 
p<0.001* 
-0.070, 
p=0.017 
Bilirubin -0.028, 
p=0.343 ns 
-0.285, 
p<0.001* 
-0.310, 
p<0.001* 
0.187, 
p<0.001* 
-0.053, 
p=0.069 ns 
Table 4.15 Combined cohort – associations of independent variables significantly affecting 
survival with Bonferroni correction. HCC=hepatocellular cancer; EHD=extra-hepatic disease; 
AFP=alphafetoprotein; NLR=neutrophil to lymphocyte ratio; SII=systemic immune-inflammation 
index. 
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4.6.5 Combined cohort - survival analysis 
Univariate and multivariate analyses were carried out as for the previous cohorts 
Table 4.16A-C.  In the combined cohort, prognostic factors that remained very highly 
significant in the multivariate analyses included: HCC tumour size, EHD, PVT, AFP, albumin, 
INR and treatment (p<0.001) Table 4.16B.  The number of tumours (p=0.009), bilirubin 
(p=0.002) and ascites (p=0.026) also remained significant too.  Of the circulating cell counts 
and scores, neutrophils and the SII were highly significant independent predictors of prognosis 
(p<0.001) Table 4.16B-C.  WCC (p=0.007) and the NLR (p=0.005) were also independent 
predictor of prognosis Table 4.16C. 
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A. Univariate 
analysis 
Variable 
Signific
ance 
 
B. Multivariate 
analysis 
Variable 
Signific
ance 
HR 95% Confidence 
Interval 
Lower Upper 
Cirrhosis 0.023 
 
Number of HCC 0.009 1.042 1.010 1.074 
Number of HCC <0.001 
 
Size of largest HCC <0.001 1.047 1.031 1.064 
Size of largest HCC <0.001 
 
EHD <0.001 1.473 1.232 1.761 
EHD <0.001 
 
PVT <0.001 1.989 1.693 2.336 
PVT <0.001 
 
Ascites 0.026 1.213 1.023 1.438 
Ascites <0.001 
 
AFP <0.001 1.000 1.000 1.000 
Encephalopathy 0.371 
 
Albumin <0.001 0.963 0.950 0.977 
AFP <0.001 
 
Bilirubin 0.002 1.002 1.001 1.004 
Albumin <0.001 
 
INR <0.001 1.671 1.280 2.180 
Bilirubin <0.001 
 
Rx (OLTx) <0.001    
INR <0.001  Rx (resection) <0.001 2.968 1.715 5.136 
Sodium 0.528  Rx (RFA) <0.001 5.314 3.283 8.603 
Creatinine 0.822  Rx (HAT) <0.001 7.954 5.049 12.530 
Rx <0.001  Rx (Medical) <0.001 10.476 6.363 17.247 
WCC <0.001  Rx (BSC) <0.001 15.310 9.692 24.187 
Neutrophils (cont.) <0.001  WCC 0.006 1.019 1.005 1.033 
Lymphocytes 
(cont.) 
0.193  Platelets 0.487 1.000 1.000 1.001 
Platelets <0.001  Neutrophils <0.001 1.082 1.054 1.111 
NLR <0.001       
SII <0.001       
  
 
C. Multivariate analyses - assessing the association of 
either NLR or SII (other parameters not shown – data very 
similar to above, in both analyses) 
  
 
NLR 0.005 1.015 1.004 1.025 
  
 
SII <0.001 1.000 1.000 1.000 
Table 4.16 Combined cohort - Cox regression survival analyses.  A. Univariate analysis. B-C. 
Multivariate analysis.  Variables that were significant (p<0.01) in a univariate analysis were 
entered into a multivariate analysis to determine independent variables affecting survival.  
Combined cohort – differences in OS based on circulating cell count. HCC=hepatocellular 
cancer; EHD=extra-hepatic disease; PVT=portal vein thrombus; AFP=alphafetoprotein; 
INR=international normalised ratio; WCC=white cell count; NLR=neutrophil to lymphocyte ratio; 
SII=systemic immune-inflammation index; Rx = treatment; OLTx=orthotopic liver transplant; 
RFA=radiofrequency ablation; HAT=hepatic arterial therapy; BSC=best supportive care. 
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From the multivariate analysis, WCC, neutrophils, the NLR and SII were strong independent 
predictors of prognosis Table 4.16B-C.  Since lymphocytes and platelets were not significant 
in the multivariate analysis and the SII – which places more emphasis on neutrophils – was 
highly statistically significant (p<0.001) it can be inferred that neutrophils are the determining 
factor in terms of circulating inflammatory cells that predict prognosis.  Circulating 
inflammatory cell counts were categorically divided into above and below median or stratified 
into three categories as previously described.   
In the combined cohort, patients with neutrophil counts above median had a shorter median 
OS (4.4 months, 95% CI 3.7-5.1) compared to patients with a below median neutrophil count 
(13.6 months, 95% CI 11.7-15.6) Log-Rank p<0.001 Table 4.17 and Figure 4.15.  The SII 
could further stratify patients into three groups with those with a high SII (>2000) having the 
shortest median OS (1.9 months, 95%CI 1.3-2.5); compared to those with a medium SII 
(SII>500 but <2000) where median OS was 5.7 months (95%CI 4.5-6.8); compared to those 
with a low SII (<500) where median OS was 15.5 months (95%CI 12.7-18.2), Log Rank, 
p<0.001 Table 4.17 and Figure 4.15.  
When circulating cell counts were considered as categorical variables (above or below 
median, or for the SII divided into three groups), WCC (HR 1.323, 95% CI 1.147-1.527, 
p<0.001); neutrophils (HR 1.390, 95% CI 1.199-1.612, p<0.001); lymphocytes (HR 0.743, 95% 
CI 0.643-0.852, p=0.002); NLR (HR 1.478, 95% CI 1.283-1.703, p<0.001) and SII (medium 
SII HR 1.244, 95% CI 1.070-1.447, p=0.005; high SII HR 2.185, 95% CI 1.721-2.774, p<0.001) 
remained independent variables affecting survival in multivariate analyses Table 4.18. 
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Circulating 
immune 
cell/score 
Months < 
median 
95% CI Months > 
median 
95% CI 
 
p-value 
Lower Upper 
 
Lower Upper 
 
WCC 11.5 9.6 13.4 5.3 4.2 6.4 <0.001 
Neutrophils 13.6 11.7 15.6 4.4 3.7 5.1 <0.001 
Lymphocytes 5.6 4.5 6.7 11.5 9.5 13.5 <0.001 
Platelets 11.9 10.1 13.7 5.3 4.4 6.3 <0.001 
NLR 15.1 12.9 17.3 4.0 3.4 4.5 <0.001 
SII Months 
survival  
 
p-value 
SII<500 15.5 12.7 18.2  
<0.001 
SII>500<2000 5.7 4.5 6.8 
SII>2000 1.9 1.3 2.5 
Table 4.17 Combined cohort – Kaplan-Meier survival analysis.  Median survival in months in 
patients with above or below median circulating inflammatory cell counts or scores.  Median 
WCC = 6.6; median neutrophil count = 4.2; median lymphocyte count = 1.3; median platelet count 
= 172; median NLR = 3.2; SII was divided into three categories: SII<500, SII>500 but <2000, 
SII>2000).  Upper and lower 95% confidence intervals are shown along with Log-Rank p-values. 
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Figure 4.15 Combined cohort - Kaplan-Meier survival curves to show to differences 
between patients with above or below median A. neutrophil count B. lymphocyte count C. 
platelet count D. neutrophil to lymphocyte ratio.  E. Patients were divided into three groups 
on the basis of having a low (<500), medium (SII>500 but <2000) or high (>2000) SII. 
NLR=neutrophil to lymphocyte ratio; SII=systemic immune-inflammation index.
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A. Univariate 
analysis 
Variable 
 p-value 
 
B. Multivariate analysis 
Variable 
p-value HR 95% Confidence 
Interval     
Lower Upper 
WCC (cat.) <0.001  WCC (cat.) <0.001 1.323 1.147 1.527 
Neutrophils (cat.)  <0.001 
 
Neutrophils (cat.) <0.001 1.390 1.199 1.612 
Lymphocytes (cat.) <0.001  Lymphocytes (cat.) <0.001 0.743 0.648 0.852 
Platelets (cat.) <0.001  Platelets (cat.) 0.661 0.965 0.825 1.130 
NLR (cat.) <0.001  NLR (cat.) <0.001 1.478 1.283 1.703 
SII (cat.) <0.001  SII <500 (cat.) <0.001    
   SII>500 but <2000 (cat.) 0.005 1.244 1.070 1.447 
   SII>2000 (cat.) <0.001 2.185 1.721 2.774 
Table 4.18 Combined cohort – Cox regression analysis A. Univariate. B. Multivariate. Cell counts as categorical variables were also analysed.  Data were 
categorised into above or below median values (median WCC = 6.6; median neutrophil count = 4.2; median lymphocyte count = 1.3; median platelet count 
= 172; median NLR = 3.2; SII was divided into three categories: SII<500, SII>500 but <2000, SII>2000).  Neutrophils, lymphocytes and platelets were 
significant <0.01 in univariate analyses and were entered into a multivariate analysis containing the variables that were significant in the univariate analyses 
in Table 4.16. 
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4.6.6 Exploration of circulating inflammatory cell counts and scores in individual 
patient groups 
The combined cohort was used to investigate the use of circulating inflammatory cell 
counts/ scores in individual patient groups – divided on the basis of primary treatment.  
The purpose of this was to explore the clinical utility of such cell counts/scores in 
predicting prognosis in terms of median OS.  Since neutrophils, the NLR and SII 
remained statistically significant in the combined cohort in a multivariate Cox analysis, 
these were tested across different treatment groups and groups of patients divided on 
the basis of BCLC stage. 
4.6.7 The use of circulating neutrophil count, NLR and SII across different 
treatment groups 
The clinical utility of neutrophils, the NLR and SII were explored in the following treatment 
groups: orthotopic liver transplant, resection, ablation, arterial (embolization or SIRT), 
systemic medical therapy and in patients where best supportive care was provided.  In 
a Kaplan-Meier survival analysis, circulating neutrophil counts, the NLR and SII were 
effective at showing statistically different median OS times in months in patients receiving 
arterial and best supportive care Table 4.19-Table 4.21.  The SII also produced the most 
significant (Log-Rank p=0.011) prognosticator in terms of systemic/medical therapy 
Table 4.21 and the NLR also differentiated patients’ median OS receiving 
systemic/medical therapy (Log-Rank p=0.020) Table 4.19.  Neutrophils, the NLR and SII 
all failed to demonstrate difference in median OS for patients receiving surgical 
treatment.   
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Treatment Months 
survival 
Neutrophils 
<median 
95% Confidence 
Interval 
Months 
survival  
Neutrophils>
median 
95% 
Confidence 
Interval 
p-value 
Lower Upper Lower Upper 
OLTx  117.5 - - 87.8 - - 0.838 
Resection  31.5 25.6 37.4 61.4 44.8 78.0 0.054 
Ablation  30.2 27.1 33.3 30.8 18.7 42.9 0.561 
Arterial treatment  17.2 14.0 20.4 17.3 9.4 12.5 <0.001 
Systemic/medical  6.2 2.3 10.0 4.5 3.6 5.4 0.044 
Supportive care  4.9 3.8 6.0 1.8 1.4 2.2 <0.001 
Table 4.19 Kaplan-Meier survival analysis. Differences in median OS (months) in patients 
with above or below median circulating neutrophil counts were assessed in different 
treatment groups. OLTx=orthotopic liver transplant. 
Treatment Months 
survival  
NLR 
<median 
95% Confidence 
Interval 
Months 
survival  
NLR 
>median 
95% Confidence 
Interval 
p-value 
Lower Upper Lower Upper 
OLTx  - - - 79.9 26.1 133.8 0.337 
Resection  37.9 24.6 51.2 52.4 11.5 93.2 0.238 
Ablation  31.4 28.6 34.2 25.4 8.6 42.2 0.915 
Arterial treatment  17.6 14.6 20.6 9.2 6.8 11.6 <0.001 
Systemic/medical  6.6 1.9 11.2 4.6 3.7 5.5 0.020 
Supportive care  5.8 4.3 7.3 2.1 1.8 7.3 <0.001 
Table 4.20 Kaplan-Meier survival analysis. Differences in median or *mean OS (months) in 
patients with above or below median NLR counts were assessed in different treatment 
groups. OLTx=orthotopic liver transplant. 
  
 173 
 
Treatment Months 
survival  
SII<500 
95% 
Confidence 
Interval 
Months 
survival  
SII>500 
but 
<2000 
95% 
Confidence 
Interval 
Months 
survival  
SII 
>2000 
95%    
Confidence  
Interval 
p-value 
Lower Upper Lower Upper Lower  Upper 
OLTx  - - - - - - - - - - 
Resection  31.5 24.6 38.4 61.4 43.7 79.1 35.0 - - 0.025 
Ablation  31.0 28.7 33.3 26.7 10.7 42.6 12.0 - - 0.386 
Arterial treatment  19.1 15.6 22.7 11.4 9.1 13.7 4.5 2.2 6.8 <0.001 
Systemic/medical  6.0 3.8 8.2 5.1 4.4 5.9 3.7 1.6 0.5 0.011 
Supportive care  5.8 4.1 7.5 2.5 2.0 2.9 1.3 1.1 1.5 <0.001 
Table 4.21 Kaplan-Meier survival analysis. Differences in median OS (months) in patients 
with low (<500), medium (SII>500 but <2000) or high (>2000) were assessed in different 
treatment groups. SII=systemic immune-inflammation index; OLTx=orthotopic liver 
transplant.  
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4.6.8 BCLC groups 
The prognostic utility of neutrophils, NLR and SII was also explored in patients divided 
on the basis of their BCLC stage (0/A; B; C or D).  Circulating neutrophil count, the NLR 
and SII were able to differentiate BCLC grade C/D patients’ prognostically in terms of 
median OS with statistical significance Table 4.22-Table 4.24.  The NLR was the only 
score where this extended to patients staged as BCLC B (Log-Rank p=0.007) Table 
4.23.  None of the scores were able to prognosticate patients that were BCLC 0/1 in 
terms of median OS. 
BCLC 
stage 
Months 
survival  
Neutrophils<
median 
95% 
Confidence 
Interval 
Months 
survival  
Neutrophils 
>median 
95% Confidence 
Interval 
p-value 
Lower Upper Lower Upper 
BCLC 0/A 42.7 36.0 49.4 36.2 7.0 65.3 0.949 
BCLC B 20.6 16.7 24.6 17.8 12.3 23.3 0.372 
BCLC C 8.2 6.8 9.6 3.8 3.2 4.3 <0.001 
BCLC D 4.9 3.5 6.2 1.5 1.1 2.0 0.004 
Table 4.22 Kaplan-Meier survival analysis. Differences in median OS (months) in patients 
with above or below median neutrophils were assessed in patients with different BCLC 
stages. BCLC=Barcelona Clinic for Liver cancer. 
BCLC 
stage 
Months 
survival  
NLR< 
median 
95% Confidence 
Interval 
Months 
survival  
NLR> 
median 
95% Confidence 
Interval 
p-value 
Lower Upper Lower Upper 
BCLC 0/A 41.8 35.6 48.0 52.4 35.6 69.1 0.759 
BCLC B 22.6 17.7 27.4 14.9 11.1 18.7 0.007 
BCLC C 9.5 7.9 11.1 3.4 2.8 4.0 <0.001 
BCLC D 5.8 4.3 7.3 1.6 1.0 2.2 <0.001 
Table 4.23 Kaplan-Meier survival analysis. Differences in median OS (months) in patients 
with above or below median NLR were assessed in patients with different BCLC stages. 
BCLC=Barcelona Clinic for Liver cancer. 
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BCLC 
stage 
Months 
survival  
SII<500 
95% 
Confidence 
Interval 
Months 
survival  
SII>500 
but <2000 
95% 
Confidence 
Interval 
Months 
survival  
SII 
>2000 
95% Confidence 
Interval 
p-value 
 
Lower Upper Lower Upper Lower Upper 
BCLC 0/A 42.3 34.7 49.8 52.4 16.5 88.3 42.5 35.0 50.0 0.747 
BCLC B 22.5 18.9 26.1 16.8 13.9 19.6 6.2 0.0 15.6 0.301 
BCLC C 8.5 6.7 10.4 5.2 4.0 6.4 2.0 1.4 2.5 <0.001 
BCLC D 6.1 4.5 7.7 1.7 1.1 2.4 1.2 1.1 1.3 <0.001 
Table 4.24 Kaplan-Meier survival analysis. Differences in median OS (months) in patients 
with low (<500), medium (SII>500 but <2000) or high (>2000) were assessed in patients with 
different BCLC stages. BCLC=Barcelona Clinic for Liver cancer. 
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4.6.9 Clinical Utility of Inflammatory Scores within the BCLC Stage 
While the associations with individual cell types possibly allude to biological mechanisms 
associated with disease progression, the data described above supports additional 
discriminatory value in terms of clinical utility. The BCLC staging system is the one most 
commonly employed to aid management decisions and choice of therapy, although it 
does have associated limitations.  The data in Table 4.24 suggest that in patients with 
BCLC-C or BCLC-D disease, the neutrophil count, the NLR and the SII are highly 
significantly associated with outcome.  This information is not likely to be helpful for 
patients with BCLC-D disease (n=168), as there is no therapy available other than 
supportive care.  We have explored further, however, in patients classed as BCLC-C - 
making up the largest group in this combined cohort (n=584).  This stage is also the most 
heterogeneous, as patients may be classed as BCLC-C based on advanced tumour 
stage with preserved liver function, early or intermediate stage tumour but with 
deteriorating liver function, or with early/intermediate disease but with deteriorating 
ECOG performance status.  Each of these factors (tumour, liver function, PST) are 
clearly important in terms of survival, and at the time the BCLC stage was created, there 
were no evidence based treatment options reportedly improving survival in this category 
and thus these patients were recommended for supportive care or clinical trials.  This 
was not always acceptable in practice and many centres strove to offer transplant for 
those with early cancers, while others offered loco-regional therapy where liver function 
was relatively preserved, in the presence of a partial PVT, or even with a suspicion of 
small volume EHD. The subsequent introduction of medical therapy with sorafenib did 
change the options for these cases, and the BCLC algorithm has been revised 
recommending sorafenib first line for BCLC-C patients.  Many of the patients in this study 
however predated the introduction of sorafenib, and the breakdown of treatments were 
as shown in Table 4.25.  
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Treatment 
BCLC-C 
Number Survival 
(median  
months) 
Whole cohort 
number 
Whole cohort 
Median survival 
Transplant 16   (16) 82.0 53     (53) 112.4 
Resection 13   (8) 32.0 99   (51) 41.3 
Ablation 28 (27) 18.0 104   (89) 30.3 
Arterial 155 (151) 10.2 317 (296) 14.5 
Medical 110 (108) 7.0 137   (131) 7.6 
Supportive 262 (251) 7.2 458   (441) 7.2 
Overall 584 (561) 8.3 1168 (1061) 10.2 
Table 4.25 Primary treatment of BCLC-C patients (n=584).  The number of patients 
receiving each treatment regimen are given with the numbers in brackets representing 
those patients that had complete survival analysis data and were included in survival 
analyses. 
While the median survival of the BCLC-C stage was just 8.3 months, there was clearly a 
very wide range of treatments administered, and a wide range in terms of survival 
(median 7.2 – 82.0 months).  There is no doubt that within the BCLC-C stage, many 
patients benefited from treatment.  Survival within the different treatment categories for 
the whole cohort is also shown for comparison and while there was no difference in those 
receiving medical therapy or supportive care, there were differences in those receiving 
surgical or loco-regional treatments.  The challenge remains selecting those that would 
benefit and avoiding treating those that would not.  In this cohort, the numbers treated 
surgically were relatively small, but we have focused further on the BCLC-C cases 
receiving loco-regional therapy.  Data analysed by univariate Cox Regression analysis 
are shown in Table 4.26A.   
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A. Univariate analysis 
Variable 
(BCLC-C receiving 
arterial therapy) 
Significa
nce 
 
B. Multivariate 
analysis 
Variable 
Signifi
cance 
HR 95% Confidence 
Interval 
Lower Upper 
Cirrhosis (98/53) 0.949 
 
Number of HCC 0.001 1.135 1.051 1.225 
Number of HCC <0.001 
 
Sodium (cont) 0.001 0.902 0.849 0.958 
Size of largest HCC 0.247  Neutrophils 
(cont.) 
0.744 0.984 0.894 1.084 
EHD (132/19) 0.691  NLR (cont.) 0.671 1.017 0.940 1.101 
PVT (118/33) 0.017  SII (cont.) 0.671 1.000 1.000 1.000 
Ascites (120/31) 0.573       
Encephalopathy (107/2) 0.516       
AFP 0.014  C. Multivariate analyses – neutrophils, NLR & SII 
(categorical) 
Albumin 0.639  Number of HCC <0.001 1.120 1.057 1.187 
Bilirubin 0.289  Sodium 0.004 0.911 0.855 0.971 
INR 0.493  Neutrophils (cat.) 0.423 1.196 0.772 1.854 
Sodium 0.002  NLR  (cat.) 0.318 1.243 0.811 1.906 
Creatinine 0.393  
ECOG PST 0.300 
 
WCC (cont.) 0.407 
 
Neutrophils (cont.) 0.005  
Platelets (cont.) 0.075  
Lymphocytes (cont.) 0.096  
NLR (cont.) 0.003  
SII (cont.) 0.001  
Neutrophils (cat.) 0.003  
Platelets (cat.) 0.194  
Lymphocytes (cat.) 0.069  
NLR (cat.) <0.001  
SII (cat.) 0.013 
 
Table 4.26 Cox regression analysis in BCLC-C patients. A. Univariate analysis of clinical 
parameters. B. Multivariate analysis including AFP and SII as continuous variables. C. 
Multivariate analysis including AFP as a continuous variable and SII as categorical 
variable. HCC=hepatocellular cancer; EHD=extra-hepatic disease; PVT=portal vein 
thrombus; AFP=alphafetoprotein; INR=international normalised ratio; ECOG PST= Eastern 
cooperative oncology group performance status; WCC=white cell count; NLR=neutrophil 
to lymphocyte ratio; SII=systemic immune-inflammation index. 
As cases were classed as BCLC-C, they were more homogenous for liver function, 
tumour stage and PST, with far fewer factors showing a significant associations with 
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survival in the univariate analysis.  Restricting to only those variables with a p-value 
<0.01, the number of tumours, the level of sodium, neutrophils, the NLR and the SII were 
analysed by multivariate analysis Table 4.26B-C.  Only tumour number and sodium 
remained significant multivariate analyses in this sub-cohort of patients. 
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4.7 Discussion 
The Newcastle cohort was the first cohort to be investigated for the relevance of 
circulating inflammatory cell counts and scores.  In this cohort, it was found that there 
were trends between TNM stage, Child-Pugh, BCLC and ECOG performance status with 
circulating inflammatory cell counts and scores.  Circulating inflammatory cells counts 
generally increased with more advanced stage or grade except in the case of 
lymphocytes, where lymphocytes decreased with increasing Child-Pugh grade, 
advanced BCLC stage and worse ECOG PST.  Platelets also decreased with advanced 
Child-Pugh stage.  Similar patterns were observed in the Hong Kong cohort. 
In terms of associations with key HCC prognostic factors (number of nodules, HCC size, 
EHD, cirrhosis, vascular invasion, constitutional symptoms, AFP, albumin and bilirubin), 
there were similar patterns observed in the two cohorts, the majority of which reached 
high statistical significance in the combined cohort.  When assessing the prognostic 
implications of circulating cell counts and scores in a Cox multivariate analysis, 
peripheral blood neutrophil count was the only cell type to remain significant in the 
individual cohorts (Newcastle p=0.015; Hong Kong p<0.001; combined p<0.001).  The 
NLR and SII as categorical variables (p<0.001) were also significant in multivariate 
analyses in the Newcastle and combined cohort.  As categorical variables, in the 
Newcastle cohort, neutrophils, the NLR and SII remained independent in multivariate 
analyses and demonstrated statistically significant differences in median OS.  Similarities 
were seen in the Hong Kong and combined cohorts.  In the former (Hong Kong) above 
or below median lymphocyte counts remained significant in a multivariate analysis 
(p=0.017) indicating that perhaps lymphocytes have a greater role in viral hepatitis 
induced HCC.  In the latter, all cell counts/scores were highly significant as categorical 
variables except platelets. 
In the combined cohort which consisted of patients with a more varied aetiology, disease 
stage and treatment regimen; circulating neutrophil counts, the NLR and SII remained 
statistically significant in a multivariate analysis.  Lymphocytes were significantly 
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associated with survival in a univariate analysis but did not remain so in the multivariate 
analysis.  Furthermore, the NLR, although significant (p=0.002) was not as highly 
significant as circulating neutrophil counts and SII (p<0.001).  Since the SII score places 
more emphasis on neutrophils in the calculation of this score, together with these findings 
it is suggested that it may in fact be neutrophils that are the key drivers of HCC 
progression in terms of inflammatory cells as previously concluded in literature (Piccard 
et al., 2012, Sionov et al., 2015, Xu et al., 2014). 
Exploration in the combined cohort within individual treatment groups demonstrated that 
circulating neutrophil count, NLR and SII were associated with statistically significant 
differences in median OS in patient groups where the primary treatment was loco-
regional, systemic/sorafenib or where no treatment was instigated (best supportive care).  
When patients were divided on the basis of BCLC stage, there were similar significant 
prognostic associations in patients with BCLC-C or BCLC-D disease, although  none of 
the counts or scores showed any additional discriminatory benefit in in patients that were 
staged as BCLC 0/A.  Focusing on those cases classed as BCLC-C who were treated 
with loco-regional therapy, our study suggests that the number of tumours, the AFP and 
a raised SII could be used as additional factors to stratify treatment – although optimal 
cut-offs have yet to be determined.   
In the literature Xu and colleagues demonstrated a correlation with CTCs and SII (Xu et 
al., 2014).  A similar relationship was not observed when exploring this in the Newcastle 
HCC CTC cohort used in the previous Chapter 3 (n=69); possibly due to the low sample 
size. Interestingly, there were indications of an association between epithelial biomarker 
negative CTC and numbers of neutrophils (0.240, p=0.049) in the peripheral blood count 
taken on the same day. In addition, numbers of biomarker negative CTCs were weakly 
associated with the presence of PVT (0.348, p=0.004; Spearman’s Rho test). 12/14 
patients with a PVT had CTC detected and in 10 of these cases, CTCs were epithelial 
biomarker negative. 
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In summary, these cohort studies support a key role for neutrophils – either as a driver 
or at least as the most significant single peripheral blood cell count – associated with 
more advanced disease and poorer survival for patients with HCC.  As such, the potential 
role of neutrophils as a driver of tumour progression or possible suppressor of the anti-
tumour responses of other immune cells, would seem worthy of pursuit.  In terms of 
clinical utility, the combination scores generally had greater hazards ratios and were 
considered more likely to have a clinical use.  In particular, the SII may have value in the 
stratification of loco-regional versus medical therapy in patients with BCLC-C stage HCC.  
Categorical grouping of patients into above or below SII 500 demonstrated significant 
differences in OS (SII>500=9.9 months versus SII<500=12.5 months, HR1.6, Log-Rank 
p=0.002).  Returning to potentially relevant biology, in the next chapter (Chapter 5), gene 
expression analysis will be carried out on PBMCs in attempt to elucidate altered gene 
expression that may contribute to hepatocarcinogenesis. 
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4.8 Conclusions 
 Increasing neutrophils, NLR and SII are associated with a more advanced tumour 
stage, declining liver function and a worse performance status.  Conversely 
increasing lymphocyte counts were associated with less advanced stage of HCC, 
less extensive underlying liver disease and performance status. 
 Counts of circulating neutrophils and the SII were independent prognostic 
indicators of survival in all cohorts indicating that irrespective of aetiology, 
neutrophils may be key players in the inflammatory response and associated 
tumourigenicity in HCC. 
 Investigating the prognostic value of circulating neutrophils, the NLR and SII 
demonstrated that the NLR was able to determine differences in median OS in 
patients with BCLC B-D stage HCC and categorically grouping patients based on 
their SII followed by circulating neutrophil count was able to differentiate patients 
with shorter or longer median OS. 
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Chapter 5. Peripheral blood mononucleocyte gene expression 
in NAFLD/NASH-HCC patients 
5.1 Introduction 
5.1.1 Biomarkers in NAFLD/NASH-HCC  
One of the major problems with identifying universal biomarkers in HCC is that the 
aetiology of disease is highly variable geographically.  In Africa and Asia the majority of 
cases of HCC develop on a HBV aetiology whereas in the US and Europe, leading risk 
factors include HCV and NASH (Spengler and Loomba, 2015).  In Newcastle, ALD and 
NAFLD are the two most common aetiologies of CLD associated with HCC development 
(Dyson et al., 2014).  It is expected that cases of CLD caused by viral infections will 
decrease due to the implementation of HBV immunisation and the introduction of 
interferon therapy for HCV (Mahoney, 1999, Camma et al., 2001).  On the other hand, 
metabolic risk factors – including obesity and type 2 diabetes – associated with 
NAFLD/NASH-HCC are rising and it is predicted that this trend is only going to increase 
in the future (Dyson et al., 2014).  Variations in HCC aetiology indicate that there will be 
differences in gene alterations within different patient cohorts since the pathogenesis of 
disease is variable.  Currently, despite the recommendation for surveillance programmes 
in those with cirrhosis who are at higher risk, many patients present either 
symptomatically or incidentally (Dongiovanni et al., 2014, Dyson et al., 2014). There are 
a number of reasons for this.  Six monthly abdominal ultrasound (USS), with or without 
serum AFP measurement, is the most commonly implemented methodology, but actually 
has poor sensitivity for early disease detection.  Despite 6 monthly abdominal USS being 
promoted by international bodies such as EASL and AASLD (Bruix and Sherman, 2011, 
Bruix et al., 2001), direct evidence for its cost effectiveness is lacking and even in affluent 
societies it is poorly implemented. There is widespread recognition that better 
surveillance tests are needed.  
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In fact surveillance fails NAFLD patients even more than it does those with other 
aetiologies of CLD (Dyson et al., 2014).  A successful programme relies on the 
identification of the at risk population. In NAFLD, cirrhosis is often undetected prior to the 
development of HCC and the opportunity to perform surveillance is missed. In addition, 
USS is less sensitive in patients with obesity, so the test is even less sensitive.  And in 
fact, many patients with NAFLD develop HCC on a background of obesity, type 2 
diabetes and fatty liver without significant fibrosis.  For these individuals, without 
cirrhosis, there is presently no means of stratifying HCC risk and no recommendation at 
all for HCC surveillance given the size of the affected population and the lack of effective 
tools.  There is, however, a drive to identify suitable surveillance biomarkers for this HCC 
aetiology.  While the use of non-invasive tests to monitor disease progression in 
NAFLD/NASH patients is appealing, aiming to detect early disease and increase the 
possibility of patients receiving curative treatment (Ascha et al., 2010, Dongiovanni et 
al., 2014, Michelotti et al., 2013), there are limited reports of novel circulating biomarkers 
for use in the clinical management of NAFLD/NASH HCC.  Several studies have 
investigated the use of measuring markers of liver function including alanine 
aminotransferase (ALT), aspartate aminotransferase (AST) and the AST:ALT ratio in 
combination with metabolic factors to differentiate NASH from other chronic liver disease 
(Gholam et al., 2007, Sorbi et al., 1999).  Data has also demonstrated that high plasma 
levels of CK-18 is independently associated with the presence of NASH (Feldstein et al., 
2009).   
5.1.2 PBMC genomic profiling 
Recently, there has been an increase in the development of ‘liquid biopsies’.  Blood is 
an accessible and clinically routine sampling method.  Blood draws are minimally 
invasive and provide relatively low discomfort to patients compared to tissue biopsies.  
In addition to the identification, quantification and characterisation of CTCs; it has been 
considered that other components of the blood may be able to provide clinically useful 
information: including PBMCs consist of lymphoid cells (T-cells, B-cells, NK cells) and 
myeloid cells (monocytes, granulocytes, neutrophils, eosinophils, basophils and dendritic 
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cells).  Due to the inflammatory nature of HCC and immune involvement, it is 
hypothesised that there will be phenotypic differences in circulating immune cells from 
HCC patients with a NAFLD/NASH aetiology compared to respective matched controls 
without HCC, and that these might be exploited as early diagnostic or surveillance 
signatures. 
5.1.3 Development of PBMC genes signatures in HCC 
In a previous pilot study carried out by the Hui group in Singapore, a 3-gene blood 
signature was developed that could identify early HCC (BCLC 0 or A) in patients that did 
or did not have elevated serum AFP (≥20 ng/ml) and could distinguish between patients 
with HCC from healthy volunteer samples and patients with chronic hepatitis B (Shi et 
al., 2014).  The approach taken to identify this gene signature included microarray 
analysis of RNA extracted from PBMCs from 10 HCC patients, 10 healthy volunteers, 3 
pancreatic cancer patients and 3 gastric cancer patients (Shi et al., 2014).  From this 
initial analysis, 6 genes were found to be differentially expressed in PBMCs from HCC 
patients (Shi et al., 2014).  Next, validation of these 6 genes was attempted using 
multiplex PCR and univariate analysis, resulting in RAB18 – a member of the RAS 
oncogene family – dropping out due to lack of significance in a univariate analysis (Shi 
et al., 2014). Of the 5 remaining genes, 3 were able to distinguish between HCC and 
non-HCC cases (CXCR2 – chemokine C-X-C motif receptor 2 – an IL-8 receptor; CCR2 
– chemokine receptor 2 which is a receptor for monocyte chemoattractant protein-1; and 
EP400 - E1A-Binding Protein P400, a chromatin re-modelling protein) (Shi et al., 2014, 
NCBI Gene Database, 2016). 
In Chapter 4, counts and ratios of immune cells in HCC patients were explored, 
concluding that neutrophils have a key role in HCC tumourigenesis and that the SII has 
independent prognostic utility.  In this chapter, differentially expressed genes in PBMCs 
were explored in HCC patients with NAFLD/NASH aetiology and compared to that of 
NAFLD/NASH cirrhotic controls as well as a HBV-HCC set of patients.  Pilot data 
presented in this chapter is the beginning of a collaborative study with the Hui research 
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group in Singapore.  The long term view is that continued sample collection will lead to 
the generation of a training cohort to assess the possibility of generating a gene signature 
that could detect early stage disease or have prognostic value in NAFLD/NASH-HCC 
patients.  
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5.2 Materials and Methods 
5.2.1 Extraction of peripheral blood mononucleocytes (PBMCs) from HCC 
patient blood samples 
8 ml blood samples were collected in EDTA tubes from patients with NAFLD/NASH 
cirrhosis and patients that had HCC developed on a background of NAFLD/NASH under 
the care of Dr Quentin Anstee, Newcastle, UK.  Samples were obtained following ethical 
approval obtained by the Newcastle Hepatopancreatobiliary and Gastroenterology 
Research Tissue Bank.  All patients used in testing had histological confirmation of 
NAFLD/NASH.  Samples were transported on ice and processed within 2 h of collection.  
Samples were subjected to density gradient centrifugation using Ficoll-Paque PLUS (GE 
Healthcare Life Sciences) to form distinguishable layers of RBCs, density medium, 
PBMCs and plasma.  The PBMCs were removed and pelleted after two 10 min 
centrifugations at 100 x g with 10 ml PBS.  The PBMC pellet was re-suspended in 300 
µl of TRIzol® (Life Technologies) and stored at -80 oC prior to shipping. 
5.2.2 Gene Microarray 
Data presented in this chapter is kindly provided by Professor Kam Hui and colleagues 
(Dr H. Xia, Mr S.V. Pratap and Mr S. Karthik) as part of a collaborative study.  Samples 
were shipped on dry ice to Professor Kam Hui, National Cancer Centre Singapore where 
gene microarray and analyses were performed.  RNA was extracted to perform 
microarray analysis to look at the gene expression profile in PBMCs from HCC patients 
compared to the control group.  A further group of HCC patients with a HBV aetiology 
were included for further comparison.  The gene microarray was performed using the 
Illumina HumanHT-12 v4 Expression BeadChip platform (Illumina, US).  The HT-12 v4 
BeadChip provides genome wide coverage of 31,000 genes with >47,000 probes derived 
from the National Center for Biotechnology Information Reference Sequence (NCBI) 
RefSeq Release 38 (November 7, 2009).  An overview of the method is given in Figure 
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5.1.  12 blood samples were assessed consisting of 4 NAFLD/NASH control patients, 4 
NAFLD/NASH-HCC patients and 4 HBV-HCC patients. 
5.2.3 Statistical Analysis 
Differentially expressed genes were identified using analysis of variance (ANOVA), (p-
value <0.05) between NAFLD controls, NAFLD-HCC samples and HBV-HCC samples.  
Heat map with hierarchal clustering analysis and principal component analysis (PCA) 
were carried out using Partek Genomics Suite 6.5 software.  Ingenuity® pathway 
analysis (Qiagen) was performed to identify associations between differentially 
expressed genes, associated molecules and signalling pathways. 
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Figure 5.1 Overview of sample processing for the Illumina HumanHT-12 v4 Expression 
BeadChip platform.  Adapted from Illumina 2010.   
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5.3 Aims 
 Identify differentially expressed genes between NAFLD/NASH controls and 
NAFLD/NASH-HCC patients in a pilot cohort of cirrhotic controls and HCC 
patients 
 Explore the role of up-/down-regulated genes identified by the gene microarray 
in HCC   
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5.4 Results 
5.4.1 Differential gene expression between NAFLD/NASH control, NAFLD/NASH-
HCC and HBV-HCC patient samples 
Results of the PBMC microarray using the Illumina HumanHT-12 v4 Expression 
BeadChip platform which covers 31,000 genes showed that there was differential gene 
expression between the three sample groups.  Differentially expressed genes were 
defined as those with a fold change of >1.5 and a p-value of <0.05 using ANOVA to 
assess difference between the sample groups.  There were 523 differentially expressed 
genes between NAFLD/NASH control samples compared to NAFLD/NASH HCC.  
Between the HBV-HCC PBMC samples and the NAFLD/NASH HCC samples there were 
604 differentially expressed genes.  Heat map analysis using unsupervised hierarchal 
clustering demonstrated that there were more similarities between NAFLD/NASH-HCC 
and HBV-HCC Figure 5.2.   
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Figure 5.2 Heat map analysis demonstrating differentially expressed genes between 
NAFLD/NADH cirrhotic controls (red), NAFLD/NASH-HCC patients (orange) and HBV-HCC 
patients (yellow).  Upregulated genes are coded in red whereas down-regulated genes are 
denoted in blue.   
5.4.2 More variation was observed between NAFLD/NASH controls and 
NAFLD/NASH HCC compared to HBV-HCC and NAFLD/NASH HCC 
Principal components analysis (PCA) was used to identify key variations in the data 
Figure 5.3.  Variations in the data were expressed as eigenvalues as a percentage of 
the total variation.  The first principal component separated samples on the x-axis 
accounted for 63.4% of the variance demonstrating that there were larger variations in 
the data between NAFLD/NASH controls and NAFLD/NASH HCC patients.  The second 
principal component (y-axis) accounted for 16.4% of the total variance and distinguished 
HBV-HCC from NAFLD/NASH-HCC.  The third principal component separated samples 
out on the z-axis, although this component only accounted for 7.16% of the variance.  To 
conclude, control samples were most variable between the two different HCC aetiologies 
(HBV and NAFLD/NASH) and this is also demonstrated in the hierarchal clustering 
analysis on the heat map Figure 5.2.  However, the HBV-HCC aetiology clustered 
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distinctly from the NAFLD/NASH-HCC aetiology although there was less variance 
between these two sample groups. 
 
Figure 5.3 PCA analysis demonstrated that NAFLD/NASH HCC was more similar to HBV-
HCC than NAFLD/NASH controls in terms of differential gene expression in PBMCs. 
5.4.3 Altered gene pathways in NAFLD-NASH-HCC 
Ingenuity® is a software program that can be used to explore relationships between 
differentially expressed genes in order to assess the biological relevance.  In the gene 
microarray data from the PBMCs, the top altered pathways are listed in Table 5.1.  The 
role of nuclear factor of activated T-cells (NFAT) associated with the immune response 
was identified as the top most altered pathway and is discussed further in Section 5.4.4.  
Of the other top altered pathways identified, integrin signalling was identified as the 
second most altered pathway using Ingenuity®.  Integrin association with RTKs leads to 
the activation of pathways involved in tumour cell invasion and metastasis; aiding in cell 
detachment, migration and survival and initiation of proliferation at distal sites in a 
different microenvironment (Guo and Giancotti, 2004).  Gene alterations in 
phospholipase-C signalling were also detected which have been shown to generate lipid 
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mediators responsible for metastatic processes including cell migration, invasion and 
angiogenesis in addition to proliferation (Park et al., 2012)  .  Genes involved in the 
degradation of 3-phosphoinositide (PI3K) were upregulated Table 5.1.  Lastly, genes 
(TAF1C, POLR1C) associated with the assembly of RNA polymerase I complex required 
for formation of the pre-initiation complex (PIC) which is in turn required for initiation of 
transcription were downregulated .  
Pathway p-value Altered genes 
Role of NFAT in Regulation of the Immune 
Response (10 / 160) 
0.005 GSK3B, GNAZ, FYN, PPP3R1, ITPR3, 
GNG11, CD79B, MEF2D, MAPK3, 
FCGR3A/FCGR3B 
Phospholipase C Signalling (11 / 221) 0.017 
PPP1R14A, ARHGEF3, FYN, PPP3R1, 
ITPR3, GNG11, CD79B, RHOT1, MYL9, 
MEF2D, MAPK3 
Integrin Signalling (10 / 194) 0.018 
ITGA2B, GSK3B, CAPN3, FYN, CTTN, 
RHOT1, ITGB3, MYL9, ACTN1, MAPK3 
3-phosphoinositide Degradation (8 / 139) 0.018 
DUSP10, ALPL, DUSP8, PPP1R14A, 
PPP2R5A, PTPN22, INPP4A, DUSP16 
Assembly of RNA Polymerase I Complex (2 / 9) 0.018      TAF1C, POLR1C 
Table 5.1 Top altered pathways in NAFLD/NASH-HCC identified using Ingenuity®.  
Upregulated genes are denoted in red and downregulated genes are denoted in green. 
 
5.4.4 The role of NFAT in the regulation of the immune response - the top altered 
candidate pathway in NAFLD/NASH-HCC 
In the PBMC gene microarray, the role of NFAT in the regulation of the immune response 
was the top altered pathway in NAFLD/NASH-HCC.  The five members of the NFAT 
family of transcription factors are essential to T-cell development and function but the 
role of different NFAT isoforms have been implicated in a range of different cancers 
including breast, pancreatic and lymphoma (Macian, 2005, Pan et al., 2013). In cancer, 
evidence of NFAT overexpression, its constitutive activation and associated proteins 
involved in cell survival, proliferation, migration, invasion and angiogenesis have led to 
investigation of NFAT as a drug target (Lu and Huan, 2007, Qin et al., 2014).    
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Role of NFAT in Regulation of the Immune Response (10 / 160) 
(p value = 0.005) 
Gene Gene Function 
GSK3B Glycogen synthase kinase 3 beta.  Phosphorylates NFAT promoting 
nuclear export 
GNAZ Guanine nucleotide binding protein (G protein), alpha z.  Associated 
with Akt signalling. 
FYN Protein-tyrosine kinase oncogene family. It encodes a membrane-
associated tyrosine kinase that has been implicated in the control of 
cell growth.   
PPP3R1 Protein phosphate 3, regulatory subunit B alpha.  Encodes 
calcineurin subunit B type 1.  Associated with PI3K and MAPK 
signalling. 
ITPR3 Inositol 1, 4, 5 –triphosphate receptor type 3.  Mediates the release 
of intracellular calcium. 
GNG11 Guanine nucleotide binding protein (G protein), gamma 11.  
Regulates cell senescence. Encodes a cell membrane protein 
involved in transmembrane signalling. 
CD79B CD79b molecule, immunoglobulin-associated beta.  Forms part of 
the B cell receptor.  Often mutated in lymphoma 
MEF2D Monocyte enhancer factor 2D.  Related to Akt signalling. Role in 
leukaemogenesis. 
MAPK3 Mitogen activated protein kinases/ extracellular signal-regulated 
kinases (ERKs), act in a signalling cascade that regulates various 
cellular processes such as proliferation, differentiation, and cell cycle 
progression in response to a variety of extracellular signals 
FCGR3A/FCGR3B Fc fragment of IgG, low affinity IIIa/b receptor (CD16a/b).  
Responsible for the removal of antigen-antibody complexes in the 
circulation.  Also expressed on natural killer (NK) cells, FCGR3B is 
expressed on polymorphonuclear neutrophils.  
Table 5.2 Differential expression of genes associated with the role of NFAT in the 
regulation of the immune response.  Upregulated genes are denoted in red and 
downregulated genes are denoted in green. (Genecards, NCBI Gene, Ingenuity®)  
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Although the role of NFAT and associated genes have been well characterised in the 
immune system, their roles are multifaceted.  Calcineurin signalling is required for NFAT 
translocation to the nucleus and due to the weak association of NFAT with DNA, the 
recruitment of other factors is required for NFAT-mediated gene transcription (Fric et al., 
2012, Pan et al., 2013).  NFAT isoforms were initially discovered in T-cells, responsible 
for the transcription of the cytokine interleukin-2 (IL-2) (Pan et al., 2013).  Further 
research led to the discovery that they were in fact responsible for range of cytokines: 
IL-2, -4, -5, -8, -13, tumour necrosis factor-alpha (TNFα); interferon-gamma IFNγ and 
granulocyte macrophage colony stimulating factor (GMCSF) (Im and Rao, 2004).  In 
addition to T-cells, NFAT proteins are also activators of mast cells, B-Cells, NK cells, 
mast cells, megakaryocytes and monocytes (Muller and Rao, 2010).  
 
Figure 5.4 The role of NFAT in the immune response was identified as the top altered 
pathway in NAFLD/NASH-HCC. Red=upregulated, green=downregulated (Ingenuity®, 
Qiagen). 
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5.5 Discussion 
Firstly, it is important to note that this is pilot data and a larger number of samples would 
be required in order to confirm differences in genes differentially expressed in this small 
study.  A HCC gene signature that has the ability to detect early-HCC has been 
developed using similar methods for patients with HCC developed on a HBV aetiology, 
however this required large numbers of patient samples identify and validate key genes 
in the development of a gene signature (Shi et al., 2014). That signature remains to be 
validated and as yet has no clinical utility.  
In this preliminary data, there were large differences in the numbers of differentially 
expressed genes between the three different sample groups.  Interestingly, principal 
component and heat map analyses demonstrated that there were NAFLD/NASH-HCC 
was more similar to HBV-HCC than it was to NAFLD/NASH, suggesting that there was 
more variation between the NAFLD/NASH control samples and HCC samples than there 
was between the two different aetiologies of HCC Figure 5.2 and Figure 5.3. 
Investigations into pathway analysis showed that the role of NFAT in the immune 
response was the top altered pathway.  The role of NFAT in the immune response has 
been well characterised (Fric et al., 2012).  NFAT proteins are responsible for the 
activation of a wide range of immune cells as wells as the expression of multiple 
cytokines (Im and Rao, 2004, Muller and Rao, 2010).  NFAT is a transcription factor that 
has been linked to various cancer types and it is currently being investigated as a drug 
target (Lu and Huan, 2007, Pan et al., 2013).  There are limited reports of the role of 
NFAT in HCC.  One study showed that the NFATc1 isoform was upregulated in 76 HCC 
samples by IHC and siRNA knockdown of NFAT led to decreased proliferation in HepG2 
cells (Wang et al., 2012a).   
Although this data is preliminary, it would be interesting to investigate a larger number of 
NAFLD/NASH-HCC patients and controls in order to see if these genes were still 
identified as having a role in the transition from NAFLD/NASH cirrhosis to HCC.  
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Furthermore, a larger study may identify key genes that could give more insight into the 
transition from NAFLD/NASH cirrhosis to HCC and lead to the development of a genetic 
signature that could be utilised as a non-invasive test used to monitor patients with the 
aim of identifying patients at the early stage of disease progression, rendering them 
suitable to receive curative treatment.  
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5.6 Conclusion 
 There were 523 differentially expressed genes between NAFLD/NASH controls 
and NAFLD/NASH-HCC and 604 differentially expressed genes between 
NAFLD/NASH-HCC and HBV-HCC.  Data suggests that there was more variation 
between NAFLD/NASH controls and NAFLD/NASH-HCC compared to 
NAFLD/NASH-HCC and HBV-HCC. 
 Data in this chapter suggests that the role of NFAT in the immune response is 
the top altered pathway in PBMCs from NAFLD/NASH -HCC. 
 Sample size is small and a large validation cohort would be required to make 
definite conclusions.  Future work required would include increased sample 
collection to form a training cohort to identify differentially expressed genes that 
could differentiate between NAFLD/NASH controls and NAFLD/NASH-HCC. 
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Chapter 6. Summary, final conclusions and further directions  
Currently in patients with HCC, liver tissue studies are not routinely employed to guide 
treatment decisions and serum AFP is the only clinically used tissue biomarker.  
Limitations associated with the use of AFP include its poor diagnostic sensitivity and 
specificity, but it is used for monitoring disease progression and for treatment 
stratification. Alternative biomarkers - that could be clinically useful in terms of diagnosis, 
prognosis and treatment stratification - are desirable. As liver biopsy is an invasive 
procedure that carries with it associated risks, including bleeding and tumour cell 
seeding, low risk and cheap blood-based biomarkers would be particularly attractive.  
Blood based biomarkers might evaluate serum or plasma proteins, cytokines or cell free 
DNA. They might also evaluate an aspect of circulating blood cells – either non tumour 
or tumour cells.  So far, no such biomarkers have been clinically validated for use in 
HCC. 
The description of CTCs was reported more than a century ago by Australian physician 
Thomas Ashworth (Ashworth, 1869).  Since then, with the advent of new technologies 
that are able to detect CTCs more readily and with improved accuracy, further 
investigations into the clinical utility of CTCs have been performed.  The CellSearch 
system has been clinically validated for use in metastatic breast, prostate and colorectal 
cancer (Cohen et al., 2008, Cristofanilli et al., 2004, de Bono et al., 2008); however these 
assays are based on enumeration of epithelial cells alone.  It has been considered that 
characterisation of CTCs may further enhance knowledge of metastasis and hence 
enhance the clinical utility of CTCs e.g. treatment stratification or prediction of prognosis.  
The Imagestream has several key benefits over the CellSearch in that cells imaged are 
of high-resolution; making it possible to discriminate between cells and debris on the 
basis of morphology using high-quality brightfield images.  Furthermore, using the 
Imagestream meant that it was possible to implement multiple biomarkers into one panel 
in attempt improve characterisation of CTCs.  It was still necessary to ensure that the 
method developed would be accurate and reproducible as well as practicable for use on 
clinical samples.  Whilst it was possible to run non-enriched samples through the 
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Imagestream, this was timely, costly and produced vast amounts of data that were not 
easy to analyse.  On the other hand, enrichment techniques often led to poor recovery 
rates of spiked cells, bias in the cells that were enriched (often on the basis of biomarker 
expression) or samples that were loaded with debris rendering them unsuitable for 
Imagestream analysis.   
Data presented here previously (Chapter 2) demonstrated that enrichment of CTCs 
could be achieved following red cell lysis, using an immunomagnetic depletion of CD45-
positive WBCs, resulting in a ≥95% reduction in haematopoietic cells whilst maintaining 
a CTC recovery rate of 51.3-65.37%.  A further advantage of this method was that it 
depleted the sample of CD45-positive leucocytes meaning that it was quicker to run and 
analyse samples but at the same time the depletion method did not positively select for 
CTCs on the basis of a biomarker, meaning that bias was not introduced into the isolation 
procedure.  Following this CTC enrichment step, samples were rendered suitable for use 
with the Imagestream; something that had failed by trialling other methods of CTC 
depletion due to reductions in recovery of spiked cells or production of debris that was 
imaged by the Imagestream; resulting in unmanageable data files.  Heterogeneity in 
HCC cell lines was observed in initial cell line studies making it an important 
consideration during the generation of an antibody panel.  It was possible to implement 
a panel of 6 biomarkers (including a DNA dye) without compromising on sensitivity.  
Furthermore, this method was found to be practical from a clinical perspective and 
reproducible for the isolation of CTCs in other cancer types including ovarian, 
oesophageal and thyroid (Dent et al., 2015).   
Following optimisation of a method for CTC isolation and detection using the 
Imagestream, blood samples from an HCC patient cohort were tested for the presence 
of CTCs using a biomarker panel consisting of EpCAM, CK, AFP, DNA-PK, GPC3 and 
SULF2 (Chapter 3).  This patient cohort consisted of patients with varying aetiology and 
stage of disease and samples were obtained at different points throughout their clinical 
management.  Between 1 and 1642 CTCs were detected in 45/69 (65%) of HCC patients 
compared to 0 CTCs detected in cirrhotic or healthy control samples.  In this study, 
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observers were not blinded to patient status – a potential source of bias – which could 
be overcome by getting additional observers to review the data files in a blind manner.  
The presence of ≥1 CTCs/4ml indicated a remarkably worse prognosis in terms of 
median OS (24.5 months) compared to CTC-negative samples (12 months), Kaplan-
Meier with Log-Rank test p<0.0001.  In patients with ≥1 CTC/4 ml, TTP was also shorter 
as well using Kaplan-Meier survival analysis with Log-Rank test p=0.006.  The 
percentage of HCC patients with CTCs detected was higher in this cohort than in other 
CTC studies in HCC, attributed to the inclusion of biomarkers in addition to CK and 
EpCAM (Morris et al., 2014, Schulze et al., 2013).  Of the biomarkers that were included 
in the panel, the epithelial biomarker pan-CK was the most commonly expressed (in 29% 
of CTC-positive samples).  Of the exploratory biomarkers, DNA-PK was the most 
commonly detected (in 24% of CTC-positive samples).  In a smaller separate cohort of 
patients (n=14), CTC expression of two further biomarkers were tested: pERK  as a 
surrogate marker of Ras/raf/MAPK pathway activation and c-Met, which may identify 
patients that would respond to the c-Met inhibitor tivantinib (Newell et al., 2009, Santoro 
et al., 2013a, Santoro et al., 2013b).  Whilst, the presence of ≥1 CTC/4ml may be used 
to provide prognostic information, biomarkers that would be able to stratify patients for 
therapy could be highly advantageous to the clinical management of HCC.  CTCs are a 
possible source to investigate such markers, since it is hypothesised that CTCs are 
responsible for disease recurrence; although it is important to note that HCC tumour 
heterogeneity and the metastatic potential of CTCs should be taken into consideration.  
One of the limitations of this study is that samples taken from patients post-treatment 
were not taken at defined time points.  Previous CTC studies have measured CTC counts 
prior to treatment and at specified time points post-treatment; concluding that patients 
whose CTC counts declined post-treatment had a better prognosis (Cristofanilli et al., 
2004, de Bono et al., 2008, Cohen et al., 2008).  It is possible that in patients where 
CTCs were measured soon after treatment that there was a surge in CTCs but, time 
permitting, it would have been interesting to follow up these patients long term, taking 
repeated CTC measurements at various time points following their treatment and explore 
survival in this group. 
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It was also possible to identify biomarker-negative cells on the basis of size and DNA 
content, which discriminate CTCs from WBCs (Chapter 2-3).  Biomarker-negative cells 
detected correlated with poor HCC prognosticators including tumour size, 
encephalopathy and inversely with serum albumin.  It is possible that these cells 
expressed biomarkers not included in the panel, potentially mesenchymal markers.  
Some methods of CTC isolation or detection are size-dependent (e.g. filtrations methods 
such as the ISET); however it was not known at the time whether or not HCC CTCs 
would be larger in size compared to other haematopoietic cells.  Further objects identified 
included clusters of CTCs and the interaction of leucocytes with CTCs although the 
clinical significance of this is not yet known.  It may be suggestive of CTCs being 
recognised by leucocytes for their destruction or that CTCs are travelling in aggregates 
with CTCs as a protection mechanism against immune destruction.  
In addition to Imagestream CTC exploration, a pilot study to see whether or not ctDNA 
might be a potential source of tumour-derived information that could be detected using 
standard biobanked blood samples from patients with HCC.  Initial attempts focused on 
KRAS mutational status, based on evidence of RAS signalling pathway activation in HCC 
(Newell et al., 2009) and the postulation that the frequency of KRAS mutations may be 
increased in patients with HCC developed on a background of NAFLD/NASH (Whitehead 
et al., 2015).  Whilst it was possible to isolate ctDNA from frozen HCC plasma samples, 
frequency of KRAS mutations was low (~5%).  Results may be improved by using a pre-
enrichment step, using a ctDNA detection technology with higher sensitivity, although it 
is possible that KRAS mutations in NAFLD HCC are not as prevalent as hypothesised.  
An attempt to detect TERT promoter mutations in ctDNA was unsuccessful employing 
similar methods. The GC rich content of the TERT promoter region proved to be a barrier 
to suitable primer design.  
HCC – along with other types of cancer - is a disease that commonly arises on a 
background of inflammation (Nikolaou et al., 2013).  While the role of the tumour 
microenvironment in HCC remains to be fully understood, it is considered that tumour-
associated inflammation is tumourigenic (Balkwill et al., 2012, Hanahan and Coussens, 
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2012, Hanahan and Weinberg, 2011).  It has been previously suggested that counts or 
ratios of circulating immune cells may be of clinical value in terms of prognosis (Dan et 
al., 2013, Xu et al., 2014, Gomez et al., 2008). 
As part of this work, data was retrospectively collected from a cohort of 585 Newcastle 
HCC patients and examined for correlations between circulating immune cell counts and 
other HCC prognostic biomarkers.  Associations with HCC stage (TNM and BCLC) as 
well as assessment of underlying liver function (Child-Pugh) and ECOG performance 
status were explored.  Low platelet counts have been associated with cirrhosis and 
worsening CLD (Qamar et al., 2009, Afdhal et al., 2008) and this was reflected in this 
data set with platelet counts decreasing with worsening Child-Pugh score.  However, 
platelet counts increased with increasing TNM stage and BCLC stage; indicating that 
increasing tumour size and spread is associated with more tumour-associated 
inflammation and increased platelet counts (Chapter 4).  The association between high 
platelet counts (thrombocytosis) and worse survival has been documented in solid 
tumours (Lin et al., 2014).  Studies have indicated that tumour cells are able to activate 
platelets resulting in tumour associated inflammation, proliferation and angiogenesis; 
promoting tumour growth and metastasis (Lin et al., 2014, Sharma et al., 2014, Gay and 
Felding-Habermann, 2011).  In multivariate Cox analyses, neutrophils were found to be 
independent prognostic indicators.  Such relationships and significance of these 
measures were also observed in a cohort of HCC patients managed in Hong Kong 
(Chapter 4).  Whilst above median counts of neutrophils were identified as being a 
significant poor prognostic indicator in this large cohort of HCC patients, the phenotype 
of neutrophils (N1 vs N2) may be of further importance since research has identified N2 
neutrophils as tumourigenic.  The role of TGF-β as an effector molecule for the switch 
from an anti-tumourigenic (N1) phenotype to a pro-tumourigenic (N2) phenotype may 
require further investigation in this context, since TGF-β has already been identified as 
a therapeutic target in HCC and inhibitors against TGF-β are being trialled (Giannelli et 
al., 2011, Giannelli et al., 2014).  In the combined cohort, high counts of neutrophils alone 
and the NLR and SII were associated with significant differences in median OS in 
patients receiving non-surgical treatment. 
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It has already been noted that the use of the TNM staging system alone in HCC is limited 
due to the absence of inclusion of assessment of the underlying liver disease.  On the 
other hand, scoring systems that have been implemented for use in HCC often fail to 
take into account characteristics of the tumour Table 1.1.  The BCLC staging system 
addresses these limitations by including both the assessment of underlying liver disease 
and tumour characteristics to stratify patients for treatment.  However, there is currently 
no scoring system for use in HCC that includes a measurement of tumour-associated 
inflammation.  The SII provides a marker of systemic inflammation though it is limited 
since it may not be representative of the tumour microenvironment and does not include 
tumour parameters; although it may be useful in adjunction with other scoring systems 
such as the BCLC staging system.  In BCLC-C patients, an above or below median SII 
was able to differentiate between patients with a better or worse median survival Table 
4.25 although the SII did not remain significant in multivariate analysis in this patient 
group.  The SII may help to determine whether or not treatment would provide a survival 
benefit in these patients although this would need to be explored in a larger cohort of 
BCLC-C patients receiving the various treatment modalities. 
Additional work was performed as part of a collaborative study with Professor Kam Hui’s 
research group at the National Cancer Centre Singapore (Chapter 5).  Professor Hui’s 
research group had previously identified a genetic signature in circulating PBMCs in HCC 
patients; demonstrating that three differentially expressed genes - CXCR2, CCR2 and 
EP400 – were able to detect early HBV associated HCC irrespective of AFP level, 
distinguishing HCC patients from healthy people and control patients with HBV (Shi et 
al., 2014).  This study was pertinent, given our data implicating counts of circulating 
inflammatory cells – particularly neutrophils as the most abundant PBMC – as 
independent predictors of poorer prognosis (Chapter 4); Due to the increasing 
prevalence of patients with HCC developed on a background of NAFLD/NASH, a pilot 
study based on a small cohort of HCC patients with this aetiology were selected along 
with NAFLD/NASH controls.  Differential gene expression of PBMCs from these two 
groups was assessed and also compared with HCC patients with a HBV/HCV aetiology.  
It was found that in terms of differentially expressed genes, the NAFLD/NASH-HCC 
samples were more similar the HBV/HCC samples than the NAFLD/NASH controls.  
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Although this study was small and confirmation in a larger cohort is needed, the NFAT 
pathway was identified as the most altered one in NAFLD/NASH HCC patients.  The 
NFATc isoform has previously been identified as upregulated in HCC, with its knockdown 
resulting in the decreased proliferation of HepG2 cells (Wang et al., 2012a).  
Furthermore, NFAT has been implicated in other cancers, with its overexpression, 
constitutive activation and associated proteins being implicated in tumorigenicity and 
metastatic spread of disease - resulting in its pursuit as a candidate therapeutic target 
(Macian, 2005, Pan et al., 2013, Lu and Huan, 2007, Qin et al., 2014).  
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6.1 Further Directions 
 Increased blood sample collection from HCC patients to assess for the presence 
of CTCs and explore the utility of biomarkers trialled in a small cohort of patients 
i.e. c-Met and pERK.  
 Concurrent CTC isolation using the DEParray or size-dependent isolation 
methods i.e. ISET would enable downstream characterisation of HCC CTCs 
which may lead to the identification of targetable key genetic drivers in 
populations of cells capable of initiating recurrence of disease. 
 Assessment of the phenotype of neutrophils in patients with HCC to determine 
whether N1 or N2 neutrophils predominate. 
 Exploration of gene signatures in PBMCs in a larger cohort of patients with 
NAFLD/NASH-HCC aetiology in order to determine key genetic alterations and 
validate these findings. 
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